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4. Abstract
The transformation biology of bovine papillomavirus type 
4 (BPV-4) was investigated using an in vitro assay
system. In vivo the virus cooperates with bracken to 
cause alimentary canal carcinoma in cattle and transforms 
via a "hit-and-run" mechanism; viral DNA is observed in 
papillomas but not in the resulting tumours. Molecularly 
cloned BPV-4 genome and subgenomic fragments were 
transfected into primary bovine palate fibroblasts 
(PalF) and their ability to induce morphological 
transformation assessed. BPV-4 is incapable of 
transformation without the introduction of a cooperating 
activated ras oncogene and the resultant cells are 
neither immortal nor tumorigenic. The major transforming 
function was found to be the E7 open reading frame (ORF) 
with a possible role for the E8 ORF. The majority of BPV- 
4 transformed lines are found to lose viral DNA on 
passage, as observed in vivo. BPV-4 and the other BPV 
subgroup B viruses BPV-3 and BPV-6 lack an E6 ORF, a 
transforming function in other papillomaviruses.
Introducing an E6 from human papillomavirus type 16 in 
cooperation with BPV-4 E7 leads to immortalisation. 
Immunocytochemistry was used to determine the cellular 
localisation of the transforming proteins of the virus. A 
possible interaction of the E8 protein with a structural 
component of gap junctions is demonstrated. A bracken
13
mutagen, quercetin, is able to initiate PalF cells, 
allowing full malignant transformation by BPV-4 and ras.
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5. Introduction
5.1 Carcinogenesis
5.1.1 Multistage Carcinogenesis
Carcinogenesis is a multistage process. In human cancers, 
the statistical analysis of age-dependent tumours 
indicates kinetics dependent on the fifth or sixth power 
of elapsed time, suggesting that five or six distinct 
sequential stages are involved in the disease (Nordling, 
1953; Peto, 1977) . The hypothesis of multistage 
carcinogenesis has been confirmed in vivo (notably in 
colorectal carcinoma (Fearon and Vogelstein, 1990)) and 
by many workers using in vitro models (see for example 
Land et al, 1983; Newbold and Overall, 1983) .
The carcinogenesis process has been subdivided into at 
least three sequential steps in animal models such as 
mouse skin tumorigenesis: initiation, promotion and
progression (Hecker et al, 1982). An outline of the major 
steps involved is shown in Fig 5.1. The progression of 
benign lesions to malignancy has been studied in this 
system by the use of chemical initiators and tumour 
promoters. In experiments of this type the initiator is 
an agent (typically 7,12-dimethylbenz(a)anthracene 
(DMBA)) which gives rise to genetic damage, whilst the 
promoter compound's (typically 12-O-tetradecanoylphorbol-
15
13-acetate (TPA) ) effects are initially reversible 
suggesting epigenetic events (see Yuspa and Poirier, 
1988). Thus the initiation step gives rise to mutations, 
rearrangements and/or amplification of cellular DNA, then 
multiple applications of promoter give rise to a clonal 
expansion of initiated cells which may then progress to 
carcinoma. It has been observed that initiation is 
dependent upon cell proliferation, perhaps requiring 
fixation of genetic damage before repair occurs (for 
example see Cayama et al, 1978) and thus viral or 
chemical agents which increase cell division rate may 
accelerate the initiation step.
Each step in the multistage process of carcinogenesis 
can be thought of as the removal of a physiological 
barrier against the development of the malignant 
phenotype. Epidemiology has identified broad classes of 
agent important in the development of malignancies. These 
include viruses (both RNA and DNA tumour viruses), 
environmental carcinogens (including radiation, chemical 
carcinogens / mutagens), host immune status and 
inheritance of predisposition to a particular tumour 
type (Eg. childhood retinoblastoma).
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Fig 5.1. Model for tumorigenesis in mouse skin.
Duplication of chromosome 
carrying H-ras mutation
Loss of normal 
H-ras genes
Normal
cell
■ >
Initiated
cell
Papilloma —> Squamous
Carcinoma
■ >
Spindle cell 
Carcinoma
Mutational activation 
of H-ras protooncogene
Mutational inactivation 
of p53 genes
Genetic alterations occurring during skin tumorigenesis.
Schematic representation of chemical induced carcinogenesis in mouse 
skin. Treatment with an initiating compound (here DMBA) gives rise to 
initiated cells by mutation of the Harvey-ras oncogene. The initiated 
cells can be expanded by the action of a tumour promoting agent (here 
TPA) to give rise to benign proliferative lesions (papillomas) within 
6-8 weeks. These benign lesions may develop into carcinomas if 
further genetic damage occurs (here mutation of the p53 tumour 
suppressor gene).
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5.1.2 Oncogenes and Tumour Suppressor Genes
The theory of oncogenes has evolved over the last decade 
to explain the nature of the carcinogenesis process at 
the molecular level. Oncogenes are the activated form of 
proto-oncogenes which are part of the genetic makeup of 
all cells. Each step in the tumorigenesis process would 
thus be the result of an oncogene activation. The 
oncogenes encode products such as growth factors, growth 
factor receptors, protein kinases, signal transducers and 
nuclear replication and transcription factors (for review 
see Klein, 1988) . The initial discovery of oncogenes was 
largely due to work on highly transforming RNA tumour 
viruses. These viruses can disrupt normal cellular 
regulation by the DNA intermediate of the virus 
integrating in or near a gene involved in normal cell 
growth regulation, the integration event leading to a 
deregulation of the gene (insertional mutagenesis) . 
Alternatively the DNA stage of the retrovirus can combine 
with the host genome and then become excised after 
recombination with a cellular gene. This can give rise to 
an activated cellular oncogene under strong retroviral 
control. A large number of genes which, when mutated, can 
give rise to activated oncogenes were identified as a 
result of the study of cancer-causing retroviruses (for 
review see Cooper, 1990).
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At this point it is interesting to consider oncogene 
activation in papillomavirus associated malignancies. 
Reports exist of papillomaviruses (PVs) consistently 
integrating near the locus of the c-myc nuclear 
proto-oncogene (Durst et al, 1987; Couturier et al, 
1991), and in some cases sequences flanking the 
integration site are amplified suggesting a mechanism for 
oncogene activation in these cases (Lazo et al, 1989; 
Wagatsuma et al, 1990). Cellular oncogene involvement in 
these malignancies could also be either via epigenetic 
disruption of the regulation of these genes by 
papillomavirus proteins, or by genetic mutation by 
environmental factors. The c-Ha-ras proto oncogene (a GTP 
binding protein involved in signal transduction) is found 
to be mutated in a significant percentage of PV 
associated cervical carcinomas, as is the c-myc nuclear 
proto oncogene (for example see Riou et al, 1988) 
suggesting that these oncogenes may cooperate with the PV 
genome in the progression of cervical carcinoma. This is 
confirmed by the observation that HPV-16 El oncoprotein 
can cooperate with activated c-Has-ras in an in vitro 
transformation assay (Matlashewski et al, 1987). In 
addition the Ha-ras 1 gene is activated and occasionally 
amplified in papillomavirus associated cancer in cattle 
(Campo et al, 1990).
19
Another class of genes involved in cancer pathogenesis 
are the tumour suppressor genes. The observation that 
fusion of tumour cells with normal cells invariably gave 
rise to a nontumorigenic phenotype suggested that the 
genetic component of normal cells was able to suppress 
the tumorigenic phenotype of the tumour cell partners 
(reviewed in Weinberg, 1991). The fact that somatic cell 
fusions have an unstable karyotype and lose chromosomes 
allowed the correlation of the presence of particular 
chromosomes with tumor suppressing functions and from 
this observation it was suggested that the development of 
a tumorigenic phenotype may be the loss of tumor 
suppressor gene function, a hypothesis shown to be true 
for the inherited eye tumour retinoblastoma (Benedict et 
al, 1983; Sparkes et al, 1983) . In this example the 
carrier inherits a mutated copy of the retinoblastoma 
gene, predisposing the individual to the disease (should 
the second copy become mutated).
The mechanism of action of tumour suppressor genes is 
thought to be as transducers of anti-proliferative 
signals controlling cell cycle progression, 
differentiation pathways and cell mortalilty
(senescence) . Thus the loss of tumour suppressor gene 
functions leads to loss of responsiveness to 
extracellular growth-inhibitory signals. One example of
20
these exogenous signals is the phenomenon of contact 
inhibition thought to be mediated by membrane protein 
interactions (see Folkman and Mascona, 1978). Another 
class are those signals mediated by gap junction pores; 
structures which allow the passage of small molecules 
between cells. There is a substantial body of evidence 
suggesting that gap junctions allow the passage of 
growth-inhibiting molecules between cells, although the 
nature of these molecules is at present unclear (Pitts et 
al, 1988) . The action of macromolecular growth factors, 
such as tumour growth factor-ft (TGF-ii) , has also been 
shown to influence normal cell growth and differentiation 
(for review see Aaronson, 1991) . Within the context of 
papillomavirus research, it is interesting to note that a 
putative suppressor of transformation by papillomaviruses 
exists on the short arm of chromosome 11, as human embryo 
fibroblasts with a deletion in this chromosome become 
susceptible to transformation by HPV-16 alone (Smits et 
al, 1988) , and the tumorigenic phenotype of HeLa cells 
(HPV 18 positive cervical carcinoma cell line) is 
suppressed by the introduction of chromosome 11 (Saxon et 
al, 1986). Indeed a model has been proposed by zur Hausen 
that the development of HPV associated malignancy is as a 
result of the breakdown of cellular mechanisms which 
suppress papillomaviral genome functions (see zur 
Hausen, 1991). In addition, two tumour suppressor gene
21
products are of particular interest, as they have been 
shown to be the targets of papillomaviral "oncoproteins". 
These molecules are the retinoblastoma gene product 
plOS1^ , and the p53 protein.
The retinoblastoma gene product is a nuclear protein 
existing in both phosphorylated and unphosphorylated 
states (Lee et al, 1988). Phosphorylation of the protein 
is regulated throughout the cell cycle and it is believed 
that only the hypophosphorylated form of the protein 
suppresses cell proliferation (for example see Ludlow et 
al, 1990). The hypophosphorylated form of the protein is 
found to be bound by the transforming proteins of several 
DNA tumour viruses including Adenovirus E1A, SV40 large T 
antigen and papillomavirus E7 protein, via a conserved 
region of these proteins (reviewed in Green, 1989), see 
Fig 5.2. Indeed studies in tumour cells have shown 
mutated forms of plOS^k which maintain phosphorylation 
sites but cannot undergo phosphorylation are unable to 
bind SV40 large T, suggesting conformational changes or 
alterations in interactions with other cell components 
prohibiting phosphorylation (Kaye et al, 1990). In 
addition the stimulation of quiescent cells leads to 
phosphorylation of plOS^3 (Mihara et al, 1989) and 
hyperphosphorylation of the protein is observed in 
differentiating cells of the haemopoietic system
22
(Furukawa et al, 1990) which provides further evidence 
that the phosphorylation state of the protein is of 
crucial importance in cell proliferation and 
differentiation control.
The p53 tumour suppressor nuclear phosphoprotein was 
first identified as a result of its complexing with SV40 
large T and has also been shown to complex with 
Adenovirus E1B and human papillomavirus E6 (Lane and 
Crawford, 1979; Sarnow et al, 1982; Werness et al, 1990) . 
In the cases of SV40 and adenovirus, the complexing has 
been shown to stabilise p53 (Oren et al, 1981; Reich et 
al, 1983) and presumably inactivate it, while the E6 
binding causes a rapid and specific degradation of p53 
destroying its growth suppressing potential (Scheffner et 
al, 1990) . While wild-type p53 has tumour suppressor 
properties and reduces transformation by certain 
oncogenes, activating mutations can cause mutant p53 to 
act as an oncogene and augment transformation (Finlay et 
al, 1989; Eliyahu et al, 1989) and the mutant form has 
been found in a number of human malignancies, notably 
those of the colon (Vogelstein et al, 1989) and lung 
(Takahashi et al, 1989).
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Fig 5.2. Adenovirus Ela, SV40 LT and HPV E7 homology.
BPV4 E7 aal MKGQNVTLQD.IAIELEDTISPINLHCEEEI.E.TEEVDT...... PNP.FA
HPVI6 E7 aal MHGDTPTLHEYM.LDLQ. . PETTDLYCYEQLNDSSEEEDEIDGPAGQAEPDRA 
Ad Ela aa36 SHFEPPTLHE.L . YDL^^EVIDLTCHEAGFPPSDDEDE 
SV40 LT aa6 NREESLQLMD.L .LGL^^pNEENLFCEEEM.PSSDDEAT
Region i Region 2
r
BPV4 E7 aa43 . . . ITATCYACEQVLRLAWTST.EGIHQLQQLLFDNLFLLCAACSKQVFCNRRPERNG? 
HPVI6 E7 aa51 HYNIVTFCCKCDSTLRL. CVQSTHVDIRTLEDLLMGTLGIVCPICSQKP
Zn++ hydrophobic Zn++
Notes: Identical or similar amino acids are denoted in
bold type. Region 1 and Region 2 are the domains 
important in binding the tumour suppressor gene product 
plOS^k. zn++ refers to the Cys-X-X-Cys zinc binding 
domain. (The arrow in he BPV-4 E7 sequence denotes the 
engineered 31 deletion which removes the second of the 
two Zn=++ binding domains in the E7+E7_ constructs which 
are used in transfection studies in this thesis (see 
Results and Discussion section 7.2)).
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Suggested roles of p53 in neoplastic transformation 
include transcriptional activation of genes which 
suppress proliferation and control of initiation of DNA 
synthesis (reviewed in Marshall, 1991).
The observation that adenovirus, SV4 0 and the oncogenic 
human papillomaviruses all interact with both the pl05Rb 
and p53 tumour suppressors makes it tempting to speculate 
that the dysfunction of these two molecules can act in 
concert, and indeed recent work has suggested that they 
may be involved in two stage in vitro cellular 
senescence (Shay et al, 1991). Thus the DNA tumour 
viruses outlined above would provide for two steps in the 
multistage transformation process which in vitro may only 
require the disruption of three or four oncogenes / 
tumour suppressor genes (for example see Voglestein et 
al, 1989) .
5.1.3 Viruses in Carcinogenesis
Recent estimates suggest that viral infection may have a 
significant and specific role in approximately 15 percent 
of human malignancies (see Table 5.1.), with cervical 
and hepatocellular carcinomas accounting for some 80 
percent of these tumours (reviewed in zur Hausen, 1991) . 
In each case viral presence alone is insufficient to 
induce cancer, and the long latency periods (often
25
several decades) of these diseases suggest that 
additional factors are required after viral infection. 
Examples of viral involvement in carcinogenesis by 
indirect mechanisms such as the immunosuppression induced 
by human immunodeficiency virus (HIV) or the general 
mutagenic / DNA amplifying activity of herpes simplex 
virus (HSV) are not relevant to this thesis and will not 
be considered further.
A major group of viruses implicated as having a direct 
role in cancer development, (both on the basis of 
epidemiological data and in vitro experimental models) 
are the papillomaviruses, particularly the anogenital 
HP Vs, whose role in multistage carcinogenesis will be 
considered for the remainder of the introduction.
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Table 5.1. Viruses in human cancers.
Virus type Benign proliferations Malignant tumor
EBV
HBV
HPV types 5, 8, 14, 
17, 20
HPV types 16, 18, 
31*, 33, 35*, 39*, 
45*, 51*, 52, 56*, 
58*, 59*, 61*
HPV types 6, 11
HTLV-I
*Only rarely found.
Hairy leukoplakia 
Infectious mono­
nucleosis
Focal liver hyperplasia
Cutaneous plaques and 
papillomas in patients 
with EV
Cervical intraepithelial 
neoplasia; vulvar, 
penile, and perianal 
intraepithelial 
neoplasias
Condyloma
acuminatum
Smouldering leukemia
Burkitt’s lymphoma 
Nasopharyngeal cancer 
B-lymphomas in 
immunosuppressed 
individuals 
Hepatocellular 
carcinoma 
Skin carcinomas usually 
at sun-exposed sites 
in renal allograft and 
in EV patients 
Cervical cancer 
Vulvar cancer 
Penile cancer 
Perianal and anal 
cancer 
Verrucous carcinoma 
of vulva and penis, 
Buschkc-Lowenstein 
tumors 
Adult T cell leukemia
From: zur Hausen (1991)
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5.2 The Papillomaviruses
The papillomaviruses are small DNA tumour viruses which 
cause mainly benign lesions (papillomas or "warts") in a 
wide variety of animals including man. The benign 
papillomas induced by the viruses usually regress but 
with the synergistic co-operation of cofactors they may 
persist and develop into a carcinoma. Not all 
papillomavirus types are able to sustain this transition 
however, suggesting the involvement of specific viral 
factors. Clearly the papillomavirus system is an 
excellent model for investigation into the multistage 
carcinogenesis process. For example, Cottontail Rabbit 
(Shope) Papillomavirus (CRPV) was the first DNA tumour 
virus to be isolated and characterised (Shope and Hurst, 
1933) . Much of the groundwork on co-carcinogenesis was 
provided by the CRPV model system where virus-induced 
benign papillomas in rabbits were observed to progress to 
carcinomas with the co-operation of chemical cofactors 
(Rous and Friedewald, 1944).
The overall genome organization is similar in 
many of the papillomavirus types (see Fig 5.3.) . The 
viral genome is in the form of a closed double stranded 
circle of 7-8 Kb. The genetic information is encoded in
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one strand only, consisting of large overlapping open 
reading frames (ORFs), the other strand being punctuated 
with stop codons. ORFs often show conservation of 
position and also homology between different virus 
species. Transcription is unidirectional and the 
mRNAs are generated by complex splicing mechanisms 
which juxtapose non-contiguous ORFs leading in some cases 
to fusion proteins.
Research in the papillomavirus field has been hindered to 
a great extent by the lack of an in vitro tissue culture 
system permissive for lytic propagation of the viruses. 
Papillomaviruses only grow in differentiated mucosal or 
cutaneous epithelium at highly specific anatomical sites 
with papillomavirus production thought to be tightly 
coupled to cell differentiation during epithelia 
development. With the advent of molecular biology 
techniques this limitation has been overcome to some 
extent. In particular the ability of some of the animal 
papillomaviruses (notably Bovine Papillomavirus type 1) 
to transform rodent fibroblasts in culture together with 
molecular biology techniques has allowed the assignment 
of functions to discrete areas of the viral genome.
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Fig 5.3. Papillomavirus genome organisation.
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Schematic representation of the genomes of BPV-1 and BPV-4. Major 
viral open reading frames are shown as boxes and functions 
demonstrated for BPV-1 ORFs are described beneath them. Significantly 
BPV-4 lacks an E6 ORF, an important transforming ORF in both BPV-1 
and the oncogenic human papillomaviruses. The above diagram is not 
drawn to scale.
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These functions include promoters, enhancers, the origin 
of DNA replication, plasmid maintenance sequences, 
transforming regions, sequences involved in trans­
activation/repression and the genes encoding viral capsid 
proteins. The viral genome can be classified into three 
general areas:
Early: the genes involved in transformation, plasmid 
maintenance etc.
Late: The viral capsid protein genes.
Long Control Region (LCR): Sequences involved in
transcriptional regulation of the virus.
Although the early region of PVs is involved in 
transformation, recent evidence has suggested that the 
late region may play a significant role in some viruses. 
Thus although the bovine virus BPV-1 suffers no loss of 
transforming potential of established cells when its 
entire late region is deleted (Lowy et al, 1980; Campo 
and Spandidos, 1983) the CRPV genome contains two late 
elements which influence transformation efficiency. The 
first found within the 31 end of the LI ORF is required 
for transformation of keratinocytes, while the second 
element, which localises to the 51 portion of L2 is found 
to have an inhibitory effect on transformation of NIH 3T3 
cells (Meyers and Wettstein, 1991) .
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More recent (and sophisticated) tissue culture techniques 
such as the use of collagen rafts (for example see 
McCance et al 1988) and the nude mouse xenograft system 
(Kreider et al, 1985) have allowed investigation into in 
vitro transformation by the HPVs, but the use of the 
animal papillomaviruses model systems uncovered the 
initial molecular transformation mechanisms of 
papillomaviruses. In addition, certain aspects of 
papillomaviral transformation, such as the role of 
environmental cofactors and host immune response can only 
readily be addressed using animal models where direct 
experimentation is possible. Bearing these points in 
mind, an interesting animal system is bovine 
papillomavirus type 4 (BPV-4) associated carcinoma of the 
alimentary canal in cattle. In this case the cofactors of 
the disease are well characterised (discussed in detail 
later in this introduction) , and the system is providing 
an understanding of host immune response against 
papillomaviruses with a view to anti-papillomavirus 
vaccine development (Jarrett et al, 1991) .
Recently a primate papillomavirus from rhesus monkeys 
(RhPV) has been isolated and characterised. This system 
has exciting possibilities as a model for HPV in 
anogenital carcinoma as RhPV infects the genital tract
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and has been found associated with a range of lesions 
from benign to malignant (Ostrow et al, 1990). In 
addition the in vitro transformation characteristics of 
RhPV (Schneider et al, 1991) are very similar to HPV 16 
(Matlashewski et al, 1987) in that the virus requires a 
cooperating ras oncogene to transform primary cells. DNA 
sequencing has established that both RhPV and HPV-16 have 
very similar genomes (Ostrow et al, 1991) . Although other 
primate PVs have been isolated and characterised (Kloster 
et al 1988; Resza et al, 1991), the similarities between 
RhPV and HPV-16 make the RhPV system the most suitable 
model for the human genital PVs at present.
The papillomaviruses can be characterised into those that 
cause fibropapillomas and those which cause purely
epithelial lesions. The use of in vitro transformation 
assays has demonstrated that in general the
fibropapillomaviruses such as the bovine viruses BPV-1 
(Morgan and Meinke, 1980) and BPV-2 (Jarrett, 1985) 
contain sufficient genomic information to transform
primary cells. The viruses induce a readily detectable 
morphological transformation in culture, and thus much of 
the groundwork in determining the oncoproteins of 
papillomaviruses was provided using the BPV-1 virus (see 
below). In contrast the epithelial papillomaviruses such 
as RhPV and HPV-16 require an activated oncogene (ras)
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for transformation of cultured cells and do not induce 
striking changes in morphology.
5.3 Human Papillomaviruses
The driving force behind the explosion in papillomavirus 
research in the last decade or so comes from the 
observation that papillomaviruses are found to be 
associated with a number of human malignancies. The first 
association of papillomaviruses with a human malignancy, 
reported in 1978, was in the hereditary condition 
Epidermodysplasia verruciformis (EV) which is 
characterised by disseminated skin warts. Squamous cell 
carcinomas arising from these warts were found to harbour 
a papillomavirus: HPV-5 (Orth et al, 1978 and reviewed 
in Orth, 1987) . More recently, the discovery that HPVs 
16 and 18 are aetiologically associated with cervical 
carcinoma greatly encouraged research in papillomavirus 
biology (Durst et al. 1983, Boshart et al. 1984).
Cervical cancer is a major killer of women presenting at 
greater than 500,000 cases per year world-wide and is 
fatal in approximately 45% of these (even with medical 
intervention).
Epidemiological studies on cervical cancers suggest that 
a sexually transmitted agent is involved in the disease.
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For example, it has been known for over a century that 
the disease does not present in nuns or other virgins. 
Another observation is that the sexual partners of men 
whose first wives had cervical cancer are themselves at 
much greater risk of contracting the disease (Kessler
1986). While some controversy exists at the moment as to 
the prevalence of HPV infection in normal tissue (see for 
example Munoz et al, 1988; de Villers et al, 1987), 
biopsies from genital and anal cancers regularly reveal 
the presence of HPV DNA (see for example zur Hausen 
1988) . HPV 16 DNA accounts for around 50% of these 
biopsies, HPV 18 20% and HPV 33 a little less than 10% 
(the remaining 10% being made up of other HPV types) . 
Despite an accumulating body of epidemiological evidence 
for HPV involvement in cervical cancer, some workers have 
expressed concern over the apparently ubiquitous presence 
of HPV in the general population (de Villers et al, 1987) 
and the design of existing epidemiology studies (for 
example Munoz et al, 1988) . Currently the strongest 
evidence for HPV oncogenicity comes from in vitro 
transformation studies.
5.3.1 HPV In Vitro Transformation Studies
There is good evidence from these in vitro studies that 
papillomavirus infections are responsible for the
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premalignant lesions which precede genital carcinoma. The 
development of a typical condyloma morphology in 
heterografted human foreskin tissue infected by HPV 11 
demonstrates that this virus is capable of inducing this 
type of lesion (Kreider et al, 1985) . In vitro 
transformation of primary human keratinocytes with HPV 16 
and 18 has been shown to lead to an "immortalised" 
phenotype, although these transformed cells are not 
tumorigenic in athymic mice, unlike cell lines derived 
from malignant cervical tumours (Durst et al 1987, Pirisi 
et al 1987). Recent work utilising differentiating human 
keratinocytes in a "raft" system has demonstrated that 
HPV 16 transfection leads to the development of a 
morphology sharing histological similarity with cervical 
intraepithelial neoplasia (CIN) (McCance et al 1988).
In general, HPV DNA when detected in non malignant 
tissue is found to be in an episomal state. In HPV 
associated malignancies, however, the viral DNA is found 
integrated in the host genome, often at high copy number 
(Durst et al 1985). Integration of the viral DNA does not 
appear to favour any particular location in the host 
genome, but the integration event usually occurs within 
the 31 end of the El ORF or the 5' end of the E2 
(Schwartz et al 1985) an event which is postulated to 
disrupt the viral regulatory mechanisms (for review see
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Ward et al 1989). There are, however, exceptions to this 
general rule. HPV DNA is has been observed to remain 
episomal in fully developed carcinoma and premalignant 
lesions with integrated viral DNA have been observed (for 
example see Matsukua et al 1989) .
5.3.2 Oncoproteins of The Human Papillomaviruses
When HPV related tumour biopsies are assayed for the 
expression of HPV genes, the E6 and E7 ORFs are found to 
be consistently retained and expressed, implying a direct 
role for these ORFs in maintaining the transformed 
phenotype (Schwartz et al 1985) . The E6 and E7 proteins 
have been shown to contain Cys-X-X-Cys repeats which have 
been shown to mediate zinc binding in HPV 18 and BPV 1 
(Barbosa et al, 1989) . These ORFs are required for the 
morphological transformation of rodent cells in culture 
(Bedel et al 1987) and also in cooperation with activated 
ras for the transformation of primary keratinocytes 
(Matlashewski et al, 1987).
HPV is found to be capable of transforming both human 
primary fibroblasts and keratinocytes (Pirisi et al
1987). The transformed fibroblasts have an extended life­
span but are not immortal while the transformed 
keratinocytes appear almost identical to control cells
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but have an indefinite life-span in tissue culture. The 
expression of both HPV-16 E6 and E7 is required for the 
extended life-span observed in fibroblasts although 
partial extension can be achieved using E6 alone 
(Watanabe et al 1989) (The lack of a quantitative in 
vitro bioassay for HPV E6 has limited work on this gene 
and most of the work on transformation properties of the 
E6 have been performed using BPV-1 and rodent cells). 
Using E7 alone in these assays is ineffective in 
extending the life-span of primary human fibroblasts 
despite the observation that the E7 product is sufficient 
to immortalise and transform rodent cells (Kanda et al
1988) . In primary genital epithelial cells however, both 
E6 and E7 are required for efficient immortalisation (see 
for example Munger et al, 1989a). HPV-16 transformation 
of human cells appears to be different from HPV-16 
transformation of rodent cells as the human cells lack 
morphological characteristics of transformed cells and 
are not tumorigenic in athymic mice.
Once the E7 ORF was identified as a transforming region 
of oncogenic HPVs, workers began to attempt to define a 
function for the E7 protein. A number of domains have 
been assigned to the HPV-16 E7. These include a plOS1^ 3 
binding domain, a casein kinase II (CKII) phosphorylation 
domain and two Cys-X-X-Cys zinc binding domains (Dyson
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et al, 1989; Munger et al 1989b; Barbosa et al, 1990). 
The transformation potential of HPV-16 E7 depends 
primarily on the Rb and zinc binding domains as mutations 
in either of these two domains abolishes transformation 
(Edmonds and Vousden, 1989; Chesters et al, 1990) .
The HPV-16 E7 product has been shown to encode 
transactivation and transformation functions similar to 
those of adenovirus E1A (Phelps et al, 1988) and the 
amino acid sequence of the E7 shows striking sequence 
homology with the pl05Rb binding domains 1 and 2 of the 
Adenovirus E1A protein (see Fig 5.2.). These studies 
demonstrated that E7 is capable of acting as a 
transcriptional transactivator, having the ability to 
transactivate the adenovirus E2 promoter. E7 also shares 
sequence homology with large T antigen of SV40. As 
previously mentioned, both Adenovirus E1A and SV4 0 large 
T have been shown to bind the product of a tumour 
suppressor gene, the retinoblastoma gene product 
(plOS1^ 3) , the depression of which is observed in a number 
of human malignancies. The removal of plOS^ by these 
viruses has been postulated to allow uncontrolled cell 
proliferation (Linzer, 1988). It has been shown that HPV 
16 E7 can bind the Rb product (Dyson et al, 1989) with 
greater affinity than HPV 6b which is associated with 
benign lesions and this may explain the difference in
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malignant potential between these two viruses (Gage et al
1990). The binding of E7 to plOS1^ 3 prevents the cellular 
protein from interacting with its normal targets (Defeo- 
Jones et al, 1991; Rustgi et al, 1991).
The E6 protein of HPV-16, like E7, has Cys-X-X-Cys 
motifs and binds zinc (Barbosa et al, 1989) . In common 
with the BPV-1 E6 (Lamberti et al, 1990), HPV-16 E6 can 
function as a transcriptional activator (Sedman et al,
1991), and a possible oncogenic function is therefore 
transcriptional activation of target cellular genes. The 
HPV-16 E6 also binds a tumour suppressor protein, p53
(Werness et al, 1990) and enhances its degradation by the
ubiquitin dependant pathway (Scheffner et al, 1990). The 
removal of p53 in this way will thus negate its role as a 
suppressor of cell proliferation. Studies on the
relationship between p53 binding and degradation have 
demonstrated that degradation requires E6 sequences which 
are different from those required for complexing and 
transactivation functions (Crook et al, 1991d). In 
addition these studies showed a possible reason for the 
difference in oncogenic potential of different HPV types. 
While the benign HPV types (6 and 11) encode a conserved 
C-terminal p53 binding domain, the N-terminal domain
(shown in these studies to direct p53 degradation) is not 
conserved, explaining why HPVs 6 and 11 show some p53
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binding capacity, but no degradation of the protein is 
detectable. The importance of p53 dysfunction in 
anogenital cancer is demonstrated by the finding that 
while HPV positive carcinomas contain wild type p53 
sequences, in HPV negative lesions mutant p53 is present 
(Crook et al 1991a, 1991b; Scheffner et al, 1990) . In
addition, the presence of wild type p53 is found to 
reduce the ability of E7 and ras to transform baby rat 
kidney cells, while mutant p53 transfection increases 
transformation in this system (Crook et al, 1991c).
In summary there is good experimental evidence for the 
involvement of certain papillomavirus types in anogenital 
malignancies. This involvement is insufficient for cancer 
development, and chemical and physical cofactors 
affecting the infected cell are likely to play an 
important role in the carcinogenesis process. The role of 
environmental cofactors will be considered later in the 
Introduction.
5.4 The Bovine Papillomaviruses
The bovine papillomaviruses are a valuable model for work 
on the human viruses as both systems share a number of 
common factors:
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a) Large number of viral types
b) High lesion specificity of the 
different virus types
c) Examples of malignant progression 
in both systems
d) Proposed role of cofactors
To date six types of Bovine Papillomaviruses (BPVs) have 
been isolated and characterised and these have been 
divided into two subgroups , A & B, on the basis of their 
pathology, site specificity and genome homology (Campo et 
al., 1980, 1981; Campo and Coggins, 1982; Jarrett et al
1984) :
SUBGROUP A: Contains BPVs 1,2 & 5. These viruses cause
fibropapillomas.
SUBGROUP B: Contains BPVs 3,4 & 6. These viruses cause
true epithelial papillomas.
BPV type 4 is found associated with true carcinoma (of
the alimentary canal) in vivo and this virus shows a very 
high target specificity for the mucosal epithelia of the 
alimentary canal, only inducing tumours when injected
into this site and not when innoculated into cutaneous 
epithelia (Campo et al, 1980; Jarrett, 1985) . The virus
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is evolutionarily distinct from the subgroup A viruses as 
demonstrated by the lack of any cross reactivity between 
antisera raised against BPV-4 and any of the subgroup A 
viruses (Jarrett et al., 1980, 1984). Similarly the DNAs
from members of different subgroups do not cross
hybridize in Southern blot analysis, even at low 
stringency.
There are two naturally occurring cancers in cattle which 
have been shown to be associated with papillomavirus 
infection; those of the urinary bladder and upper
alimentary canal.
Early observations showed that extract made from bovine 
cutaneous warts contained a transmissible agent which 
when injected into the bovine bladder could induce 
carcinoma (Olson et al, 1959) . In the reciprocal
experiment, extracts from naturally occurring bladder 
carcinomas had the potential to cause papillomas (of 
skin and vagina) and polyps and fibromas in the bladder 
of experimental cattle (Olson et al, 1965) . These 
experiments were performed before the existence of 
multiple bovine papillomavirus types was established (see 
above), and hence the particular virus involved was not 
established. In addition, bracken fern grazing was shown 
later (by epidemiological analysis) to be a significant
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risk factor in the disease progression (Pamukcu et al, 
1967) but was not considered in the original experiments. 
Experimental animals fed bracken fern develop bladder 
tumours indistinguishable from those observed in field 
cases (Price and Pamukcu, 1968). Bracken fern is known to 
contain carcinogens, mutagens (Evans I.A. et al, 1982) 
and immunosuppressants (Evans W.C. et al., 1982) . More
recent experimentation by Campo and Jarrett has addressed 
both the viral type involved and the cooperative effects 
of bracken grazing in long term experiments. In these 
studies bracken fed cattle were innoculated with BPV-2 
and developed cutaneous warts at the site of injection. 
In addition, the animals (which were chronically 
immunosuppressed due to the bracken diet) developed 
bladder carcinomas indistinguishable from field cases 
(Campo and Jarrett, 1986; MS Campo, personal 
communication). Bladder carcinoma did not develop in 
animals with a bracken-free diet which developed skin 
warts only. Animals which did not receive virus but were 
fed bracken did however develop tumours of the bladder 
and subsequent analysis revealed that these tumours 
contained viral DNA, which may have been activated by 
bracken induced immunosuppression. In these experiments 
Southern blot analysis established that 69% of the 
induced bladder carcinomas contained BPV-2 DNA while 4 6% 
of field cases were positive for BPV-2 (or the closely
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related BPV-1 virus). This frequent association of viral 
genomes with these tumours strengthens the hypothesis 
that there is a viral component in the disease 
progression.
BPV-4 has been shown to be the causative agent of 
papillomatosis of the alimentary canal in cattle (Campo 
et al, 1980). The benign papillomas usually regress, but 
in cattle of the West Highlands of Scotland, which 
continuously ingest bracken fern, the papillomatosis is 
more widespread and persistent, showing a much greater 
incidence of progression to carcinoma (Jarrett et al., 
1978; Jarrett, 1981). A schematic outline of the disease 
progression is shown in Fig 5.4. Immunosuppression and 
widespread papillomatosis have been reproduced
experimentally in animals using the immunosuppressant 
azathioprine and virus alone (Campo and Jarrett, 1986). 
Scarification of bovine epithelium followed by infection 
with BPV-4 leads to the development of benign papillomas 
which regress with time due to the host immune response. 
Immunosuppressed animals given virus had much more 
widespread and persistent papillomatosis.
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Fig 5.4. Model for BPV-associated carcinoma in vivo.
Interaction Between BPV-4 and Bracken Grazing in the 
Production of Carcinomas in W.Hiahland Cattle.
BPV-4
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Schematic representation of BPV-4 associated carcinoma of the 
alimentary canal in cattle. Viral infection gives rise to benign 
papillomas which usually regress. In the presence of chemical 
cofactors (bracken fern) these lesions may progress to carcinoma 
however. The viral DNA, while present in the papillomas, is 
undetectable in the resultant carcinomas suggesting that the virus 
has a role in the initiation of the disease but is not required for 
the maintenance of malignancy.
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Development of alimentary canal carcinoma was found to
occur in experimental animals which were given BPV-4 and 
fed on a diet of bracken confirming the observations of 
field cases. Clearly this system is an excellent model 
for the study of multistage carcinogenesis.
An interesting observation is that while viral DNA is
detectable as high copy number episomes in benign 
lesions, it is absent in both naturally occurring and
experimentally induced carcinomas (Campo et al., 1985).
The viral DNA is therefore required for the initiation 
but not the maintenance of the transformed state. The 
"Hit and Run" action of BPV-4 is consistent with the
mechanism postulated for transformation by herpes simplex 
virus, human cytomegalovirus and Adenovirus where viral 
sequences are not consistently maintained or expressed in 
transformed cells (for review see Macnab, 1987). This 
situation is in contrast with the human papillomaviruses 
HPV 16 and HPV 18 which are involved in carcinoma of the 
cervix. In this case the viral genome is generally found 
to be episomal in pre-malignant lesions and in an 
integrated state in the carcinomas (Durst et al., 1985;
Schwartz et al., 1985). The fidelity of loss of BPV-4 DNA 
in alimentary canal carcinoma is perhaps the most 
interesting aspect of BPV-4 transformation biology and 
will be discussed in some detail later in this thesis.
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5.4.1 Bovine Papillomavirus Type 1 Transformation Jn 
Vitro
The discovery that BPV-1 (or its naked DNA) could 
efficiently transform rodent fibroblasts in vitro was a 
major breakthrough in papillomavirus research. Although 
recently research has shifted largely to the oncogenic 
human papillomaviruses HPV 16 and HPV 18, much of the 
groundwork in papillomavirus transformation biology was 
performed using BPV-1 transformation of rodent 
fibroblasts. The oncoproteins of BPV-1 have been 
identified as the E5 and E6 (Schiller et al, 1984, 1986;
Yang et al, 1985; Schlegel et al, 1986).
The major transforming ORF of BPV-1 appears to be the E5 
which encodes a 44 amino acid protein which exists as a 
transmembrane dimer (Schlegel and Wade-Glass, 1987). The 
protein contains two cysteine residues which are 
important for dimerisation, but mutation of these 
residues does not totally abolish transformation 
potential, suggesting that dimerisation is not crucial 
for this property (Horwitz et al, 1988) . The E5 is 
required for efficient transformation of C127 cells and 
can transform in the absence of other viral ORFs (see for 
example Burkhardt et al 1987). The protein is found to be
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associated with the plasma membrane and Golgi apparatus 
(Burkhardt et al, 1989). Rawls and co-workers have 
demonstrated that DNA synthesis is induced in quiescent 
contact inhibited C127 cells when cloned BPV-1 E5 is 
introduced (Rawls et al, 1989). Microinjection of 
synthetic E5 peptides into the nucleus of quiescent C127 
cells will also produce this effect, while a cytoplasmic 
injection will not (Green and Lowenstein 1987), a result 
seemingly at odds with the observed cytoplasmic location 
of the E5 protein (Burkhardt et al, 1989). The ability of 
E5 to stimulate DNA synthesis has been shown to reside in 
the terminal third of the protein (Green and Lowenstein,
1987) while the hydrophobic core of the protein increases 
the efficiency of the induction of DNA synthesis but can 
be replaced by a random sequence of hydrophobic amino 
acids (Horwitz et al, 1989) suggesting that a 
transmembrane localisation may be important. E5 has been 
shown to affect the activity and metabolism of the 
receptors for epidermal growth factor (EGF) and colony 
stimulating factor 1 (CSF-1) (Martin et al, 1989). It has 
been shown to interact with another receptor , the 
platelet derived growth factor (PDGF) receptor. The 
observation that treatment of quiescent cells with PDGF 
results in DNA synthesis and that PDGF receptor 
activation occurs following infection (Petti et al, 1991) 
supports the hypothesis that a principal role of the E5
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protein is to directly bind and activate this receptor. 
The E5 binding to PDGF receptor may be via the region of 
homology between the E5 of fibropapillomaviruses and the 
PDGF molecule (Petti et al, 1991) . BPV-1 E5 has also 
been shown to bind a 16Kd cellular protein, the binding 
of which may be important for the process of 
transformation (Goldstein and Schlegel 1990) . The 16kd 
cellular protein shares the physical properties of a 
protein identified as a structural component of gap 
junctions (Finbow et al, 1990) and it is feasible that 
removal of the gap junction protein and subsequent 
disruption of intercellular communication may be a major 
role of the BPV-1 E5 although this has yet to be 
demonstrated.
The BPV-1 E6 has also been defined as a transforming 
ORF; expression of E6 from a strong heterologous promoter 
can induce focus formation and anchorage independence in 
C127 cells while mutations in E6 reduce the 
transformation efficiency of the whole viral genome 
(Schiller et al, 1984) . BPV-1 E6 contains Cys-X-X-Cys 
Zinc binding domains (Barbosa et al, 1989) and has been 
proposed to act as a transcriptional activator (Lamberti 
et al, 1990) . In this respect one function of the BPV-1 
E6 may be to transcriptionally activate crucial cellular 
genes as part of the transformation programme.
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The E7 region of BPV-1 partially overlaps the E6 with the 
E6/E7 region being complex and potentially encoding a 
number of products. Some dispute exists as to whether 
BPV-1 E7 mutation has any effect on transformation 
although recent work has suggested that both the E6 and 
E7 ORFs are required for full transformation of C127 
cells by BPV-1 (Neary and DiMaio, 1989). The E7 proteins 
of both BPV-1 and the benign human HPV-8 lack independent 
transformation potential (Iftner et al, 1988) possibly 
because the retinoblastoma binding domain and the CKII 
site present in HPV-16 E7 are missing (Iftner et al, 
1990). It should be noted however, that CRPV E7 lacks the 
CKII domain but is still essential for tumorigenesis in 
vivo (Brandsma et al, 1991) . In addition the CKII sites 
of HPV-16 E7 have been shown to be less critical than the 
Rb binding domains and Cys-X-X-Cys motifs (Watanabe et 
al, 1990; Storey et al, 1990).
5.4.2 Bovine Papillomavirus Type 4 Transformation In 
Vitro
Early attempts to investigate the transforming properties 
of BPV-4 in vitro used established murine NIH-3T3 and 
C127 fibroblasts These studies showed that BPV-4 encoded 
all the required information to transform NIH-3T3 cells
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to a full malignant phenotype at a frequency of focus 
formation similar to BPV-1 (Campo and Spandidos, 1983). 
The transformation of C127 cells required low cell 
density or the presence of the tumour promoter TPA (Smith 
et al, 1987; Smith and Campo 1988). TPA has been shown to 
cause a disruption of intracellular communication (Murray 
and Fitzgerald, 1979), and these observations suggest 
that the presence of neighbouring normal cells may 
inhibit the manifestation of the transformed phenotype in 
this cell type. As TPA induces a host of cellular 
changes, however, the precise mechanism by which the 
drug enhances transformation is unclear. Serum 
stimulation was found to increase transformation by BPV-4 
and this suggests that growth factors present in the 
serum may allow manifestation of the transformed 
phenotype. The physical state of the input DNA was shown 
to be important, as circular BPV-4 genome was less 
capable of transformation; linear genome (interrupting 
the El ORF) or a cloned 3.6 kb fragment containing the 3' 
half of the LI, E7, E8 and the 51 half of the El ORFs 
were found to be effective. Interruption of the El ORF 
may be the crucial factor here, as functions which 
negatively control DNA replication and transcription have 
been mapped to the El and E2 ORFs respectively in BPV-1 
(Berg et al, 1986; Roberts and Weintraub, 1986; DiMaio, 
1986; Lambert et al, 1987) and similar functions may
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exist in BPV-4.
BPV-4 DNA is absent from the majority of transformed C127 
clones, a situation similar to that found in the in vivo 
cancers.
The experiments using C127 cells have provided
interesting data concerning which areas of the BPV-4 
genome may be important in transformation and
highlighting some of the cofactors and cellular responses 
which may play a role in this system. The cell type 
being employed is quite remote from the natural host cell 
of the virus, however, being established, fibroblastic 
and of a different species. A more relevant system would 
be the use of primary bovine cells in similar
experiments. Initial observations using primary bovine 
fibroblasts have shown that BPV-4 is capable of
transforming these cells only in the presence of an 
activated ras oncogene, and while the cells appear 
morphologically transformed, they are unable to induce 
tumours in athymic mice (Jaggar et al., 1990) .
Recent work has shown that bovine epithelial cells from 
the palate can be infected in vitro with BPV-4 and when 
placed in the renal capsule of athymic mice will produce 
virus-producing papillomas with identical morphology to
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those induced in cattle (Gaukroger et al., 1989). This
system obviously has exciting possibilities for research 
into BPV-4 transformation biology.
5.5 Environmental Factors in Papillomavirus Associated 
Malignancies
The long latency period of papillomavirus associated 
carcinomas (notably HPV in anogenital carcinoma, and 
BPV-4 in alimentary canal carcinoma) implies that the 
dysfunction of a number of crucial proto-oncogenes or 
tumour suppressor genes must occur before the onset of 
carcinoma, and it is likely that environmental factors 
play a role in the disease progression. The major 
environmental cofactors in BPV-4 associated alimentary 
canal carcinoma have been identified as the chemicals 
found in bracken fern (outlined above) although the 
precise bracken constituents required for cooperation 
with the virus have not yet been identified. In other 
papillomavirus systems the cooperation of environmental 
carcinogens is less clear.
Historically, the first observations that PVs could 
cooperate with chemical cofactors in carcinogenesis came 
from work on CRPV in the 1930s and 40s. In this system it 
was observed that when tar and/or methylcholanthrene
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were administered in conjunction with the virus the rate 
of progression of papillomas to carcinomas was greatly 
accelerated from that observed with either virus or 
chemicals alone (see Rous and Friedewald, 1944).
Epidemiological studies on human cervical carcinoma has 
suggested that several different cofactors may be 
involved in disease progression. The major chemical 
cofactor suggested to play a role in this disease is 
cigarette smoking, first proposed following a study by 
Winklelstein (1977) and subsequently confirmed by other 
epidemiologists (the evidence for this association has 
been reviewed in Winklestein, 1990). Further 
epidemiological studies have also identified smoking as a 
significant risk factor in anal cancer (for example Holly 
et al, 1989) and the progression of laryngeal papillomas 
to carcinoma (Lindenberg et al, 1986) . Using the 
Salmonella typhimurium mutagenicity test, specific 
fractions from cigarette smoke have been shown to be 
mutagenic (Keir et al, 1974), these fractions may 
accumulate in the cervix as the cervical mucus of smokers 
has been shown to be mutagenic by this assay (Holly et 
al, 198 6). Indeed, some non-smokers have mutagenic 
cervical mucus (Holly et al, 1986) which may be the 
result of passive smoking (Slattery et al, 1989) or other 
environmental mutagens. Another significant consequence
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of cigarette smoking is the impairment of the immune 
response, including a reduction in the activity of both 
natural killer and T cells, and a significant reduction 
in immunoglobulin concentration (reviewed in Holt, 1987) .
Other chemical cofactors implicated in cervical carcinoma 
include oral contraceptives (see for example Beral et al,
1988) which may act by activating the glucocorticoid 
responsive element in the HPV genome, increasing viral 
transcription (Gloss et al, 1987) which it turn has been 
shown to increase transformation in an in vitro assay 
(Durst et al, 1989). Also, in one individual dietary 
factors, (namely fried pork intake), were shown to cause 
prolonged HPV-11 associated papilloma growth of the 
urinary tract (Schneider et al, 1990), which may be due 
to the elevated mutagenic potential of human urine 
following fried pork consumption (Baker et al, 1982).
Both epidemiological studies and in vitro models have 
demonstrated that chronic irritation and/or inflammation 
may contribute to carcinogenesis. Epidemiological work on 
anal cancer identified these factors as a significant 
risk (Holly et al, 1989) and cervical deformation from 
surgical lacerations during child birth were found more 
frequently in women presenting with cervical carcinoma 
(Stanimirovic et al, 1990). Mechanical irritation of the
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skin has been found to activate latent genomes of the 
rodent Mastomys nataliensis papillomavirus (MnPV) 
(Seigsmund et al, 1991) confirming early observations by 
Rous and Beard (1935) that inflammation resulting from 
the use of chemical irritants encouraged the malignant 
conversion of CRPV induced papillomas.
Another risk factor in certain papillomavirus associated 
tumours is radiation. Patients with the inherited disease 
epidermodysplasia verruciformis (EV), a skin condition 
characterised by multiple papillomavirus induced lesions, 
have a high chance of developing carcinomas in sun 
exposed areas, implicating UV radiation as a cofactor 
(Orth 1987). Radiotheraphy has also been shown to elevate 
the risk of malignant conversion of laryngeal papillomas 
(Lindeberg et al, 1986).
The ability of viral genomes to cooperate with chemical 
promoters has been considered using the chemical TPA in 
in vitro model systems. Viral replication has been shown 
to increase for a number of virus types including BPV-1 
(Amtmann and Sauer, 1982) and BPV-4 (Smith et al, 1987; 
Smith and Campo, 1988). Also of relevance is the 
observation that gene expression can be upregulated in 
the presence of TPA as demonstrated for the ras oncogene 
(Dotto et al, 1985), and for BPV-1 (Amtmann and Sauer,
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1982), BPV4 (Smith et al, 1987) and HPV 18 (Gius and 
Laimins, 1989) viral genes. In addition TPA presence has 
been shown to increase the transforming potential of BPV- 
4 (Smith and Campo, 1988) and BPV-1 (Tsang and Stich, 
1988) . The viral replication and transcriptional 
activation phenomena may be as a result of the ability of 
TPA to activate the transcription factor API (Angel et 
al, 1987). Levels of expression of papillomaviral 
oncoproteins may determine the efficiency of 
morphological transformation by these genes as shown for 
HPV-16 (Lees et al, 1990) and proposed for BPV-4 (Jaggar 
et al, 1990). The relationship between efficiency of in 
vitro transformation and levels of BPV-4 gene products 
will be considered in more detail later in this thesis.
Another consequence of TPA treatment may be the 
disruption of junctional communication. Co-culturing 
experiments have shown that normal cells have an 
inhibitory effect on the growth of co-cultured 
transformed cells, an effect which is abolished by TPA 
treatment (Sivak and van Duuren, 1970) . TPA has been 
shown to inhibit junctional communication in in vitro 
studies by a number of workers (for example see Newbold 
and Amos, 1981) . More recent work on mouse skin in vivo 
has suggested that TPA treatment may serve to disrupt the 
junctional communication patterns of the skin leading to
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inappropriately formed communication compartments (Kam 
and Pitts, 1988).
The observation that papillomaviruses can cooperate with 
TPA would suggest that the viral genomes can act as 
initiating agents. The possibility that papillomaviruses 
could also act as promoters has not been addressed by 
many workers and indeed experiments using the rodent 
papillomavirus MnPV demonstrated that this virus had no 
observable capacity to cooperate with DMBA (Amtmann et 
al, 1987) . It seems plausible, however that the 
proliferative stimulus afforded by papilloma production 
in vivo may serve to amplify a population of cells which 
have been initiated by environmental mutagens and in this 
sense the papillomaviral genome could function as a 
classical tumour promoter. Indeed experiments using BPV-4 
have demonstrated that the virus can cooperate with both 
initiators and tumour promoters in vivo. In these 
experiments fetal bovine palate tissue was infected with 
BPV-4 and subcutaneously implanted in nude mice. The 
animals then had slow releasing TPA or DMBA pellets 
implanted subcutaneously at different sites, and in both 
cases a carcinoma developed from the infected bovine 
tissue (25% and 59% of animals respectively) (J.M. 
Gaukroger, personal communication) , a result not observed 
in control animals implanted with uninfected tissue and
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considerably higher than the spontaneous carcinoma 
development observed in animals which received infected 
tissue but no chemical implant of either kind (less than 
2%) (Gaukroger et al, 1991) . These results suggest that 
BPV-4 can act as a promoter on a population of cells 
which have been chemically initiated. Indeed the 
observation that BPV-4 DNA is absent from carcinomas in 
vivo would suggest that either the viral genome acts as 
an initiator by causing host DNA damage before the viral 
genome is lost (for example as a DNA amplifying agent as 
demonstrated by Smith and Campo, 1989) or as a promoter 
of initiated cells during viral presence. The latter 
hypothesis will be considered in the Results and 
Discussion section of this thesis.
5.6 Summary; Cellular Targets in Papillomavirus 
Associated Malignancy
In summary, a variety of PV types have been implicated 
in multistage carcinogenesis on both epidemiological 
evidence and on the basis of their transformation 
potential in vitro. The associated long latency of these 
tumours implies that papillomaviruses do not contain 
sufficient genetic information to induce these tumours on 
their own, and indeed activated oncogenes have been found
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to be involved in a significant number of cases (e.g. 
c-Ha-ras and c-myc frequently found in HPV associated 
anogenital cancer and Ha-ras 1 activation in BPV-4 
associated alimentary canal carcinoma). Further evidence 
for the role of oncogene activation in these systems are 
the requirement for activated ras cooperation for 
transformation of primary cells in vitro, and the 
discovery of the suppressor of HPV transformation on 
chromosome 11.
In vitro assays have identified the oncoproteins of some 
papillomaviruses, notably the E6 and E7 proteins of the 
oncogenic HPV types 16 and 18. The targets of these 
oncoproteins are the tumor suppressor gene products 
plOS1^ 5 and p53 which are bound (EV-plOS1^ 3) or bound and 
degraded (E6-p53 complex). The dysfunction of these 
regulatory proteins by papillomaviral oncoprotein binding 
is postulated to lead to deregulated cell division, one 
factor in the multistage carcinogenesis process. The 
importance of disabling these regulatory proteins in 
anogenital cancer is shown by the observation that HPV 
negative lesions have alterations in the genes for these 
proteins or altered patterns of their expression (Wrede 
et al, 1991) .
The interaction of environmental cofactors is likely to
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play a crucial role in the PV associated malignancies as 
the primary lesion caused by papillomavirus infection is 
benign, and in the absence of cofactors will usually 
regress. These cofactors have been identified in BPV-4 
associated alimentary canal carcinomas (the mutagens, 
carcinogens and immunosuppressants present in bracken 
fern) and in sufferers of the rare condition EV (UV 
radiation exposure) , although the cofactors in HPV 
associated anogenital carcinoma are less well understood.
Thus although recent studies have demonstrated the direct 
cellular targets of papillomaviral oncoproteins, an 
examination of the role of contributing factors (such as 
environmental mutagens, host immune status etc) should 
provide a deeper understanding of the papillomavirus 
associated tumours as a multistage progression.
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5.7 Aims of Ph.D. Research
The effects of the products of CRPV, BPV-1 and the 
oncogenic human papillomaviruses in in vitro assay 
systems have been characterised in many laboratories over 
the last decade (as outlined in this Introduction) and 
the ORFs involved in transformation and immortalisation 
have been identified. Initial studies on BPV-4 have 
indicated only which general regions of the viral genome 
may encode transformation functions. The aims of the work 
presented in this thesis were to determine more precisely 
the viral genes with transformation potential (both alone 
and in cooperation with other ORFs) and to characterise 
the phenotype of cells transformed by these genes. In 
addition, it was envisaged that the cellular localisation 
of these gene products would be determined, in order to 
provide an initial indication of possible interaction 
between viral proteins and cellular structures. The 
multifactorial nature of BPV-4 transformation in vivo 
would also be considered by the use of a bracken mutagen, 
quercetin, in cooperation with BPV-4 genes in an in vitro 
transformation assay.
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6. Materials and Methods
6.1 General Laboratory Practice
6.2 Solutions and Reagents
Chemicals were of analytical grade where possible and 
were weighed out to an accuracy of O.Olg in plastic boats 
using a Mettler PM3000 balance. Chemical suppliers were 
BCL, BDH Ltd., Gibco-BRL Ltd., Pharmacia or the Sigma 
Chemical company.
Water was distilled using a MilliQ Reagent Grade Water 
Purification System (Millipore).
Phenol, "phenol/chloroform" and chloroform were prepared 
and stored as recommended in Sambrook et al (1989)
6.2.1 Solution Preparation
Chemicals were dissolved by stirring at room temperature 
(or 65°C if necessary) using a magnetic stirring bar. 
Solutions were adjusted to correct pH using appropriate 
acids and bases and the pH was monitored using a Tris 
electrode Kent 7045/46 (Russell). Solutions were 
sterilised by autoclaving in a pressure cooker for 20 
mins. Heat labile solutions were sterilised by passing 
through a Millipore 0.22nm "Acrodisc" filter.
6.3 Materials
6.3.1 Enzymes
Restriction enzymes were purchased from Pharmacia and 
came complete with appropriate buffer.
Calf Intestinal Phosphatase (CIP) was purchased from BCL. 
T4 DNA Ligase was purchased from BRL.
Lysozyme, proteinase K and ribonuclease A (RNase A) were 
published from Sigma.
6.3.2 Radiolabelled Compounds
Radioisotopes were obtained from Amersham International 
pic.
[35S]dATPaS (cat No. SJ1304)
(Specific activity>lllT Bqmmol”1)
[a-32-P]dCTP (cat No. PB10205)
(Specific activity>37T Bqmmol” )^
6.3.3 Plasticware
Nunclon tissue culture flasks and 1.9ml ampoules for 
storage of cells in liquid nitrogen were obtained from 
Gibco.
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Petri dishes, disposable pipettes and polypropylene tubes 
were obtained from Falcon.
Sterile universal tubes were obtained from Millipore.
1.5ml microcentrifuge tubes were obtained from Sarstedt. 
Disposable micropipette tips were obtained from 
Labsystems Group.
6.3.4 Molecular Biology Kits
A number of molecular biology techniques were performed 
using reagents supplied in kit form. Manufacturer's 
instructions for storage and use were adhered to 
throughout unless stated otherwise.
Random Prime DNA Labelling kits were obtained from BCL. 
Geneclean kits were obtained from Bio-101 Inc. 
"Sequenase" DNA sequencing kits were obtained from
USB.
"VectorStain" Alkaline Phosphatase detection kits were 
obtained from Vector Laboratories.
6.3.5 Plasmids
All plasmids were propagated in E.coli strain DH5-atm 
competent bacteria. Generation of new plasmids will be 
discussed in the results section.
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pSV2neo is a PBR322 derived vector encoding the neomycin 
(neo) resistance gene of Tn5 cloned under the control of 
SV40 early promoter with 3'poly(A) site (Southern and 
Berg, 1982).
pZipneoSV(X)1 (pZipneo) is a Mo-MuLV derived vector with 
a unique BamHI cloning site and a selectable neo 
resistance gene (Cepko et al, 1984).
pT24 is a pUC13 derived plasmid containing the activated 
human c-Ha-ras oncogene from the T24 human bladder 
carcinoma line originally cloned in pBR322 (M. O'Prey 
unpublished results, Santos et al, 1982).
pBV4Bl is the whole BPV-4 genome cloned in the BamHI site 
of pAT153 (Campo and Spandidos, 1983).
pSVE8+E7+ comprises the intact E7 and E8 ORFs (XhoII 
fragment) cloned as a 2.0Kb fragment (nt 6487-1274) in 
the BamHI site of pSV2neo (Jaggar et al, 1990).
pSVE8+E7- is as pSVE8+E7+ but the cloned fragment has a 
200bp EcoRl fragment deleted in the 3'third of E7 (Jaggar 
et al 1990) see Fig 5.2.
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pZipE8+E7+ as pSVE8+E7+ but the fragment is cloned in 
pZipneoSV(X)1 (Jaggar et al, 1990).
pZipE8+E7“ as pSVE8+E7“ but the fragment is cloned in 
pZipneoSV(X)1 (Jaggar et al 1990).
pZipE2 contains the E2 ORF of BPV-4 (nt 2741-4334) cloned 
in the pZipneoSV(X)1 vector (Jaggar et al 1990).
pZipE7 contains the E7 ORF (nt 652-1250) of BPV-4 cloned 
in pZipneoSV(X)1 (G.J. Grindlay, unpublished).
pZipE8 contains the E8 (nt 236-458) ORF of BPV-4 cloned 
in pZipneoSV(X)1 (G.J. Grindlay, unpublished).
pJ4£2l6.E6 was a gift from Lionel Crawford. The plasmid is 
a pBR322 derivative . The vector has the HPV-16 E6 7 00bp 
fragment cloned into the BamHl/Bglll site being driven by 
the Mo-MULV LTR and containing the SV40 T poly (A) site. 
(Storey et al, 1987).
A diagrammatic map of each plasmid used is given in Fig 
6.1. for BPV-4 containing plasmids and in Fig 6.2. for 
the pJ4£2l6.E6 and pT24 plasmids.
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Fig 6.1. Structure of BPV-4 containing vectors.
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Notes: BPV-4 recombinant plasmids. pBV4 contains the full viral
genome cloned in the BamHI site of pAT153 (Campo and Coggins, 1982). 
pSVE8+E7+ and pZipE8+E7+ contain the XhoII fragment (nt 6487 to 1274) 
cloned in the BamHI site of pSV2neo and pZipneoSV(XI) respectively, 
the pSVE8+E7“ and pZipE8'rE7” plasmids contain the same fragment but 
with a deletion spanning nt 905 to 1138 (symbolised by an inverted 
triangle) . pZipE2, pZipE7 and pZipE8 contain the E2, E7 and E8 ORFs 
of BPV-4 cloned in the pZipneoSV(XI) vector respectively. The filled 
arrowheads indicate the BPV-4 LCR (nt 7000 to 300) . Vector and insert 
sequences are not drawn to scale. SV=SV40 promotor; LTR=MoLV LTR; 
A=poly(A) site; neo=g418 resistance gene; SVori= SV40 DNA replication 
origin; p ori=plasmid DNA replication site. The polyadenylation site 
in pZipE2 is the early poly(A) site of BPV-4. Numbers refer to BPV-4 
map coordinates.
E=EcoRI restriction enzyme site.
Fig 6.2. Structure of pJ4£2l6.E6 and pT24 vectors.
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N o te s :  A) structure of the HPV-16 E6 containing plasmid pJ4£2l6.E6. A 
map of the HPV genome is shown (ORFs are represented by closed boxes) 
and below it a diagramm where the regions of the genome present in 
this construct are represented by solid bars. MCS=multiple cloning 
site; SD=splice donor site; SA=splice acceptor site. The diagram is 
not to scale and is adapted from Storey et al, 1988. B) Structure of 
pT24 plasmid. The 6.6kb insert was isolated from a human bladder 
carcinoma (T24) and was originally cloned in pBR322 (Santos et al, 
1982) and transferred to pUC13 (M. O'Prey, unpublished results). MCS- 
multiple cloning site. Plasmid and vector sequences are not to scale.
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6.3.6 Other materials
DNA Markers: HindiII digested bacteriophage lambda
Haelll digested bacteriophage PX174
Biodyne nylon membrane for use in Southern transfers was 
obtained from Pal Process Filtration Ltd.
X-Omar XAR5 film for autoradiography was obtained from 
Kodak.
6.4 General Methods
Phenol/Chloroform Extraction: Removal of contaminating
protein from DNA-containing solutions was performed by 
the addition of an equal volume of phenol/chloroform 
followed by vortex mixing for 15 secs. The tube was then 
centrifuged for 5 mins in a microfuge and the aqueous DNA 
containing phase transferred to a fresh tube. Care was 
taken not to transfer any of the interphase in the 
process.
Ethanol Precipitation: DNA in solution was precipitated
with salt and ethanol to facilitate concentration of 
dilute solutions or a change of sample buffer. To the 
solution 1/10 volume of 3M NaOAc pH5.2 and 2 volumes of
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absolute ethanol were added. The sample was vortexed and 
allowed to stand on ice for lOmins before centrifugation 
in a microfuge at 4°C for 15-30 mins. The supernatant was 
then carefully removed and the pelleted DNA washed free 
of salt by adding 1ml of 70% ethanol and recentrifuging 
for lOmins. The supernatant was carefully removed, excess 
solvent drained onto a paper towel and the DNA pellet 
dried in a freeze drier before being resupended in a 
suitable volume of TE.
6.5 Centrifugation
Small samples of less than 1.5ml were routinely 
centrifuged in an Eppendorf 5414 bench-top microfuge. The 
pelleting of small bacteria samples or trypsinised cells 
in plastic universal tubes was performed in a MSE Mistral 
4L low speed centrifuge. Large volume, low speed 
centrifugation was performed in a Sorvall RC-5B 
centrifuge. Ultracentrifugation, as used in CsCl density 
gradient purification of plasmids, was performed using a 
Kontron Instruments Centrikon T-2070.
6.6 Handling of Bacteria
Work with bacteria was carried out in a category 1 
containment work area. Contamination of cultures was
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avoided by following standard microbiological handling 
techniques as described in Sambrook et al (1989) .
6.6.1 Bacterial Media and Antibiotics
Luria Broth (L-broth) : 1% (w/v) bactotryptone (Difco)
0.5% (w/v) yeast extract (Difco) 
170mM NaCl
L-Agar: L-broth containing 1.5% agar
Superbroth Solution A: 1.33%(w/v) bactotryptone 
2.66% (w/v) yeast extract 
0.44% (v/v) glycerol
Solution B: 0.54M KH2P04
0.27M K2HP04
Solution A and B are autoclaved separately. Superbroth is 
made by adding lOOmls of solution B to 900mls of solution 
A.
SOC: 2% (w/v) bactotryptone
0.5%(w/v) yeast extract 
lOmM NaCl 
2.5mM KC1
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lOmM MgCl2 
lOmM MgS04 
20mM glucose
If required, ampicillin was added at a concentration of 
50 mg/ml to growth media following autoclaving and 
cooling to 50°C. Ampicillin was kept as a stock solution: 
50mg/ml in dH20 stored at -20°C until use.
6.6.2 Preparation of DNA for cloning
Vector DNA was prepared for cloning as follows. 50ug of 
vector DNA was digested for 4 hours at 37°C with 200 U of 
appropriate restriction enzyme in a volume of 200 fll. The 
vector was then incubated at 37°C twice for 30 mins with 
1U of calf intestinal phosphatase. Proteinase K was added 
to a concentration of 100 jig/ml and the sample incubated 
at 37°C for a further 15 mins. The now cut, 
dephosphorylate and deproteinased vector was phenol 
chloroform extracted, ethanol precipitated and then 
resuspended to approximately 200 ng/ml in TE pH8.0 and 
stored at -20°C.
Insert DNA was prepared as follows. Parental plasmid was 
restricted with appropriate restriction enzyme(s) and run 
on a 1-3% agarose gel. Fragments to be cloned were
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identified by size comparison with marker DNA and cut out 
of the gel as a discrete band. The DNA was extracted from 
this band using the "Geneclean" tm kit (Bio-101 Inc.) 
using manufacturer's instructions. This method involves 
melting the agarose at 55°C in the presence of a high 
concentration sodium iodide which acts as a chaotropic 
agent. The DNA in the melted agarose is bound to a silica 
matrix at this high salt concentration. The silica matrix 
and bound DNA are pelleted in a microfuge and washed 
several times in an ice cold salt/ethanol solution before 
the matrix is pelleted and the DNA eluted in a low salt 
solution. Approximately one fifth of the extracted DNA 
was then checked for size and purity by running on a 1% 
agarose minigel.
6.6.3 Ligation of Insert and Vector DNA.
Linear vector DNA (typically 100-200 fmol) was mixed with 
a threefold excess of insert DNA, ethanol precipitated 
and resuspended in 8 |il of TE pH8.0. In order to denature 
any self annealed cohesive ends the mixture was heated to 
65°C for 5 mins then annealing was allowed to occur by 
incubating the mixture on ice for 1 hour. To the annealed 
mixture 1 p.1 of 10 X ligase buffer (0.66M Tris.Cl pH 7.6, 
0.1M MgCl2 and lOmM DTT) , 0.5 Hi of 20 mM ATP and 0.5 U 
of T4 DNA ligase were added and the mixture was
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incubated for 18-20 hrs at 15°C.
6.6.4 Transformation of Bacteria
All plasmids were propagated in the E.coli strain DH-5a 
(tm) supplied as frozen stocks by BRL and stored at -70°C 
until use. Bacteria were transformed as per manufacturers 
instructions. After thawing on ice 50 p.1 of bacteria were 
added to a polypropylene Falcon 2059 tube on ice and l|il 
of ligation reaction previously diluted 1 in 5 with TE 
pH7.4 was added and mixed by gently moving a pipette tip
through the mixture. The tube was left on ice for 30 mins
before being heat shocked for 45 seconds at 42°C. The 
tube was returned to ice for 2 mins then 950 |ll of SOC 
medium was added. The tube was then transferred to a 
shaking 42°C incubator (275 rpm) for 1 hour. Following 
this the bacteria were spread on an L-agar plate 
containing appropriate antibiotics and transformants 
selected by incubating the plate overnight at 37°C.
6.6.5 Small Scale Preparation of Plasmid DNA
Transformant colonies were screened to identify correct 
clones by performing a small scale DNA extraction as 
described by Birnboim and Doly (1979) . Colonies were 
picked and grown overnight in 5 ml cultures in sterile
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universal tubes. 1.6mls of the culture was then used to 
prepare DNA, the remainder being stored at 4°C. The 
bacteria were pelleted by centrifugation for 2 mins in a 
microfuge. The supernatant medium was poured off and all 
traces of medium removed by a micropipette. The pellet 
was resuspended in 100^ .1 of Solution I (25 mM Tris, lOmM 
EDTA pH8.0, 50 mM glucose and 4 mg/ml lysozyme) and left 
at room temp for 5 mins. 200 |il of freshly prepared 
Solution II (0.2N NaOH, 1% SDS) was then added and the 
tube was inverted rapidly to mix the contents and then 
placed on ice for 10 mins. 150 |il of Solution III (3M 
KOAc pH4.8) was added, the tube shaken rapidly and then 
returned to ice for 10 mins. The chromosomal DNA was 
pelleted by spinning the tube for 15 mins in a microfuge 
and the supernatant was transferred to a fresh tube. The 
plasmid was phenol/chloroform extracted then ethanol 
precipitated at room temperature. The pellet was 
resuspended in 50 |ll TE pH8.0 containing boiled RNase A 
at a concentration of 50 (ig/ml. The sample was then 
digested with diagnostic restriction enzymes to verify 
the clone.
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6.6.6 Large Scale Preparation of Plasmid DNA.
Large quantities of plasmid DNA were prepared using a 
modification of that described by Birnboim and Doly 
(1979) in that the growth medium used was Superbroth. 
Solutions I-III were as described in the previous 
section.
Bacteria containing the plasmid of interest were streaked 
onto an L-agar plate containing appropriate antibiotics 
and grown overnight at 37°C. A single colony was picked 
from this plate and used to inoculate 5mls of Superbroth 
medium which was then put in a shaking incubator at 
225rpm for approximately 8 hours at 37°C. This culture 
was then added to 500mls of Superbroth then returned to 
the shaking incubator for 36 hours.
The culture was spun at 4000rpm for 10 mins at 4°C to 
pellet the bacteria. The supernatant medium was removed 
and the bacterial pellet was resuspended in two 30 ml 
aliquots of Solution I. The suspensions were left at room 
temperature for 5 mins. To each aliquot was added 60 mis 
of ice-cold Solution II and the solutions were mixed by 
inverting the bottles gently. This allows the lysis of 
the bacteria and denaturation of the chromosomal DNA. The 
bottles were placed on ice for 10 mins then 45mls of 
Solution III was added. The bottles were shaken rapidly
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then returned to ice for a further 10 mins allowing the 
precipitation of the renatured chromosomal DNA. The 
chromosomal DNA was then pelleted by centrifugation at 
10, 000 for 10 mins at 4°C. The supernatant was then
carefully removed and retained by filtration through 
several layers of sterile tissue. The nucleic acid in 
this cleared lysate was precipitated by the addition of 
72 mis (i.e. 0.6 volumes) of isopropanol. The lysates
were mixed and left for 10 mins at room temperature after 
which the nucleic acid was pelleted by centrifugation for 
10 mins at lOOOrpm at 4°C. The supernatant was then
withdrawn and the nucleic acid pellet washed with 50mls 
of 70% ethanol to remove any salt. The solution was then 
centrifuged again for 10 mins at lOOOrpm at 4°C and the 
supernatant withdrawn. The pellet was allowed to dry for 
10 mins before being resuspended in 8 mis of TE.
Caesium chloride equilibrium centrifugation was then used 
to further purify the plasmid DNA. 9.3 g of CsCl was 
added to the solution and allowed to dissolve at room 
temperature. Ethidium bromide was then added to a final 
concentration of 600 p.g/ml. The refractive index of this 
solution was then determined and adjusted to 1.4. The
solution was transferred to 13.5 ml Kontron tubes and
centrifuged at 38, 000 rpm for 48 hrs. After this period 
contaminating RNA is pelleted to the bottom of the tube,
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while protein floats to the top. Two distinct bands are 
observed; the lower band contains residual chromosomal 
DNA while the upper contains the plasmid DNA. The upper 
band was removed by carefully inserting a syringe needle 
below it and gently drawing the band off.
Ethidium bromide was removed by several extractions with 
CsCl saturated isopropanol. The CsCl was then removed by 
dialysing the solution in dialysis tubing (Sartorius) 
against 3 changes of TE. The DNA was then precipitated 
with ethanol, resuspended in 1-3 mis of TE (dependent on 
size of pellet), before being quantitated by 
spectrophotometry. The plasmid solution was aliquoted and 
stored at -20°C.
6.7 Tissue Culture
6.7.1 Media and Antibiotics
Cells were grown routinely in Dulbecco's Modified Eagle's 
Medium DMEM supplemented with lOOmls foetal calf serum 
and lOmls of 200 mM L-glutamine per lOOOmls. Penicillin 
(50 units/ml) , streptomycin (50 |ig/ml) and amphotericin B 
(2.5 ng/ml) were added to inhibit microbial 
contamination. All tissue culture reagents were supplied 
by Gibco with the exception of foetal calf serum (NBL). 
All reagents were stored at 4°C except glutamine, foetal
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calf serum, antibiotics and trypsin which were stored 
frozen at -20°C until needed.
6.7.2 Stock Solutions
Phosphate Buffered Saline (PBS) pH7.3: 137 mM NaCl, 44 mM 
KC1, 1.4 mM KH2P04 and 8.4 mM Na2HP04.7H20 
PBS/EDTA (PE): As PBS but with the addition of EDTA to 1 
mM.
Trypsin Solution: made fresh from a 2.5%(w/v) frozen 
stock by diluting 1 in 10 with PE. Trypsin solution was 
stored at 4°C and used for up to 2 weeks.
Geneticin (G418): Made to 100 mg/ml in dH20 and stored 
frozen at -20°C until use.
Quercetin: A stock lOmM solution of quercetin was made up 
in ethanol and stored frozen at -20°C until use.
6.7.3 Isolation of Primary Bovine Fibroblasts
Primary bovine palate fibroblasts (PalF cells) were 
isolated as follows. Short term bovine foetuses (less 
than 5 months gestation term) were obtained from the 
Glasgow University Veterinary College. The soft palate 
tissue was removed by dissection and surface sterilised 
by a 30 second wash in 70% ethanol. The tissue was then 
dissected into small cubes of less than 2 mm using
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crossed scalpels. The cubes of tissue were placed in 
Falcon 10 cm diameter petri dishes (approximately 12 
cubes per dish) and placed in a dry 37°C incubator for 5 
mins to allow the pieces of tissue to adhere to the 
plastic. Following this, 5 mis of medium were added to 
each petri dish, care being taken not to disturb the 
explants. The explants were fed twice weekly for two 
weeks to allow fibroblasts to grow out and keratinocytes 
to differentiate and die. After this time the fibroblasts 
were trypsinised and reseeded in 125 cm^ flasks. At this 
stage aliquots of cells were frozen down in liquid 
nitrogen for future experiments.
6.7.4 Maintenance of Cells in Culture
Cells were fed twice weekly as described in Freshney 
(1987) . Old medium was withdrawn into a buschner flask 
and fresh medium added. PalF cells were grown until just 
sub confluent when they were split and replated 1 in 10. 
Replating was performed as follows: medium was withdrawn 
and cells were washed in PBS. To a 75 cm^ flask 1-2 mis 
of trypsin solution (pre-warmed to 37°C) was added. 
Flasks were transferred to the 37°C hot room until the 
cells had detached from the flask. The trypsin / cell 
suspension was then transferred to a sterile universal, 
10 mis of complete medium added and the cells pelleted by
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centrifugation at lOOOrpm for 10 mins. The pellet was 
then resuspended in fresh medium and the cells replated 
at the appropriate density.
6.7.5 Quercetin Initiation of Primary Fibroblasts
PalF cells were initiated with quercetin with a modified 
technique to that described by Sakai et al (1990) . 
Actively growing PalF cultures were exposed to quercetin 
at one of the following concentrations: 0 L^M (ethanol
only) , 5 |1M, 20 JIM or 45 |1M. Cells were incubated for 48 
hours after which the cultures were washed twice with 
fresh medium. The cells were then split and replated at 
appropriate density and allowed to settle for a further 
24 hours before transfection by calcium phosphate 
precipitation.
6.8 DNA Transfection of Primary Bovine Cells
DNA transfection was performed using the calcium 
phosphate precipitation technique. PalF cells were 
trypsinised and seeded at a density of 5x10^ cell in an 
80 cm^ flask. The cells were fed with 9 mis of growth 
medium 24 hrs prior to addition of the calcium 
phosphate-DNA precipitate.
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The coprecipitate was formed as follows. DNA (20 p.g) was 
diluted in 450 |ll of 0.1 X TE pH8.0 and 50 p.1 of 2.5M 
CaCl2 was added. This mixture was slowly added drop-wise 
to an equal volume of 2 X HBS (HEPES 50 mM, NaCl 280 mM, 
Na2HP04 1.5 mM pH7.12) with gentle shaking. The mixture 
was then left for 30 mins to allow the precipitate to 
form. After this time the precipitate was slowly added to 
the flask of cells and the flask incubated overnight. 
After withdrawal of the medium the flask was washed twice 
in serum free medium and then fresh complete medium was 
added.
6.9 Selection of Transfected Cells
Following removal of the precipitate, cultures of 
transfected PalF cells were left in complete medium for 
48hrs. The cultures were selected in medium containing 
500|ig /ml G418 for 21-28 days being fed twice weekly 
during this period. After this time G418 resistant 
colonies were scored and either picked or stained.
6.10 Isolation of Clonal Populations
Neomycin resistant clones were identified and marked
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using a permanent marker pen. The cells were then washed 
in sterile PBS. The top of the flask was removed using a 
red hot scalpel and the identified colonies were ringed 
using sterile 6mm stainless steel cloning rings with high 
vacuum silicone grease. 100 p.1 of trypsin solution was 
pipetted within the cloning ring using a micropipette, 
and the cell suspension was then transferred to a 
multiwell plate for expansion into cell lines.
6.11 Staining of Cells
Cells were washed twice in sterile PBS then fixed in 
methanol for 10 mins. The methanol was removed then 5-10 
mis of freshly filtered Geimsa stain was added. The flask 
was shaken gently for 5-10 mins after which the Geimsa 
was removed and the flasks rinsed in tap water until it 
ran clear. The flasks were air dried overnight before 
being scored and/or photographed.
6.12 Growth of Cell Lines in Methocel
The extent of transformation of cell populations was 
assayed by their ability to grow in a methocel based 
medium. The medium was prepared as follows: 3 g of
Methocel 4000CP (Fluka) was added to 200 mis of df^O and 
autoclaved. The methocel was left to dissolve with
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stirring for 2-3 days at 4°C. To the methocel solution 
the following was added: 22 mis of 10 X SF12 medium
(Gibco) , 4 mis of 50x essential amino acids, 4 mis of
0.1M sodium pyruvate, 2.5 mis of 0.2M glutamine, 5 mis of 
7.5% sodium bicarbonate and 100 mis of foetal calf serum. 
Cells to be assayed were trypsinised and counted and 10^ 
cells were added to 15mls of methocel mix in universals 
by shaking. The mixture was added to bacterial petri 
dishes to discourage cells adhering to the bottom of the 
dish and left at 37°C for 7-10 days before being scored.
6.13 Storage of Cells under Liquid Nitrogen
Long term storage of cells under liquid nitrogen at 
-196°C retains growth viability and cell characteristics. 
Cells were trypsinised, pelleted and resuspended at a 
concentration of 10^ cells /ml in growth medium. DMSO 
was then added at a concentration of 10% (v/v) to act as
a cryoprotectant, inhibiting the growth of ice crystals. 
The cell suspension was transferred to plastic ampoules 
in 1ml aliquots, the ampoules wrapped in cotton wool, 
placed inside a polystyrene box and then placed in a 
-70°C freezer overnight to ensure a slow rate of cooling. 
The ampoules were then transferred to a liquid nitrogen 
storage rack and stored until required. Recovery of cells 
was performed by removing the ampoules from the nitrogen
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and immediately transferring them to a beaker containing 
water at 37°C. After thawing the cells were pelleted by 
centrifugation then resuspended in fresh medium and 
transferred to a 80cm^ tissue culture flask. The cultures 
were then left for 48hrs before being refed.
6.14 Athymic Mouse Tumorigenicity Assay
The malignant potential of a population of cells was 
assayed by subcutaneous injection into athymic nude mice. 
Cells were trypsinised, counted and pelleted. The cells 
were then resuspended in sterile PBS to give a 
concentration of 10® cells/ml. Mice (three per assay) 
were each injected with 0.1 mis of this suspension (107 
cells) and examined for tumour growth at one week 
intervals following injection. If no tumours developed at 
the injection site by 15-20 weeks after injection the 
injected cells were considered to be non-tumourigenic.
6.15 Immunocytochemistry
To determine localisation of the E7 and E8 gene products, 
immunocytochemistry was performed. PalF cells were seeded 
out at 5x10^ cells per 75cm^ tissue culture flask, left 
to settle overnight, washed and fed with fresh medium and 
then transfected by calcium phosphate precipitation. The
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medium was replaced 24 hours later. After a further 24 
hours the cultures were washed in PBS, trypsinised, 
pelleted by centrifugation (1000 rpm for 5 mins) then 
resuspended in 1 ml of PBS. The suspension was counted 
using a haemocytometer and PBS was added to give a 
concentration of 2xl04 cells / ml. 500 fll of this 
suspension was then spun onto glass slides using a 
Cyto-Tek cytospin centrifuge for 5 mins at 500 rpm.
Slides were air dried before being treated with goat 
serum for 1 hour to remove non-specific background. All 
antibody incubations were performed at room temperature 
in a humid box and slides were washed in freshly prepared 
TBS (0.5M Tris/HCL diluted 1/10 in 0.15M NaCl) for 5 mins 
between each incubation step. Positive controls used were 
anti-bovine MHC monoclonal antibody or anti-rat ras 
monoclonal antibody which is known to bind the bovine ras 
gene product. All antisera were raised in rabbits with 
the exception of the anti-ras antibody which was raised 
in mouse. As a negative control, no primary antibody was 
used (TBS only) . Slides were treated with (in order) ; 
primary antiserum (1 hour), secondary anti-rabbit (or 
anti-mouse for ras detection) in the monoclonal antibody 
conjugated to an alkaline phosphatase enzyme (1 hour), 
alkaline phosphatase substrate (Vector laboratories) 30 
mins. Slides were then washed, air dried and mounted
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using a water based resin.
6.16 Microinjection
Neighbouring cells can communicate with each other by 
allowing the passage of small molecules through 
specialised membrane structures called gap junctions. 
Cells which can communicate by allowing passage of 
molecules through these structures are said to be 
chemically coupled. Microinjection dye-transfer 
experiments can be used to see if a culture of cells are 
communicating in this way. A fluorescent dye, lucifer 
yellow, is injected into a single cell using 
microinjection apparatus. After some time the culture of 
cells can be examined under fluorescent light: the extent 
of spread of the injected dye from the original injected 
cell to its neighbours is a measure of the extent of dye 
coupling and hence junctional communication. 
Microinjection was kindly performed by Dr J.D. Pitts of 
the Beatson Institute.
Cultures to be examined were grown until almost 
confluent. A single cell was then iontophoretically 
injected using microelectrodes made from Quick-fil 
capillaries (1.2 o.d., Clark electro-Medical Instruments,
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Reading, England, with a tip resistance of 10 Mohm when 
filled with 3M KCL), back filled with a 4% aqueous 
solution of Lucifer Yellow CH (Sigma). Each injection was 
monitored using a Leitz Orthoplan microscope equipped 
with both UV and visible light sources. Iontophoresis was 
performed with the aid of a Neurolog system (Digitimer, 
Welwyn Garden City, England) using pulses of 20nA, 1 Hz
and 500 ms duration for 5 mins. The injection site was 
then photographed under both visible and UV light.
6.17 Eukaryotic DNA analysis
Cell lines transfected with BPV-4 DNA were examined by 
preparing high molecular weight genomic DNA and examining 
this DNA for the presence of viral sequences by the 
technique of Southern blotting (Southern 1975). The 
principle of this technique is as follows. The DNA was 
digested with an appropriate restriction enzyme, 
separated on an agarose gel and then transferred to a 
nylon membrane. The membrane was then examined by 
treating with a radiolabelled single stranded BPV-4 DNA 
probe to allow the detection of viral sequences in the 
genomic DNA.
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6.17.1 Preparation of Genomic DMA from Cell Lines
Genomic DNA was prepared from cell lines using a 
modification of the technique of Miller et al (1988). 
The cells from a confluent 75 cm^ tissue culture flask 
were trypsinised, pelleted and then washed with PBS. The 
cell pellet was resuspended in 3 mis of lysis buffer (10 
mM Tris-HCl, 400 mM NaCl and 2 mM Na2EDTA, pH8.2) and 
digested overnight at 37°C with 0.5 mis of a protease K 
solution (1 mg protease K in 1% SDS and 2 mM Na2EDTA) . 
After digestion, 1 ml of a saturated NaCl solution was 
added and the tubes shaken vigorously for 15 seconds. The 
samples were then spun at 2500 rpm for 15 mins to 
precipitate the protein pellet. The supernatant was 
carefully transferred to another tube and 2 volumes of 
absolute ethanol (room temperature) were added. The tubes 
were inverted several times until the DNA precipitated 
and the DNA strands were removed using a pasteur pipette. 
Excess ethanol was removed then the pellet was allowed to 
air dry before being resuspended in 100-200 p,l of TE. The 
DNA was allowed to dissolve for 2 hours before being 
quantitated.
6.17.2 DMA Restriction and Agarose Gel Electrophoresis
Genomic DNA (typically 20 jig) was digested overnight with 
100U of restriction enzyme (usually EcoRI) in the 
appropriate buffer supplied by the manufacturer. The
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digested DNA was then phenol / chloroform extracted and 
precipitated in ethanol. The DNA was then resuspended in
60 |il of gel loading buffer, loaded onto a 1% agarose gel
and electrophoresed at 50V until the marker dye 
(bromophenol blue) had run approximately 2 cm from the
bottom of the gel. To allow fragment sizes to be 
assessed, one lane of the gel was loaded with 1 p.g 
bacteriophage lambda DNA cut with the restriction enzyme 
Hindlll. The gel was then stained by the addition of 
ethidium bromide and photographed using a UV
transilluminator.
6.17.3 Southern Transfer
The restricted genomic DNA was transferred from the gel 
to a nylon membrane using the blotting technique 
described by Southern (1975). The gel was placed in 0.25 
N HC1 for 10 mins causing partial depurination of the
DNA. The gel was then transferred to a solution 
containing 0.5 N NaOH, 1.5 M NaCl for 30 mins. This 
allows hydrolysis of the DNA at the sites of depurination 
causing fragmentation of the DNA which in turn 
facilitates efficient transfer. Denaturation of the DNA 
also occurs with this treatment. The gel was then 
transferred to a neutralising solution of 0.5M Tris.Cl 
pH7.4, 3 M NaCl for 1 hour.
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A large tray was filled with a reservoir of 20 X SSC 
transfer buffer (3 M NaCl, 3 M sodium citrate pH7.0). In 
this tray was placed an inverted baking tray such that 
the bottom of the tray was above the level of transfer 
buffer. A piece of 3M paper was then placed on the 
inverted dish so that the sides of the paper extended 
down into the reservoir and any air bubbles under the 
paper were removed by gently rolling a pipette over the 
paper. The gel was placed on top of the 3M paper and the 
area around the gel made water tight by placing pieces of 
X-ray film around it. This prevents "short circuiting" of 
the blotting apparatus so that the only transfer of 
buffer is through the gel. A piece of nylon membrane (Pal 
Biodyne) was cut to the size of the gel, pre-soaked in 2 
X SSC and then placed over the gel. Air bubble were 
avoided by rolling a pipette gently over the gel surface. 
On top of the gel, three thicknesses of 3M paper were 
placed followed by a 10 cm thick pile of paper towels. An 
inverted baking dish was placed on top of the apparatus 
followed by a 2 kg weight. The apparatus was then left 
overnight. This process facilitates the transfer of gel 
buffer from the reservoir into the paper towels by 
capillary action, the DNA being transferred in the 
process. After transfer was complete the nylon membrane 
was baked in an 80°C oven for 2hrs to cause the DNA to
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cross link to the membrane.
6.17.4 Radiolabelled Single Stranded DNA Probes
DNA probes for hybridisation were prepared using a 
"random prime" kit purchased from BCL which utilises the 
method of Feinberg and Vogelstein (1983). DNA probes were 
prepared from their parental plasmid by digestion with 
appropriate restriction enzymes, electrophoresis on a 1% 
agarose gel and then purification of the probe from the 
agarose slice using the "Geneclean" kit as per 
manufacturer's instructions. 50ng of the probe DNA was 
used per labelling reaction.
The DNA was made up to a volume of 9 p.1 with dH20 and 
denatured by boiling for 10 mins followed by cooling on 
ice. 2 jil of reaction buffer was added (0.5 M Tris.HCl 
pH7.4, 50 mM MgCl2/ 2 M HEPES pH6.6, 120 mM
ft-mercaptoethanol and 600 fig/ml random hexanucleotides) 
followed by 3 H-l of labelling mixture (500 |JM dATP, dGTP 
and dTTP) . To this 1.85 MBq of [^P-]dCTP was added 
followed by 1U of E.Coli DNA polymerase I (Klenow 
fragment). The mixture was incubated at 37°C for 30mins. 
Unincorporated nucleotides were removed from the mixture 
by passing it through an Elutip-d column as described in
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the manufacturers instructions. Prior to use in 
hybridisation the probe was denatured by boiling for 10 
mins.
6.17.5 Prehybridisation and Hybridisation of Membranes
To reduce non-specific binding of probe to membrane the 
membrane was prehybridised in 10 mis of prehybridisation 
solution [5 X Denhardt1s (100 X Denhardt's solution is 
2%(w/v) Ficoll, 2% (w/v) Polyvinylpyrrolidone and 2%(w/v) 
bovine serum albumin), 5 X SSC, 0.1% SDS and 500 (lg/ml of 
denatured salmon sperm DNA] for 3 hours at 65°C before 
the labelled probe was added. The hybridisation was then 
carried out overnight at 65°C. Prehybridisation / 
hybridisation was carried out in heat sealed plastic 
bags, all air bubbles being carefully removed.
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6.17.6 Washing of Hybridised Membranes and 
Autoradiography
In order to remove non-specifically bound probe, 
membranes were washed initially in a solution of 2 X 
SSC, 0.1% SDS for 10 mins at room temperature to remove 
unbound probe. The membrane was then washed with 0.1 X 
SSC, 0.5% SDS for 1 hour at 65°C with changes of buffer
every 15 minutes. After washing the filters were air
dried then exposed to X-ray film at -70°C.
Blots were stripped for reprobing by washing them for 1 
hour in a stripping solution (0.5 x SSC, 0.1% SDS) at 
90°C) with changes of buffer every 15 mins. The blot was 
then autoradiographed overnight to ensure all the
radioactive probe had been removed.
6.18 DNA Sequencing
6.18.1 Preparation of Plasmid for DNA Sequencing
Plasmids were sequenced using the "Sequenase" (tm) kit 
from USB. Manufacturers instructions were adhered to
throughout. Plasmid (approx 4 (ig) was diluted to a final 
volume of 1 8 \L1 before being denatured by the addition of 
2 jil of 2 M NaOH. 8 p.1 of 5M ammonium acetate (pH7.5
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filter sterilised) was added followed by 100 jil of
ethanol. The plasmid was precipitated by spinning in a 
microcentrifuge for 15 mins at 4°C then the ethanol was 
carefully removed using a micropipette. The pelleted 
plasmid was washed with 70% ethanol, air dried, then
resuspended in 7 p.1 of water immediately before use.
6.18.2 Preparation of Synthetic Oligonucleotide Primers
Initial sequence was obtained using M13 "universal" 
forward and reverse primers as supplied in the 
"Sequenase" (tm) kit. This strategy allow for
approximately 200-300 base pairs to be sequenced from 
each end of the insert. Further sequence was obtained by 
designing synthetic oligonucleotide primers of 15-20 base 
pairs to anneal near the ends of the sequence obtained 
using the universal primers. Oligonucleotides were 
synthesized using an Applied Biosystems oligonucleotide 
synthesizer. The synthesized oligonucleotide was removed 
from the cartridge by repeatedly passing 5mls of ammonia 
through the cartridge for 2-3 hours. The collected 
ammonia was left in a glass vial at 45°C overnight, then 
the oligonucleotide was precipitated with ethanol. The
pellet was resuspended in 1 ml of TE then the 
concentration of oligonucleotide was quantitated by 
spectrophotometer. The concentration of oligonucleotide
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was a justed to 4 (ig/|il by the addition of TE.
6.18.3 Sequencing Plasmid DMA
Plasmid DNA was sequenced using a "Sequenase" tm kit 
(USB) which employs the dideoxy sequencing technique of 
Sanger et al (1977) . To denatured plasmid DNA (4 |ig in 7 
(ll TE) 2 (il of "Sequenase" buffer and 1 p.1 (4ng) of
appropriate primer were added. The primer was allowed to 
anneal to the template by heating to 65°C for 2 mins then 
allowing to cool slowly. "Sequenase" labelling mix (dGTP) 
was diluted 1:5 in dH^O. "Sequenase" enzyme was diluted 
1:8 in ice-cold TE. To the annealed DNA mixture the 
following was added: 10 |il of DTT (0.1M), 2 (il of diluted 
"Sequenase" labelling mix, 0.5 (il of [^S] dATP and 2 (il 
of diluted "Sequenase" enzyme. The reaction was mixed and 
allowed to stand at room temperature for 5 mins. The 
labelling reaction was then terminated by transferring
3.5 (il of the labelling reaction to separate eppendorf 
tubes containing 2.5 p.1 of either G, A, T or C
"Sequenase" termination mixes. These tubes were then 
incubated at 37°C for five mins. The reaction was stopped 
by adding 4 (il of "stop" solution. The samples were 
heated to 75°C for 2 mins immediately before loading. 
Samples were run on a 6% acrylamide gel as described in 
Sambrook et al (1989). Following electrophoresis the gel
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was fixed for 30 mins in a 10% methanol / 10% acetic acid
solution. The gel was then transferred to a piece of
filter paper and dried using a gel drying apparatus. 
Dried gels were then autoradiographed.
6.18.4 Computer Analysis of DNA Sequence Data
Sequence data were aligned and compared to other
sequences using the Genetics Computer Group sequence
analysis software (University of Wisconsin Biotechnology 
Centre, Madison, WI).
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7. Results and Discussion
7.1 DNA Sequencing
The six bovine papillomaviruses isolated to date have 
been divided into two subgroups: Subgroup A (BPVs type
1.2 & 5) cause fibropapillomas while the Subgroup B
viruses (BPVs 3,4 & 6) cause true epithelial papillomas. 
An important transforming gene in the well characterised 
BPV-1 virus and in the oncogenic human papillomaviruses 
is E6. Previous sequencing analysis of BPV-4 predicted 
that no E6 ORF is present (GenEMBL Accession No. X59063) 
making BPV-4 unique among sequenced papillomaviruses in 
this respect (Jackson et al, 1991) . The significance of 
the absence of E6 in BPV-4 is exemplified by the fact 
that integrity of the BPV-1 E6 is essential for the 
development of a fully transformed phenotype (Neary and 
DiMaio, 1989) . In order to address if the lack of an E6 
ORF was a general feature of the subgroup B BPVs, 
molecular cloning of the LI to El genome areas of BPV-3 
and BPV-6 was performed and followed by DNA sequence 
analysis .
BPV-3 Sequencing: The appropriate region of the BPV-3
genome was subcloned from the pBV3 plasmid which is 
described in Coggins et al, 1983. The 950bp EcoRI to 
Hindi! B 1 and the 250bp BamHI D fragments of pBV3 were
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isolated by restriction enzyme digestion and subcloned 
into pAT153 (Twigg and Sherratt, 1980). Each recombinant 
was sequenced initially using pBR322 multiple cloning 
site sequencing primers. Synthetic oligonucleotides were 
used to extend sequence readings as described in the 
Materials and Methods section and the sequence was 
extended further across the LCR and into the LI region by 
sequencing using synthetic primers designed to anneal to 
the parental pBV3 plasmid. Sequencing reactions were 
performed on one strand only, but a minimum of three gel 
runs were performed for each primer to ensure the reading 
of sequence was accurate.
BPV-6 Sequencing: BPV-6 DNA was subcloned from the pBV6
plasmid as described in Jarrett et al 1984. The 1.4kb 
BamHI fragment of pBV6 was subcloned into pIC20H (Marsh 
et al 1984) . Initial sequence was obtained with M13 
forward and reverse primers. The sequence was extended 
using synthetic primers as in the BPV-3 sequencing and 
part of the El ORF sequence was obtained by sequencing 
the parental pBV6 plasmid. As in the case of BPV-3, 
sequencing was usually on one strand only, but several 
gel runs were performed using each primer to ensure 
accuracy of sequence.
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The sequences of the subgroup B BPVs were found to have 
strong homology throughout most of the region analysed 
(Fig 7.1.). The E7 and E8 ORFs and part of the El and LI 
ORFs of BPVs 3 and 6 were identified by the homology of
their putative translation products to those of BPV-4
(Fig 7.2.). The sequence homology within the E8, E7, El
and LI ORFs is high, with only a few deletions or 
insertions of exactly three or six nucleotides 
maintaining the reading frames. Similarly, the LCR 
region, in general the least conserved region between 
different PV types, shows considerable sequence identity 
among the three subgroup B BPVs (Fig 7.3.). Open reading 
frame analysis demonstrates that the subgroup B BPVs have 
no ORF resembling an E6 between the E8 and E7 ORFs (Fig 
7.1.; Fig 7.4.). Indeed sequence homology between the 
three viruses breaks down in this region and large
deletions or insertions are found suggesting that this 
region is not used to encode a function common to all 
three viruses, an argument strengthened by the three
viruses possessing strong conservation of sequence in all 
other regions examined (El, E7, E8, LI and LCR) in the
three viral genomes.
The ORF analysis of the subgroup B viruses (Fig 7.4.)
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shows the existence of a number of small ORFs with 
potential coding capacities of between 36 and 4 6 amino 
acids from the first methionine codon. Although the "a" 
and "b" ORFs of BPV-4 and BPV-6 appear unrelated in terms 
of sequence data, the "c" ORFs of BPV-3 and BPV-4 have 
considerable homology, and in the same position in BPV-6 
there is a short ORF of 25 codons from the first 
methionine codon with homology to the other "c" ORFs 
(Fig 7.2.C.). As the first five codons of the putative 
"c" ORFs encode the C-terminal four amino acids and stop 
codon of the E8 ORF, the sequences are necessarily 
constrained in this region. Nucleotide and amino acid 
homology breaks down after this short region however, 
with large deletions/insertions prohibiting the existence 
of an E6 ORF (Fig 7.1.).
103
Fig 7.1. Nucleotide homology between B group BPVs.
50
CGCACCGTTT GAGGTACATA TAAAAGG.CT GCAGCTCACT TTCACTACAT 
CGTACCGAAT CGGGTGCATA TATAAGGAGA GCAGTGCGGA TTTGGTGCAT
TGCACCGTTT CAGGTCGATA TAAAA A GCAGACAAAG CTAGTTTCTG
-G-ACCG--T --GG7--ATA TA-AA GCAG----- -T T-C--
451 500
9pv3 TGCAATTAAA AATGAAGGGC CAGGACGTGA CTTTGAAAAA CGTTGCTGTA
3pv4 TTCAA..GAA AATGAAGGGG CAGAACCTGA CATTACAGGA CATTGCAATA
Bpv6  CAGAAA AATGAAGGGC CAGAGCATGA TTTTGAAAGA CTTAGCTGCA
Cons----------AA AATGAAGGG- CAG--C-TGA — TT— A--A C-T-GC---A
51 100
GGACCTTTGG GCTCCATCTG CATTATGAGC TTGACTCTAA TTTACTGGTT
GAGGCAGTAG CTCTCATC...... ATGTCT TTGTGGCTTA TCTATGTTTT
TGGAGCTTAG GTTCCA7C.. GATCATGCGC TTAACTCTGA TCTTTTGGTT 
----- T - G -----CATC— ----ATG---TT-----CT-A T-T-----TT
501 550
Bpv3 GAATTAGAGG ATGTAGTCAG TCCAATTATA TTGGATTGCG AGGAGGAGAT
Bpv4 GAATTAGAGG ATACAATTAG TCCAATTAAC TTGCATTGTG AAGAGGAGAT
Bpv6 GAATTAGAAG AGGTAGTCAG TCCAATTAAC TTGGACTGTG AAGAAGAGAT
Cons GAATTAGA-G A A-T-AG TCCAATTA-- TTG-A-TG-G A-GA-GAGAT
101 ISO
ATTGCTGCTC TGGGTTTCAT TTCACTTTCT GTCATTGTGC CTTGCTATTA 
GTTGCTTTTC TGGTGTGCTT TTAATTTTCT TGCACTGTTA TTTGCAATTA 
GTTGTTGCTC TGGTGTGGGT TTCACTTGGC TGCTCTCTGC ATAGCCATTA
-TTG-T— TC TGG— T T TT-A-TT----- C— T-T—  -T-GC-ATTA
151 200
TATTGTATTT GCTGTTAATG TCTACTATTA CTAGTTTACA TGGATGGGAT 
TTGTGTACCT TCTGTTAATT TCTACTATTA CTCGGTTAGA TGGATGGGAT 
TTCTTTTT'-T GCTTTTACTA TCTGCTATTG ATGAACTAAA TGGATGGGAC
7--T-T T -CT-TTA-T- TCT-CTATT- -T TA-A TGGATGGGA-
2 0 1  250 
TGAAGC7GTT TTATT7ATAC TGTTAATCAT CTTTATTTGC GA.CGCGATT 
TGAATT7TTA 7T7ATTG7GT TTATTATTTG CTTGATTTCT GATTTGCTTT 
TGAATCGCAC ATGTT7GTAT TACTATTGAT ATTGGTTTGT GATCGATTTT 
TGAA-------T— TT-T—  T--T--T -TT--TTT-- GA------- TT
251 " 300
7TCTTGAATG TTAGGGAGTT TCTGCAGACA TTGCTGTTTT TGTCTTTGTT 
7G.CTATATA TAGTGGAGAT TATGCGTTTG GTGTTATTGC TGTCTTTGCT 
7G77TAAATG TGCATGATTT GTTAGAGGGT TTCGTGTTGC TTTCTGTATT 
• T— AT- 7 GA— T — T--------T— T-TT—  T-TCT-T-
301 350
ATATGGGGAG GACTAGCTTG ................................
AGATGAATTA GAACAGGAGG AACAGTAAAT AGAATATTGC TGTGCTTTTA
AG7TGGTGAC GAGGA.......................................
A--TG GA— A --------------------- -----------
351 400
...TTAACAC CTTAAGGGTT TGGCCACTTA TAATAGCTGA CCTTTGCTCT
CATTTGAGAA GGATTGTAGG TGTGGGCATT TAAAAGCTGA CCTTCCAGTC
  CTAGTTTAGG TGTGGACATT TAAGAGCAAT CTTGACCTGT
   C - t - TAA-AGC C-T----------
401 450
GCAATT..AA GTGGCGTCTT AAAGGGAGTT ATTTAAGCCG TGTAGAGTTT 
TTAATTGCAG TAGGCGCCTA AGAGGGTGGT GGTGGTATAA GTTCAAGTTT
GTAATTAAAA AAGGCGCTTA A ...................G TGTAGCGT..
--AATT— A GGCG--T- A-------------------- --T GT—
551 600
Bpv3 AGAAACTGAG GAAGTAGACT GTCCGGCCCC GTAT...GCT GTAGAGGCTG
3pv4 TGAAACTGAG GAGGTGGACA CCCCTAACCC TTTTGCAATA ACAGCAACT.
Bpv6 TGCAAATGAG GAAGTTGACT GTCCTGTCAC CTTTTGCTTA GTTGAAGCTG
Cons -G-AA-TGAG GA-GT-GAC- — CC C-C -T-T--------  G-CT-
601 650
9pv3 TTTGTTATGT TTGTGAAAAC CCCTTACGTT TAGCTCTCGT CTCCTCACCG 
Bpv4 ..TGTTATGC TTGCGAGCAA GTCCTTCGTT TAGCTGTTGT AACGTCAACA 
Bpv6 TGTGTCATGT TTGTGAACAA GTTTTGCGTT TAGCCGTCGT TGCCTCGCCA
Cons --TGT-ATG- TTG-GA— A-  T-CGTT TAGC--T-GT --C-TC--C-
651 700
Bpv3 GACGGGATCC ATCAACTGCA TCAA...CTG CTGTTGGACT GCATCTCCTT 
3pv4 GAAGGAATTC ATCAACTGCA GCAA...CTG CTGTTCGACA ACCTCTTTCT 
3pv6 GACGGGATAC TGCAATTGCA GCAACTCCTG CTGACGGACT CCCTCTCGTT
Cons GA-GG-AT-C --CAA-TGCA -CAA CTG CTG GAC- -C-T-T T
701 750
9pv3 ACTGTGTGCA AACTGCTCTA GAGAGGTCTA CTCTAACCGC AGACCCCAAC 
Bpv4 ACTGTGTGCA GCTTGCTCCA AACAAGTGTT CTGTAACCGC AGACCCGAGC 
Bpv6 TCTGTGTACA AGCTGCTCTA GAGAAGCGTT CTGTAACCGC AGACCACAAC
Cons -CTGTG7-CA  TGCTC-A -A-A-G— T- CT-TAACCGC AGACC--A-C
751 900
Bpv3 GAAATGGACC CTAA  AGGTATTACC GGGCAAAGTT TTCTTGACGA
Bpv4 GAAATGGACC CTAA  AGGTACTACC GTGCTTGACT TTATTGAGGA
Bpv6 GCAATGGATC CTAATGAAAA AGGTATTGAA GTGCTGAGTT TTATAGATGA 
Cons G-AATGGA-C CTAA AGGTA-T—  G-GC T TT-T-GA-GA
801 850
Bpv3 CCAAGCAGAA TGTAGTGAAT CTCATAATAG CCAGCAAGGG TGTGAAGAAA 
Bpv4 ACAAGCAGAA TGTAGTCAAT CTG...ATAG CGAGCAAGGC AGTGAAGAAA 
Bpv6 ACAAGCAGAA TGTAGAGGGT CAG...ATAG CGAGGAAGGG TATGAAGAAA 
Cons -CAAGCAGAA TGTAG T C-G ATAG CGAG-AAGG- --TGAAGAAA
851 874
Bpv3 GCCTGTC7GA TTTGTCTGAC CTAA 
Bpv4 ATTGTTCTGA TATATCTGAC CTAA 
Bpv6 GCCAGTCTAG TCTGTCCGAC CTAA 
Cons  TC7-- T-T-TC-GAC CTAA
Comparison of E8 to LI regions of the subgroupB BPVs. The E8 and E7 encoding 
regions are indicated in bold type and the initiation codons for thw "c” 
polypeptides and El are underlined. Dots represent insertions/deletions and 
the consensus indicates regions of homology between the viruses. The regions 
of sequence analysed are BPV-3 697—1521, BPV—4 264—1113 and BPV—6 747—1524.
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Fig 7.2. B group BPVs putative translation product
homology.
1 60 
3PV3.E7 MKGQDVTLKN VAVELEDWS PIILDCEEEI ETEEVDCPAP YA.VEAVCYV CENPLRLALV 
3PV4.E7 MKGQNVTLQD IAIELEDTIS PINLHCEEEI ETEEVDTPNP F A .ITATCYA CEQVLRLAW
3PV6.E7 MKGQSMILKD LAAELEEWS PINLDCEEEI ANEEVDCPVT FCLVEAVCHV CEQVLRLAW
Consens MKGQ L—  -A-ELE S PI-L-CEEEI — EEVD-P— -------A-C—  CE— LRLA-V
..... SV40 LT/Ad E1A homology......  CXX C
3PV3.E7 
3PV4.E7 
3PV6.E7 
Consens
B
61 100 
SSPDGIHQLH QLLL.DCISL LCANCSREVY SNRRPQRNGP 
TSTEGIHQLQ QLLF.DNLFL LCAACSKQVF CNRRPERNGP 
ASPDGILQLQ QLLLTDSLSF LCTSCSREAF CNRRPQRNGS
-S— GI-QL- QLL— D LC— CS -NRRP-RNG-
cxxc
3PV3.E8 
3PV4.E8 
3PV6 . E8
3PV3.E8 
3PV4.E8 
BPV6.E8 
Consens
-57
anctvcgavshtkvsvvinnslfnMlllapdsvapfevhikgcsslslhgplgsici
gkyqlhpirsyrigciykessadlvheavali
vpsi
1 42
MSLTLIYWLL LLWVSFHFLS LCLAIILYLL LMSTITSLHG WD 
MSLWLIYVLL LFWCAFNFLA LLFAIIVYLL LISTITRLDG WD 
MRLTLIFWLL LLWCGFHLAA LCIAIILFLL LLSAIDELNG WD 
M-L-LI— LL L-W— F L— All— LL L-S-I— L-G WD
1 44
3PV1.E5 MPNLWFLLFL GLVAAMQLLL LLFLLLFFLV YWDHFECSCT GLPF
1 45
3PV3.0RFC MDGIEAVLFI LLIIFICDAI FLNVREFLQT LLFLSLLYGE D*
3PV4.ORFc MDGIEFLFIV FIICLISDLL LLYIVEIMRL VLLLSLLDEL EQEEQ*
BPV6.ORFc MDGTESHMFV LLLILVCDRF LFKCA*
Consensus MDGIE FV LLIILICD—  LL E -L-LSLL -----
HPV8 E6 MDGQDKASYS LDTNKDELPS TIKELAAALG IPLQDCSVPC NFCGN...
Notes: A) Comparison of the E7 products of BPVs 3, 4 and 6 showing
conserved Cys-X-X-Cys motifs and region of homolgy to SV40 LT/ 
Adenovirus Ela (ie potential plOS1^ 5 binding site). Consensus 
indicates amino acids common to all three proteins. B) Putative E8 
comparison. Upstream sequences to the proposed product (upper case) 
are shown in lower case letters and the first methionine of BPV-3 E8 
is undelined and in uppercase. Amino acids common to all three 
products are given in the consensus sequence. C) Comparison of the 
potential products of the putative "c" ORFs of the B group BPVs with 
the E6 of HPV-8. The consensus indicates identical amino acids shared 
by two of the three ORFs. * represents a stop codon.
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The protein encoded by the E7 ORF of all three viruses 
contains the putative plOS1^ 3 binding domains and the two 
Cys-X-X-Cys zinc binding motifs but lacks the CKII 
phosphorylation site in common with CRPV, HPV-5 and HPV-8 
(Fig 7.2.a). The consequences of the absence of the CKII 
phosphorylation site will be discussed in more detail 
later in this thesis.
The E8 ORFs of all three viruses share a common 
methionine codon, with BPV-3 having an additional 
methionine codon 5* to the common one (Fig 7.2.b). If 
translated from the first AUG codon, the putative BPV-3 
E8 peptide would be extended by 33 residues. However, the 
amino acid homology breaks down sharply upstream of the 
common methionine, suggesting that translation begins at 
the common AUG and that the major product from this 
region is 42 amino acids long in all three viruses. This 
protein is 52% homologous between the three viruses. All 
three of the postulated peptides are highly hydrophobic 
with a leucine content similar to BPV-1 E5 (BPV-3 E8 33%, 
BPV-4 E8 29%, BPV-6 E8 33%, BPV-1 E5 34%) . Indeed when 
the hydrophobicity of the three E8 peptides and the BPV-1 
E5 peptide are compared (Kyte and Doolittle, 1982) a 
striking similarity is observed (Fig 7.5.) suggesting 
that the subgroup B E8 peptides and BPV-1 E5 may share a 
common function.
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Fig 7.3. LCR homology between B group BPVs.
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Fig 7.4. ORF analysis of B group BPVs.
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ORF analyses for the Ll to El regions of BPVs 3, 4 and 6. Stop codons 
in all three reading frames (A, B and C) are given by vertical lines. 
Below each stop codon analyses is a representation of the ORFs where 
the first ATG is indicated by a vertical line. Only ORFs of greater 
than 35 amino acids from the first ATG are shown. Major ORFs (whose 
products are identifiable papillomaviral proteins) are shown with 
bold lines, minor ORFs by finer lines. Nucleotides 6789-1112 of the 
BPV-4 sequence are displayed with the corresponding areas of the 
other two viruses.
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The BPV-1 sequence V-X-W-D-X-F-X-C-X-C, shown to be 
crucial for transformation is absent from the putative E8 
peptide of BPVs 3, 4 and 6. The E5a peptide of HPV-6 
however, has been shown to have transformation activity 
despite lacking this sequence, although it does contain a 
C-X-C motif in the C-terminus (Chen and Mounts 1990). The 
similarity of BPV-4 E8 to the BPV-1 E5 protein suggests a 
possible role of the E8 peptide in the transformation 
mechanism of BPV-4. This question will be addressed more 
fully both in transformation assays (Section 7.2.) and in 
possible interactions between BPV-4 E8 and cellular
proteins (Section 7.4.).
As mentioned previously, the E6 gene is important in the 
transformation mechanism of the oncogenic human
papillomavirus types. The mode of action of the E6
protein in these viruses has been shown to be the
complexing with, and subsequent degradation of, the p53 
tumour suppressor gene product, thus deregulating the 
cell cycle (Werness et al, 1990; Scheffner et al, 1990) . 
The observation that both the E7 and E6 genes are often 
maintained and transcribed in papillomavirus associated 
carcinomas is evidence for the role of the E6 in 
tumorigenesis in vivo (Schwartz et al, 1985). The lack of 
an apparent E6 function raises interesting questions
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Fig 7.5. Hydrophobicity plots (BPV-1 E5 / B virus E8s).
4.5 i BPV1 E5
3.0
1.5
Ij  4.5
E
3.0
-1.5BPV4 E8
_i
O
O
Q
o8
LU
H>
1.5
>
H 4.5 
O
CD 3.0 -
O
X
S  1-5
DC
O
>■
X
4.5
BPV3 E8 -1.5
-1.5BPV6 E8
3.0
1.5
-1.5
10 403020
RESIDUE NUMBER
Kyte and Doolittle hydrophobicity plots for the E5 protein of BPV-1 
and the proposed E8 proteins of the subgroup B BPVs. The residue 
specific hydrophobicity indices were averaged over nine amino acids. 
Regions above the x-axis (positive) are hydrophobic, those below the 
axis (negative) are hydrophillic. Average hydrophobicity values of > 
+1.6 are indicative of membrane-integrated domains.
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regarding the transformation biology of BPV-4 both in 
vivo and in vitro. A viral E6 function is obviously not 
required for virus infection and propagation leading to 
the conclusion that either the subgroup B BPVs do not 
require E6 functions, or that these functions are 
provided by other viral or host proteins. It may prove 
interesting to examine the status of the bovine p53 gene 
and its expression in papillomas and carcinomas. Recent 
work on anogenital lesions has shown that the progression 
of squamous cell carcinoma (SCC) requires p53 dysfunction 
either through binding and degradation by HPV E6 or by 
mutation in the host p53 protein in HPV negative lesions 
(Crook et al, 1991a, b). If p53 dysfunction is crucial in 
the development of alimentary canal SCC in cattle, then 
p53 mutations might be expected to be found in papillomas 
and especially carcinomas. At present nothing is known 
about the bovine p53 gene or protein, but work is 
currently underway using PCR primers against the 
conserved consensus regions of the human p53 gene to 
attempt to sequence the bovine p53 homolog and examine 
its status in normal, papilloma and carcinoma biopsies 
(M. Jackson, personal communication). Another question is 
whether the introduction of an E6 function from a 
heterologous virus could enhance the transformation 
potential of BPV-4 in in vitro transformation assays. 
This point was addressed experimentally, and will be
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considered later in this thesis.
7.2 Transfection of PalF cells
The transforming properties of BPV-4 were investigated by 
transfecting various constructs containing cloned BPV-4 
sequences into PalF cells. All the plasmids used in these 
studies are described in the Materials and Methods 
(Section 6.3.5) and a summary of the plasmids is given in 
Figures 6.1. and 6.2. A cooperating ras gene function was 
provided by the pT24 plasmid. Transformation was assessed 
by using a neomycin resistance assay. Where G418 
resistance was not conferred by the plasmids being used, 
the pZipneo plasmid was cotransfected at a ratio of one 
to ten of the other transfected constructs. PalF cells 
were explanted from fetal palate tissue and grown in 10% 
FCS DMEM medium, cells being split before reaching 
confluence. Early passage cells were transfected using 
the calcium phosphate transfection protocol, then 
selected in G418 containing medium as described in the 
Materials and Methods section. The susceptibility of PalF 
cells to G418 has previously been assessed (Jaggar, 1990; 
Jaggar et al, 1990) and 500 |ig/ml was found to be 
suitable. Individual experiments were scored on the 
number of G418 resistant macrocolonies (greater than 5mm 
in diameter) present at the end of the 21-28 day
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selection period. Small G418r microcolonies of less than 
5mm were observed in all transfections. These small 
colonies had a flat morphology and appeared identical to 
untransfected PalF cells. Expansion of these colonies 
proved to be impossible, except as a pool of colonies
from a single flask, and with continued passage these 
pooled cells senesced and died. This microcolony
formation was taken to represent cells which were G418 
resistant but untransformed and microcolonies were not 
scored.
Most individual transfection experiments were repeated 
between four and six times but transfection efficiency 
was found to vary considerably from experiment to 
experiment. A number of precautions were taken to 
minimise changes in conditions between experiments.
Whenever possible cells derived from the same original 
palate biopsy and of an equivalent passage number were
used in each repetition of an experiment. Cells were only 
deemed suitable for transfection up until the fifth 
passage following isolation as preliminary experiments 
not presented here demonstrated that later passage cells 
were more difficult to transfect. In addition 
transfection solutions were stored at 4°C for a maximum 
of 4-6 weeks before being discarded and fresh solutions 
made. Newly made reagents were tested before use, by
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transfection of pzipneo into PalF cells and subsequent 
G418 selection.
To allow comparison between experiments, the results from 
multiple repetitions of transfections were averaged 
before being standardised to the number of macrocolonies 
observed on transfection with pBV4 + ras, which is used 
as a "baseline". Thus the average number of macrocolonies 
obtained with pBV4 + ras is taken to be 100% and the 
average values for other transfections were scaled 
accordingly (Table 7.2.). It was hoped that assigning 
average values would facilitate the identification of 
general trends. In all cases the raw data of numbers of 
macrocolonies are given before normalisation (Table
7.1.). it is recognised that, as transfection efficiency 
appears to be highly variable, the average of multiple 
experiments is only useful to identify these general 
trends rather than assign strict quantitative values to 
them. It may be possible in the future to repeat the 
experiments using a more reliable and consistent 
transfection protocol, such as lipofection. However, 
whilst the quantitative aspects of transformation 
experiments were often variable, qualitative aspects were 
not: transformation parameters such as colony morphology 
and growth in semi-solid media were totally reproducible 
from experiment to experiment.
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7.2.1 Introduction of pBV4 into PalF Cells
Introduction of the plasmid pBV4 into PalF cells 
consistently had very little effect. Morphologically, the 
cells were almost identical to controls, and like control 
cells senesced on passage. This is in marked contrast to 
the subgroup A fibropapillomaviruses, BPV-1 and BPV-2, 
which are capable of transforming PalF cells efficiently 
and to full malignancy (W.F.H. Jarrett, unpublished 
results). Results using HPV-16 transformation of primary 
rat kidney epithelial cells have shown that an activated 
ras is required for transformation (Matlashewski et al 
1987) confirming previous observations that primary cells 
can only be transformed with the cooperation of two or 
more oncogenes (Land et al 1983). This is interesting in 
the case of BPV-4, as in vivo BPV-4 associated carcinomas 
have an activated ras gene (Campo et al 1990) suggesting 
an important role for cellular oncogenes in the disease 
progression. Work in our laboratory by a previous PhD 
student has shown that PalF cells cannot be transformed 
by a single oncogene hit (Jaggar, 1990) confirming the 
oncogene cooperation theory in this cell type.
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7.2.2 Cotransfaction of pBV4 with the pT24 activated ras 
plasmid.
Cotransfection of pBV4 with pT24 gave rise to a number 
of macrocolonies with a partially transformed phenotype. 
The colonies consisted of elongated cells, had a 
"tighter" appearance and were larger than control (neor 
only) colonies (Fig 7.6.). The cells occasionally adopted 
a "criss-cross" morphology, especially at the fringe of 
colonies, but in general the colonies appeared to be 
contact inhibited (Fig 7.6.). This effect is not solely 
due to ras as transfection of the pT24 ras plasmid with a 
pZipneo selectable marker gave a result identical to 
control pZipneo only transfected cultures as reported in 
Jaggar et al, 1991. The pBV4 + ras transformed colonies 
could also be expanded individually, unlike control G418r 
colonies which could only be expanded as a pool. This 
indicates that while BPV-4 + ras cotransfection does not 
lead to a full morphological transformation, the 
macrocolonies have a considerable growth advantage over 
control cells. This growth advantage is limited however, 
as expanded pBV4 + ras colonies were not immortal and 
eventually senesced and died after prolonged subculture.
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Fig 7.6. Morphology of BPV-4 + ras transformed PalF 
cells.
Notes: Panels above are; A) control PalF cells; B) BPV-4+ras, giant 
cells; C) a BPV-4+ras "giant" cell; D) BPV-4 + ras ; E) pSVE8^"E7++ras; 
F) pZipE8+E7++ras. All cells were G418 selected. The cells were fixed 
in methanol and stained as described in the Materials and Methods 
section. M a g n i f ication=xl8
KmisSs
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Table 7.1. Transformation efficiency of BPV-4 constructs 
with co-operating ras and HPV-16 E6 constructs.
Constructs Expl Exp2 Exp3 Exp4 Exp5 Exp 6 Average
Neo 0 0 0 0 0 0 0
BPV-4+ras+neo 17 20 10 20 14 7 14.67
BPV-4+ras+ZipE2 26 8 nd 24 25 9 18.40
SVE8+E7++ras 18 28 nd 8 nd 7 15.25
SVE8+E7++ras+ZipE2 23 23 10 9 9 7 13.50
ZipE8+E7++ras nd 10 9 nd 36 15 17.50
ZipE8+E7++SVE8+E7“+ras nd 10 8 nd nd 18 12.00
ZipE7+ras 19 11 7 16 23 18 15.67
ZipE8+ras nd 2 0 0 2 4 1.60
ZipE7+SVE8+E7~+ras nd 8 10 nd 20 19 14.25
ZipE7+ZipE8+ras 3 15 10 2 24 5 9.83
ZipE7+ZipE8+E7-+ras nd 19 16 nd nd 5 13.33
16E6+neo 0 0 0 1 4 0 0.83
16E6+ras+neo 0 14 9 8 0 13 7.33
16E6 + ZipE7 + ras 13 17 20 9 18 28 17.50
16E6+ZipE7+ZipE8+ras 10 14 17 9 30 24 17.33
Notes: nd=not done, 16E6=HPV-16 E6 containing construct pJ4£2l6.E6. 
Expl= experiment 1, Exp2=experiment 2 etc.
Column marked Average is the numerical average of experiments 1-6. 
Transfections were performed as outlined in Materials and Methods.
Addendum
Constructs Exp A Exp B Exp C
Neo 0 0 0
BPV-4+ras 14 6 16
BPV-4+ras+pZipE2 19 13 26
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Table 7.2. Standardised average transformation efficiency 
of BPV-4 constructs with co-operating ras and HPV-16 E6 
constructs.
Construct(s) Transformation
Efficiency
Neo 0%
BPV-4+ras+neo 100%
BPV-4+ras+E2 125%
SVE8+E7++ras 104%
SVE8+E7++ras+E2 92%
ZipE8+E7++ras 119%
ZipE8+E7++SVE8+E7-+ras 82%
ZipE7+ras 107%
ZipE8+ras 11%
ZipE7+SVE8+E7~+ras 97%
ZipE7+ZipE8+ras 67%
ZipE7+ZipE8+E7“+ras 91%
16E6+neo 6%
16E6+ras+neo 50%
16E6+ZipE7+ras 119%
16E6+E7+E8+ras 118%
The above data were obtained by standardising the average macrocolony 
(Table 7.1) numbers obtained to BPV-4+ras which is taken as 100%.
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These observations for BPV-4 are in accordance with the 
transforming potential of other strictly epitheliotrophic 
viruses such as HPV-16 and HPV-18. In general the 
epitheliotrophic PVs do not cause obvious morphological
transformation and focus formation and induce more subtle 
effects on cell morphology and growth potential than do 
the fibroblastic viruses such as BPV-1 (Burnett and
Gallimore, 1985; Chesters and McCance, 1985; Nesseri and 
Wettstein, 1986) .
7.2.3 Formation of "Giant" Cells on Transfection with 
pBV4 and pT24
An interesting observation is that when primary cells 
were transformed by full genome BPV-4 in cooperation with 
activated ras a proportion of the transformed colonies 
contain greatly enlarged cells with correspondingly 
enlarged nuclei (Fig 7.6.). These areas of "giant" cells 
appeared approximately 2 to 3 weeks after transfection 
and persisted for approximately 10-14 days before
developing into a regular tight focus. A similar giant 
cell morphology has been reported by other workers 
investigating BPV-1 transformation of murine C127
fibroblasts and in this case the giant morphology has 
been shown to be associated with very high levels of 
viral DNA replication (Burnett et al 1989). It is
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therefore conceivable that the giant cell morphology 
observed with BPV-4 and ras transfected cells is 
similarly due to maximal viral DNA replication in this 
system. An initial investigation into this possibility 
proved to be inconclusive and time constraints prohibited 
pursuing this matter further. It should be possible, 
however, to assess if maximal DNA replication is taking 
place in these "giant" cells by employing the technique 
of in situ DNA hybridisation.
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Fig 7.7. Standardised transformation efficiency of BPV-4 
transforming region with cooperating ras.
■TSS3Sm m m
BPV-4+ras+neo
Note: The above graph represents macrocolony formation
expressed as a percentage of that observed on 
transfection of BPV-4 + ras. These results were obtained 
by using the average of all experiments (see Table 7.1.) 
and standardising them to the average value obtained by 
BPV-4 (see Table 7.2.). E2 refers to the construct 
pZipE2.
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7.2.4 Transformation of PalF Cells with the 2.Okb E8-E7 
Fragment in Cooperation with ras
Previous work using mouse fibroblasts has demonstrated 
that in these cells transformation by BPV-4 can occur 
when using a subgenomic 3.6 kb fragment encoding the E8 
and E7 ORFs (Smith and Campo 1988) . The efficiency of 
transformation using the subgenomic E8-E7 clone in this 
system is essentially the same as that observed when 
using complete BPV-4 genome suggesting that the major 
transforming region of BPV-4 is encoded by E7 and/or E8. 
The E8 and E7 ORFs, cloned as a 2.0 kb fragment in the 
pSVE8+E7+ vector give no transformation on its own, but 
when cotransfected with ras give essentially the same 
efficiency of transformation as full genome BPV-4 (Fig 
7.7.). The morphology of the resultant colonies 
transformed by pSVE8+E7+ + ras is essentially identical 
to that observed with pBV4 + ras (Fig 7.6.) suggesting 
that in this system, as in the established murine 
fibroblast experiments, the transforming function resides 
in the E8-E7 region. Efficiency of transformation may be 
linked to the level of expression of the transforming 
E8-E7 region as the 2.0 kb fragment is more efficient 
in cooperating with ras when under LTR control in the 
pZipE8+E7+ plasmid than when under BPV-4 transcriptional 
control (Fig 7.7.). As with pSVE8+E7+, pZipE8+E7+ was
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iineffective in morphological transformation without a 
cooperating ras. When under the powerful pZip retroviral 
transcriptional control, the transformation of the E8-E7 
region + ras gives rise to colonies with a more tightly 
packed and aggressive appearance (Fig 7.6). As observed 
with pBV4 + ras, PalF cells transformed by pSVE8+E7+ + 
ras or pZipE8+E7+ + ras are not immortal and senesce on 
passage.
7.2.5 Transactivation functions of the BPV-4 E2 Open 
Reading Frame
The E2 ORF encodes a protein with transactivation 
properties and cotransfection of this ORF with pBV4 and 
pT24 increases the number of G418r macrocolonies (Table
7.1. and Addendum pll8) . Although the efficiency of 
transformation is increased when using the E2 construct 
the morphology of the resulting colonies is identical to 
that observed with pBV4 + ras (Fig 7.6.) . This suggests 
that the E2 ORF can influence the level of expression of 
the transforming ORFs, but does not directly influence 
the transformed phenotype. This is seen to be the case 
for HPV 16 where elevated expression of E2 leads to an 
increased expression of the E7 product and enhanced 
cellular transformation, abolishing the requirement for 
the E7 ORF to be introduced under the transcriptional
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control of a strong heterologous promoter (Lees et al
1990). Workers in our group have also shown that BPV-4 E2 
can transactivate the BPV 4 LCR (Jackson and Campo 1991) . 
Curiously, E2 enhancement of transformation does not 
occur when the pZipE2 construct is cotransfected with 
pSVE8+E7+ and pT24 (Fig 7.7.). In this case, efficiency 
of transformation is essentially identical in the 
presence or absence of the pZipE2 plasmid. This raises 
the possibility that there is a previously unidentified 
E2 responsive element contained in the pBV4 plasmid but 
not in the pSVE8+E7+ subclone. Alternatively, it is 
possible that the SV40 element in pSVE8+E7+ interferes in 
some way with the E2 transactivation of the BPV-4 LCR 
perhaps by competing for the E2 product.
7.2.6 The Role of E7 Integrity in Transformation of PalF 
Cells
An intact E7 open reading frame is crucial for 
transformation as deletion of the 31 third of the E7 ORF 
in both the pSV and pZip cloned E8+E7” constructs results 
in a loss of transformation capability (Table 7.3.). 
Indeed, the transforming function seems to be encoded by 
the E7 ORF as pZipE7 will cooperate with ras to 
transform cells with high efficiency. These results show 
that an intact E7 ORF together with an activated ras gene 
is absolutely required for BPV-4 mediated transformation.
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Table 7.3. Requirement of E7 integrity for macrocolony 
formation.
Transfected DNA Macrocolony Formation
Expl Exp2
pSVE8+E7+ 
pSVE8+E7+ + ras 
pSVE8+E7“ 
pSVE8+E7- + ras 
pZipE8+E7+ 
pZipE8+E7+ + ras 
pZipE8+E7“ 
pZipE8+E7- + ras
0 0
<10 <10
0 0
0 0
0 0
>50 >40
0 0
0 0
Notes: Macrocolony formation was assessed in PalF cells by G418 
selection as described in the Materials and Methods section. Only 
colonies larger than 5mm in diameter and with a morphologically 
transformed appearance were scored. The above results suggest that 
both an intact E7 and a cooperating ras plasmid are required for 
morphological transformation.
Where no. of macrocolonies is given as <10, this indicated 
that between 5 and 10 macrocolonies were scored. ___
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This is in agreement with the observation that HPV-18 E7 
is capable of transforming primary rat embryo fibroblasts 
only in the presence of an activated ras gene (Bedell et 
al, 1989). Deletion of 3' third of E7 in the E8+E7~ 
clones confirms the inability of EcoRI digested BPV-4 to 
transform C127 and NIH-3T3 cells (Smith and Campo 1988). 
This deletion destroys the second of the two putative DNA 
binding motifs of E7 (Fig 5.2./ Fig 6.1.), the mutation 
of which abolishes transformation mediated by HPV 16 
(Storey et al, 1990; Watanabe et al, 1990) . This leads us 
to conclude that like HPV 16, the E7 is the ORF 
responsible for morphological transformation.
BPV-4 sequence analysis has shown that BPV-4 E7 contains 
the two plOS1^3 binding domains shown to be important in 
HPV 16 transformation (Fig 5.2.) and it is feasible, 
although as yet undemonstrated, that BPV-4 E7 indeed 
binds the bovine equivalent of plOS1^ 3 as part of the 
transformation mechanism. There have been three important 
domains identified in papillomavirus E7 sequences; the 
PIOS1^  binding domain, two Cys-X-X-Cys "zinc finger" 
putative DNA binding motifs and a casein kinase II (CKII) 
phosphorylation site. (Fig 5.2.). The most crucial of 
these domains in terms of transformation biology are the 
plOS^k binding and the Cys-X-X-Cys motifs. Site directed 
mutagenesis of these domains gives rise to a functionally
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inactive E7 in transformation assay (Edmonds and Vousden, 
1989; Chesters et al, 1990) . In addition E7 products of 
the more oncogenic HPV types are found to bind the pl05Rb 
protein with higher affinity than the more benign HPV 
types (Munger et al, 1989b; Gage et al 1990). It has been 
shown that the binding of plOS1^  by e7 prohibits the Rb 
protein from complexing with its cellular targets and 
this is the postulated mechanism for the transforming 
function of E7, while the C-X-X-C motifs have been shown 
to be crucial for the transactivation functions of E7 
(Phelps et al, 1988) . Sequence analysis of BPV-4 E7 
demonstrates that it lacks the serine residues at amino 
acid positions 31 and 32 which constitute the CKII domain 
(Fig 5.2.) and which are phosphorylated in HPV-16 E7 
(Smotkin and Wettstein, 1987) . Nevertheless the results 
of transfecting PalF cells indicate that BPV-4 E7 is 
still capable of causing morphological transformation. 
There is some evidence that the presence of a CKII site 
is not indispensable for E7 activity. Like the BPV-4 E7, 
the CRPV E7 protein also lacks the CKII domain (Barbosa 
and Wettstein, 1988) but despite this is absolutely 
required for tumorigenicity in vivo (Brandsma at al,
1991) .
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Fig 7.8. Cooperation between BPV-4 E7 and E8 ORF with ras 
in transformation.
ZipE7+ZipE*t E7 +ras
ZipE7+ZipE8+ras 
ZipE7+SVE8 E7 +ras 
ZipE8+ras
ZipE7+ras
ZipE8 E7 +SVE8E7  
+ras
+ -Y
ZipE8 E7 +ras 
BPV-4+ras+neo
m m
0% 20% 40% 60% 80% 100% 120%
Note: The above graph represents macrocolony formation
expressed as a percentage of that observed on 
transfection of BPV-4 + ras. These results were obtained 
by using the average of all experiments (see Table 7.1.) 
and standardising them to the average value obtained by 
BPV-4 (see Table 7.2.)
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In addition, deletion or mutation of the serine 31 and 32 
residues in HPV-16 do not abolish transformation 
(Watanabe et al, 1990; Storey et al 1990) and the lack of 
these residues in BPV-4 is not expected to interfere with 
the putative binding to plOS1^ 3. No information is 
currently available on a bovine plOS1^ 3 equivalent, but 
with newly developed anti-E7 antisera (G.J. Grindlay, 
personal communication), it should be possible to perform 
immunoprecipitation experiments to see if the BPV-4 E7 
complexes with any cellular proteins.
7.2.7 Effects of BPV-4 E8 on Transformation Efficiency
In experiments performed to date the E8 ORF has no direct 
transforming ability and indeed when the average of 
standardised results are considered, E8 appears to have a 
negative effect on transformation efficiency under 
certain conditions. Cells transfected with E8 and ras 
alone (either under its own transcriptional control in 
the pSVE8+E7“ plasmid, or under MoLV LTR in pZipE8+E7” or 
pZipE8) die more quickly than control cells suggesting 
that the E8 gene product may be lethal (Fig 7.8.) . In 
these experiments a number of colonies with an abnormal 
vacuolated phenotype are observed approximately 2 weeks 
after transfection. These colonies very rarely survive
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until the experiment is scored for foci and by 7-10 days 
after appearing, they had usually died.
Although the BPV-4 E8 appears to accelerate cell death when 
transfected in the absence of an E7 ORF, the data presented 
show that E8 had no demonstrable quantitative effect on 
macrocolony formation in the presence of a transforming E7 
ORF.
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As previously discussed, the predicted BPV-4 E8 peptide 
shares considerable sequence similarity to the BPV-1 E5. 
BPV-1 E5 is a transforming gene of the virus (reviewed in 
DiMaio and Neary, 1990) in stark contrast to BPV-4 E8. 
Although they share the same hydrophobicity (see Fig 
7.5.) and predicted membrane orientation (see Fig 7.10.), 
BPV-4 E8 lacks all the amino acid residues shown to be 
crucial for transformation by BPV-1 E5 (Horowitz et al, 
1988, 1989) as shown in Fig 7.10. It is thus perhaps
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unsurprising that E8 does not act as a transforming 
protein, although the hydrophobicity plots, amino acid 
similarity and predicted trans-membrane folding of the 
two peptides suggest that they may share some common 
function.
As outlined in the introduction, a principal activity of 
BPV-1 E5 has been demonstrated to be the activation of 
membrane receptors including platelet derived growth 
factor (PDGF) receptor and the epidermal growth factor 
(EGF) receptor (Petti et al 1991/ Martin et al 1989). 
Recent work has also demonstrated that the E5 binds to a 
16kd cellular protein (Goldstein and Schlegel 1990) which 
has been shown to be the 16k component of vacuolar 
proton channel-forming ATPases and gap junctions (Leitch 
and Finbow, 1990/ Finbow et al, 1991). It has been 
postulated that E5-16k complexing would disrupt the 
normal 16k H+ATPase functions of acidification of 
endosomal vesicles. This disruption in turn would lead to 
extended binding of growth factor to growth factor 
receptor and recycling of receptors to the cell surface, 
leading to sustained receptor stimulation and ultimately 
contributing to cell transformation (Goldstein et al, 
1991/ Finbow et al, 1991). It should be noted however, 
that studies using sets of E5 mutants have shown that 
complexing of BPV-1 E5 with the 16k protein is
133
insufficient in itself for transformation. Although 
complexing is not sufficient, it may still be required 
for transformation as analysis of transformation 
competent E5 mutants has shown that they all retain the 
capacity to bind the 16k protein (Goldstein and Schlegel 
1990). This observation suggests that BPV-4 E8 may 
contribute to transformation by binding the 16k protein 
although in itself it has no strict transforming ability. 
As the critical residues for the interaction of E5 and 
the 16k protein have not yet been fully mapped, it is not 
possible to predict if BPV-4 E8 meets the requirements to 
complex with the 16k protein. The use of E8 and 16K 
specific antisera in co-immunoprecipitation experiments 
on BPV-4 E8 transiently transfected cells may address 
this question. The toxicity of overexpressed E8 may prove 
to cause technical difficulties in this respect, and with 
this in mind BPV-4 E8 is currently being cloned in an 
inducible mammalian expression vector system (R. 
Anderson, personal communication). The alternative E5 or 
E8 interaction with the 16k could be to the gap junction 
form, leading to a disruption of junctional 
communication. By inhibiting junctional communication in 
this way it can be postulated that the normal growth 
control of surrounding cells via junctional communication 
would be "silenced" thus contributing to cell 
transformation. This phenomenon, if it exists, could in
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part explain the observation that E8 has no strict 
transformational activity, but may be able to contribute 
to transformation mediated by E7. The possibility that 
BPV-1 E5 and/or BPV-4 E8 can disrupt junctional 
communication will be considered in detail in a later 
section.
7.2.8 Cooperation of BPV-4 Transforming Functions, ras 
and HPV-16 E6 In Immortalisation
The lack of an E6 ORF in BPV-4 may explain why the viral 
DNA is unable to confer immortality to primary cells 
even in the presence of activated ras. The E6 ORF from 
HPV 16 (under MoLV LTR transcriptional control) was 
cotransfected with the transforming region of BPV-4 and 
activated ras into primary bovine fibroblasts to assess 
if the presence of an E6 ORF will allow the BPV-4 DNA to 
morphologically transform these cells to a greater degree 
and / or give rise to an immortal phenotype. The 
introduction of HPV-16 E6 ORF alone gives rise to no 
morphologically transformed colonies but partial 
transformation is observed when the a cooperating pT24 
construct is introduced (Fig 7.9). Cells transformed in 
this way have an elongated and retractile appearance, but 
grow very slowly and are contact inhibited (Fig 7.11.) . 
In addition, of ten colonies of pJ4Ql6.E6 + ras
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transformed cells picked, only a single colony was able 
to be expanded. Due to the sparsity of different clones 
and the slow growth rate of these cells, the immortality 
of this clone of cells has not been tested, but 
observations that HPV-18 E6 + ras transfected primary 
rat embryo fibroblasts are not immortal suggests that 
these cells may senesce if continually passaged (Bedell 
et al, 1989).
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Fig 7.9. Cooperation of HPV-16 E6 with BPV-4 E7 and E8 
ORF with ras in transformation.
16E6+pZipE7+pZipE8
+ras
VV16E6+ZipE7+ras
16E6+ras+neo
16E6+neo
BPV-4+ras+neo
0% 20% 40% 60% 80% 100% 120%
Note: The above graph represents macrocolony formation
expressed as a percentage of that observed on 
transfection of BPV-4 + ras. These results were obtained 
by using the average of all experiments (see Table 7.1.) 
and standardising them to the average value obtained by 
BPV-4 (see Table 7.2.). 16E6 refers to the HPV-16 E6
containing construct pJ4£116.E6.
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Fig 7.10. Predicted membrane orientations of BPV-1 E5 and 
BPV-4 E8 proteins.
BPV1 E5 BPV4 E8
Predicted membrane folding of the BPV-1 E5 and BPV-4 E8 proteins. 
Mutation of the shaded residues in E5 diminishes the transformation 
potential of this protein (Horwitz et al, 1988, 1989) .
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Cotransfection of pJ4£2l6.E6, pT24 and pZipE7 induces 
colonies which have an aggressive transformed morphology, 
cells being more tightly packed and piled up than
colonies obtained using pZipE7 and ras alone (Fig 7.11.). 
These colonies can readily be expanded. This morphology 
is also observed when pJ4£116.E6, pZipE7, pZipE8 and pT24 
are transfected together. When pJ4Ql6.E6, pZipE7 and 
pT24 are used in transfections (with or without a pZipE8 
construct) the resultant colonies do not senesce on
continued subculture and have been passaged routinely 
once weekly for ten months with no obvious retardation of 
growth potential. This is in contrast to cells 
transformed in the absence of HPV-16 E6. It appears 
therefore that the combined action of BPV-4 E7, HPV-16 E6 
and ras can lead to immortalisation of PalF cells. This 
observation is in accord with experiments involving 
immortalisation of rat embryo fibroblasts by BPV-1 where 
morphological transformation required an E5 gene, but the 
long term viability of these cells in culture required an 
additional E6 (Cerni et al, 1989) .
7.2.9 Growth of BPV-4 Transformed Cells in Methocel.
An experimental technique to establish the extent of
transformed phenotype of a cell line is anchorage
independence; its ability to form colonies in a soft agar
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Fig 7.11. Morphology of PalF cells transformed in the 
presence of HPV-16 E6.
•*!
Notes: A) untransfected control PalF cells; B) PalF cells transformed 
by pJ4£2l6 .E6+ras; C) PA1F cells transformed by pJ4Ql6.E6+pZipE7+ras; 
D) PA1F cells transformed by pJ4Ql6.E6+pZipE7+pZipE8+ras.
or methocel based growth medium. Some BPV-4 transformed 
cell lines were thus plated out in methocel and their 
growth in this medium assessed (Table 7.4.). 
Untransfected PalF cells have no capacity for methocel 
growth whatsoever. A positive control for the experiment 
was the established murine fibroblast line NIH-3T3 
transformed by BPV-2 (Campo and Spandidos, 1983). These 
cells are highly tumorigenic in nude mice and form 
colonies in methocel with high efficiency (Fig 7.12.). 
PalF cells transformed by BPV-4 and cooperating ras do 
form colonies in methocel (Fig) but at considerably lower 
frequency than the positive control. This was also found 
to be the case for pSVE8+E7++ras, pZipE7+pZipE8+ras and 
pJ4£2l6.E6+pZipE7 +pZipE8+ras transformed PalF cells which 
have essentially the same growth potential in methocel as 
do whole genome BPV-4+ras transformed cells. In contrast 
lines morphologically transformed by either pZipE7+ras 
or pJ4£2l6 .E6+pZipE7+ras had no capacity for growth in 
methocel whatsoever (see Table 7.4.).
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Table 7.4. Methocel growth of transformed PalF cells.
Cell Line Growth in 
Methocel
PalF control (untransfected) negative
NIH3T3-BPV2 positive
pBV4+ras (5 lines) positive
SVE8+E7++ras (3 lines) positive
SVE8+E7++ras+E2 positive
pZipE7+ras (2 lines) negative
pZipE7+pZipE8+ras positive
16.E6+pZipE7+ras (2 lines) negative
16.E6+pZipE7+pZipE8+ras (2 lines) positive
Notes: The ability of cell lines to grow in methocel was assessed as 
described in the Materials and Methods section. 16.E6- HPV-16 E6 
containing construct pJ4Ql6.E6. ras refers to the pT24 construct. 
Positive growth in methocel was assigned if the cell lines examined 
produced colonies after 7-10 days growth in methocel (see Materials 
and Methods) . The morphology of the methocel colonies is shown in 
Fig. 7.14.
Fig 7.12. Methocel growth of transformed PalF cells.
C
A
0
%
Magnification=x60
Notes: Colony formation of transformed PalF cells in methocel. A)
Untransfected PalF cells; B) BPV-2 transformed NIH3T3 cells (positive 
control); C) BPV-4 + ras transformed PalF cells; D) pSVE8+E7++ras 
transformed PalF cells. Methocel Growth assay was performed as 
outlined in the Materials and Methods section 6.12.
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From these preliminary observations it can be speculated 
that the presence of BPV-4 E8 is required for anchorage 
independence, especially as HPV16.E6+E7+ras transformed 
cells do not form colonies in methocel, but cells from 
the same experiment with an additional E8 containing 
construct (pJ4Ql6.E6+pZipE7+pZipE8+ras) do. As 
transfection of BPV-4 E8 without E7 leads to premature 
cell death, it is not possible to speculate whether a 
combination of E7 and E8 is required for this effect.
Other experiments using HPV-16 to transform human 
embryonic lung fibroblasts have shown that E6 and E7 
expressed from an SV40 early promoter give poorly 
transformed cells with an extended life-span, but 
anchorage independence was only observed in one out of 
four isolates tested (Watanabe et al 1989) . In addition a 
study by Smits and coworkers showed that HPV-16 could 
only cause anchorage independence of embryonic 
fibroblasts when the cells had a deletion in the short 
arm of chromosome 11 (Smits et al, 1988) , the site of a 
postulated tumor suppressor gene known to inhibit the 
tumorigenicity of the HPV-18 containing cell line HeLa 
(Saxon et al 1986/ Boshart et al 1984) . It should be 
noted however that HPV-18 E7 alone in cooperation with 
ras is able to induce anchorage independence in rat 
embryo fibroblasts.
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7.2.10 Tumorigenicity of BPV-4 Transformed Cells
The tumorigenicity of PalF cell lines transformed by BPV- 
4 containing constructs and pT24 was assessed by 
subcutaneous injection into athymic mice. Without 
exception, cells transformed under any conditions with 
BPV-4 or subgenomic constructs and ras proved to be non- 
tumorigenic in nude mice (Table 7.5.). This is also found 
to be true for the immortal cell lines transformed in the 
presence of HPV-16 E6. The lack of tumorigenicity of 
resultant cell lines suggests that other cellular factors 
are required before a fully malignant phenotype develops; 
a situation analogous to the long delay observed between 
BPV-4 infection and carcinoma in cattle. This is also in 
accordance with data obtained from the transfection of 
primary human fibroblasts and rat embryo fibroblasts with 
HPV 16 where the transfected cells gain an extended life­
span and become morphologically transformed but are 
non-tumorigenic in nude mice (Cerni et al, 1989; 
Matlashewski et al 1988; Pirisi et al 1987) .
Table 7.5. Tumorigenicity of transformed PalF cells.
Athymic Mouse Tumorigenicity Assay
Cell Line Tumorigenicity
PalF control negative
C4Ta2a control positive
4+ras(5 lines) negative
SVE8+E7++ras(3 lines) negative
SVE8+E7++ras+E2 negative
pZipE7+ras(2 lines) negative
pZipE7+pZipE8+ras negative
16.E6+pZipE7+ras(2 lines) negative
16.E6+pZipE7+pZipE8+ras(2 lines) negative
Athymic mice injected as described in Materials and Methods section. 
16.E6 refers to the HPV 16 E6 containing construct pJ4£2l6.E6. ras 
refers to the pT24 construct.
7.2.11 Morphological transformation of quercetin 
initiated cells by BPV-4 + ras.
The progression of BPV-4 associated lesions to carcinoma 
is associated with chemical cofactors present in bracken 
fern (see Introduction). The progression of virally 
induced papillomas to carcinoma in cattle which have not 
been exposed to bracken has never been observed 
indicating the crucial role of chemical cofactors in this 
system. One of the best characterised mutagens present in 
bracken fern is the flavonoid quercetin, 
(5,7,31,4'-tetrahydroxyflavone) the chemical structure of 
which is shown in Fig 7.13. Quercetin is a widely 
distributed flavonoid, also found in most edible fruits 
and vegetables (Ambrose et al, 1951) . Quercetin has been 
shown to bind DNA (Rahman et al, 1990) and induce a 
spectrum of genetic lesions in bacteria (Bjielanes and 
Chang, 1977/ Maruta et al, 1990) and cultured mammalian 
cells (Amacher et al 1979/ Nakayasu et al, 1986/ Ishikawa 
et al, 1987) including clastogenic damage (Ishidate, 
1988), an observation of particular significance as 
bracken grazing cattle have been found to have a wide 
spectrum of chromosomal abnormalities (Moura et al, 
1988) . In addition, quercetin has been shown to activate 
protein kinases and competitively inhibit ATP binding by 
phosphatases (Van Wart-Hood et al, 1989) .
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Fig 7.13. Molecular structure of quercetin.
QUERCETIN
Quercetin
OH
HO OH
OH
OOH
P lant F lavonol, found in  bracken  
M utagenic in  Salm onella  typhim urium
Show n to act as an  in itia tor in  tw o stage  
transform ation  in  vitro
Induces chrom osom al aberrations in  
cu ltured  m am m alian cells
Bracken grazing cattle have cytogenetic abnorm alities
Work in a number of laboratories has generally shown that 
quercetin alone does not act as a carcinogen (Ambrose et 
al 1951, Hirono et al 1981; Morino et al, 1981) . It has 
been shown that quercetin can act as an initiator in a 
two stage transformation assay in mammalian cells in 
vitro, although in the same assay it has an inhibitory 
effect when used as a promoter (Sakai et al, 1990) . In 
this respect it is interesting to note that quercetin may 
act as a cytostatic agent by interfering with a putative 
cell cycle regulatory molecule (Hosokawa et al, 1990) and 
has been demonstrated to inhibit the growth of gastric 
cancer cells in culture (Yoshida et al, 1990) .
The effects of quercetin as an initiating agent on PalF 
cells was examined by treating cultures of PalF cells 
with a single dose of quercetin for 48 hrs before washing 
the mutagen out and transfecting the cells with BPV-4 
and/or ras (see Materials and Methods 6.7.5). In the 
discussion of the following experiments, cultures treated 
with a single dose of quercetin in the manner outlined
will be described as "initiated". In all cases the
pZipneo construct was cotransfected to allow selection of 
cells in G418. Following transfection and selection
protocols, the colonies in each experiment were pooled 
and morphology, growth in methocel and tumorigenicity in 
nude mice determined. The use of a single dose of
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quercetin in this assay ensures that any observed effects 
on morphology or growth characteristics are due to long 
term mutational damage and not short term phenomena such 
as protein kinase activation.
Treatment of PalF cells with a single dose of quercetin 
has no observable changes in cell morphology of cells 
transfected with pZipneo only (Table 7.6.). This 
observation was found to be consistent for cultures 
initiated with 5 |IM, 20 pH or 45 JIM quercetin. In these 
cultures, only small contact-inhibited microcolonies were 
observed after the selection period and after these 
colonies were pooled and expanded, the resultant cultures 
were indistinguishable from untransfected PalF cells or 
uninitiated pZipneo transfected cells (see Fig 7.14.). 
This result suggests that at the concentrations examined, 
quercetin does not appear to induce any significant long 
term changes in cell morphology. This result was also 
found to be the case in cultures transfected with BPV-4 
DNA. At all three concentrations of quercetin, 
transfection with pBV4 and pZipneo gave rise to 
microcolony formation only, a result identical to 
non-initiated cultures (Table 7.6.). These cultures were 
indistinguishable from pZipneo only transfected cells 
(Fig 7.14.). This result is similar to those presented in
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Table 7.6. Effect of quercetin initiation on macrocolony 
formation by BPV-4 + ras.
Concentration of Quercetin 
0|IM 5|IM 20|iM 45|IM
A Neo 0 0 0 0
B BPV4+neo 0 0 0 0
C ras+neo 0 0 0 0
D BPV4+ras+neo 17 17 18 20
Cultures of PalF were initiated with quercetin then transfected as 
described in the Materials and Methods section. Macrocolony formation 
was assessed by neomycin resistance assay: only colonies of >5mm and 
with a transformed appearance were scored.
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the previous section, where pBV4 alone was incapable of 
inducing morphological transformation, and demonstrates 
that initiation of PalF cells with 5 }1M, 20 |1M or 45 }1M
quercetin did not overcome this limitation. The pooled 
microcolonies from these experiments had no growth 
potential in the methocel colony formation assay (Table
7.7. ) .
Transfection of quercetin initiated cells with ras and 
neo also followed the pattern observed for non-initiated 
cells; ras alone was incapable of morphological 
transformation in both initiated and non-initiated 
cultures (Table 7.6.). Again, at the three quercetin 
concentrations tested only microcolony formation was 
observed, and when pooled the resultant colonies were 
morphologically indistinguishable from control (pZipneo 
only) transfected cells (Fig 7.14.). The cells had no 
potential for growth in methocel irrespective of the 
concentration of quercetin used to initiate them (Table
7.7.) .
The above results demonstrate that these concentrations 
of quercetin did not cause transformation, or predispose 
PalF cells to transformation by pBV4 or ras alone. 
Cotransfection of initiated PalF with pBV4, ras and 
pZipneo gave rise to macrocolony formation as previously
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Table 7.7. Effect of quercetin initiation on anchorage 
independence in PalF cells.
Quercetin DNA Growth in Efficiency
(HM) Transfected Methocel
0 neo negative -
0 NIH-BPV2 positive 1.54(+/-0 .21)xlO-4
0 pBV4+ras+neo positive 4.41(+/- 0.6)xl0~4
5 neo negative -
5 pBV4+ras+neo positive 4.08(+/-0 .32)xlO-4
20 neo negative -
20 pBV4+ras+neo positive 6.95(+/-0 .45)xlO-4
45 neo negative -
45 pBV4+neo negative -
45 ras+neo negative -
45 pBV4+ras+neo positive 6.75 (+/-0.15)xl0-4
Notes: neo=pZipneo; ras=pT24
NIH-BPV2 are NIH-3T3 cells transformed by BPV2.
Efficiency of methocel colony formation was determined as follows.
10 6 cells were plated (duplicates) in a 60cm^ petri dish and
incubated for 7-10 days. Each plate was then scored for colonies by 
counting six lcm^ areas from each plate, averaging this number and 
then multiplying by 60 to give an estimate of total numbers of 
colonies. The duplicates were then averaged and the result is given 
as number of colonies per 10^ cells.
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described for non-initiated cells. At all quercetin 
concentrations examined the number of macrocolonies 
produced was similar, between 17 and 20 macrocolonies per 
transfection, implying "initiation" does not enhance 
the overall transformation efficiency of pBV4 and ras 
(Table 7.6.).
When the macrocolonies produced after non-initiated cells 
and cells initiated with 5 |1M quercetin, were pooled the 
resultant cultures in both cases were morphologically 
identical; cells were elongated and refractile but 
remained contact inhibited with very few cells piling up 
or adopting a "criss-cross" morphology as shown in Fig
7.14. , in keeping with previous experiments where PalF 
cells were transfected with pBV4 + ras. These cells were 
found to grow in methocel with the same efficiency as 
previously reported for PalF cells transformed with pBV4 
and ras (Table 7.4.).
In the process of expansion, the pooled pBV4 + ras 
macrocolonies from cultures initiated with either 20 }1M 
or 45 |1M quercetin became dominated by cells with a more 
aggressively transformed morphology. These highly 
transformed cells were in striking contrast to 
observations made on PalF cells which had been treated 
with the lower doses of quercetin. The cells were very
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elongated and retractile, appeared not to be 
contact-inhibited and adopted a "criss-cross" morphology, 
the cells piling up to form dense "foci" (Fig 7.14.). 
This morphology was observed in expanded populations 
from both the 20 JIM and 45 JIM quercetin initiated 
transformants.
On plating in methocel, these cells were found to grow 
with much higher efficiency than non-initiated pBV4 + ras 
cells; colony formation was higher (Table 7.7.) and the 
resultant colonies were of a much larger size (Fig
7.14.). The enhanced growth of these populations of cells 
in methocel, together with the striking morphological 
differences observed over controls suggests that the 
quercetin initiation procedure gave rise to a population 
of cells which can be transformed to a higher degree by 
the action of BPV-4 and ras. In addition to enhanced 
plating efficiency and growth in methocel, both pooled 
populations of cells were found to induce fibrosarcomas 
in the athymic nude mouse assay approximately 4 weeks 
after injection. These tumours initially grew to a larger 
size than those induced by the positive control cells 
(BPV-2 transformed NIH-3T3 cells), attaining maximum size 
by weeks 6-7. After attaining maximum size they regressed 
to a considerable extent although were still present at 
12-14 weeks (Fig 7.15.). The fact that the tumours
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regressed to some extent implies either the tumours were 
susceptible to the vestigial immune response present in 
the animals, and/or the injected cells lost their 
capacity for growth whilst in the animal. Surprisingly, 
the cells had a high capacity for growth in vitro, and 
were passaged weekly for approximately 16 weeks. During 
this time the cells showed no reduction in growth 
capacity, and time constraints prevented an assessment as 
to whether these cells were immortal.
The efficiency of the initiation step cannot be 
established from this experiment however, as the 
macrocolonies were pooled before growth in methocel was 
assessed, and no obvious differences in phenotype between 
individual macrocolonies were noted when the numbers of 
macrocolonies were scored. In order to address this 
limitation, the experiment was repeated for quercetin 
concentrations of 0 |1M, 20 |LLM and 45 JIM and the
morphology of resultant macrocolonies was carefully 
assessed. This was done in the hope that any
macrocolonies with an unusual morphology could be scored 
and compared to the morphology normally encountered in 
non-initiated cells transformed by pBV4 and ras.
As with previous experiments, no macrocolony formation 
was observed in cultures transfected with pBV4 or ras
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alone, irrespective of the concentration of quercetin 
used to initiate the cells (Table 7.8.). Transfection of 
the two constructs together gave rise to a number of 
macrocolonies as expected from previous experiments. Of 
the 34 macrocolonies observed following transfection of a 
flask of non-initiated cells with pBV4 + ras, none 
appeared to have a morphology any different from that 
observed in similar earlier experiments (shown in Fig 
7.6.) . This confirmed the previous observation that in
this system the action of pBV4 and ras does not lead to
dramatic changes in cell morphology. The macrocolonies 
produced on pBV4 + ras transfection of cells initiated 
with quercetin at a 20 JIM concentration were mostly of a 
morphology indistinguishable from that observed with 
non-initiated cells but between the two individual 
experiments scored, less than 5% (4 out of 91) of
macrocolonies had a highly transformed morphology similar 
to that shown in Fig 7.14. This implies that the 
initiation by quercetin has less than a 5% chance of 
causing genetic lesions which predispose a cell to full 
morphological transformation by the action of pBV4 and 
ras. A similar situation was found in cells initiated 
with quercetin at the higher concentration (45 |1M) where 
less than 3% (2 out of 70) of pBV4 + ras induced
macrocolonies had a morphology significantly different 
from pBV4 + ras transfected non-initiated cells (Table
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7.8.). The observation that the higher concentration of 
quercetin does not increase the chances of predisposing a 
cell to high morphological transformation may be a 
consequence of toxicity, or of the cells sustaining 
excessive genetic damage giving rise to loss of 
viability. Neither of these points were addressed 
experimentally in this body of work however.
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Table 7.8. Efficiency of formation of abnormal
macrocolonies by BPV-4 + ras in quercetin initiated 
cells.
Quercetin Concentration 
0|IM 2 0|!M 4 5 JIM
A Neo 0 0 0
B BPV4 0 0 0
C ras 0 0 0
D BPV4+ras(i) 34 (0) 45(3) 33 (2)
E BPV4+ras(ii) - 46(1) 27 (0)
Numbers given are macrocolonies formed as described in Materials and 
Methods section. Numbers given in brackets are macrocolonies with a 
very highly transformed morphology (see Fig 7.14.D).
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Fig 7.14. Comparison of macrocolony morphology and growth 
in methocel between initiated and non-initiated cells 
transformed by BPV-4 + ras.
Magnification=x60
A) Control PalF cells B) PalF cells initiated with 20|1M quercetin. C) 
PalF cells transformed by BPV-4+ras (G418 selected) D) Quercetin 
initiated PalF cells transformed by BPV-4+ras (G418 selected). E) 
Growth of BPV-4+ras transformed cells in methocel. F) Growth of 20|1M 
initiated BPV-4 + ras transformed PalF cells in methocel.
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Fig 7.15. Tumorigenicity of quercetin initiated BPV-4 + 
ras transfomed cells.
I I O  20 3 0  - * 0  t o  60 7 0  B O  S
Q N V 1 0 N 3  Nl  3 Q V W
A) Nude mouse tumour 
5 weeks after 
injection.
Similar sized tumours 
were observed in 
control (C4-Ta2a) and 
BPV-4 +ras transformed 
PA1F cells which had 
been initiated with 
either 20|iM or 45J1M 
quercetin.
tiinfnni
C JN V ~I 9N 3 m i  a a v w
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B) Twelve weeks 
following injection 
the tumours induced by 
quercetin initiated 
BPV-4+ras transformed 
cells had regressed to 
a considerable extent.
C) Excised regressed 
tumours (12 weeks) 
from quercetin 
initiated BPV-4+ras 
transformed cells.
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The scale of genetic damage caused by quercetin was
examined in PalF cells by cytogenetic analysis, the 
results of which are given in Table 7.9. Karyotypic 
analysis was kindly performed in the laboratory of Dr.
Ruedi Fries and Sabina Solinas in ETH, Zurich.
Non-transfected PalF cells were found to have a normal 
complement of 60 chromosomes with no rearrangements
taking place on establishment and passaging of the cells 
(Table 7.9.). A normal karyotype was also observed in 
SVE8+E7++ras transformed cells and in cells which had 
been treated with quercetin, at a concentration of 20 
}1M or 45 JIM but not transfected (Table 7.9.) . It can be 
seen from the table that some metaphases were observed to 
have a depletion in chromosome number. The chromosomes 
lost in each case were not consistent and were deemed to 
be an artefact of the karyotyping procedure (R. Fries and 
S. Solinas personal communication), and the statistically 
small number of metaphases typed prevented any valid 
conclusions being drawn. When the initiated PalF 
populations were transfected with pBV4 + r as, the 
resultant macrocolony pools were found to be tumorigenic 
as outlined earlier. The tumorigenic populations were 
also karyotyped and found to be normal, with no 
consistent chromosome loss (Table 7.9.).
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Table 7.9. Karyotypic analyses of quercetin initiated 
cells.
Line Metaphases 
Scored
Number of 
chromosomes
Sex Rearranged
PalF 5 60 XY No
59 (28) No
60 No
60 No
60 No
SVE8+E7++ras 5 60 XX No
58 (2,19) No
60 No
60 No
60 No
PQ3 5 57 (1,7,12) XY No
60 NO
60 No
59 (26) No
60 No
PQ2 5 60 XY No
60 NO
60 NO
60 No
60 No
Q3D 5 60 XY No
60 No
59 (8) No
60 No
59 (2) No
Q2D 5 60 XY No
56 (1,4,17,28) NO
60 No
60 No
58 (unknown) No
Cell lines karyotyped are as follows:
PalF= untransfected/non--initiated. control; SVE8 +E7++ras= uninitiated
PalF cells transformed by pSVE74'E8++ras; PQ3= PalF cells initiated
with 45j*M quercetin; PQ2= PalF cells initiated with 20/*M quercetin; 
Q3D= as PQ3 but cells were transformed with pBV4+ras; Q2D= as PQ2 but 
cells were transformed with pBV4+ras. Numbers in brackets refer to 
chromosomes lost.
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In all initiated and tumorigenic lines examined, the 
chromosome banding pattern was indistinguishable from 
normal PalF, suggesting that no large scale genetic 
rearrangements had occurred (R. Fries, personal 
communication). These preliminary results would indicate 
that neither initiation by quercetin or the subsequent 
transformation by BPV-4 and ras causes large scale 
genetic damage. It should be noted however that reports 
of quercetin acting as a clastogenic agent required 
considerably higher dosages than utilised in these 
studies (see Ishidate M. 1988), and its seems likely 
therefore that quercetin acts as an initiating mutagen. 
It would however be interesting to treat PalF cells with 
increasing quercetin concentrations and to monitor their 
cytogenetic status, as it has been noted that bracken 
grazing cattle display large scale chromosomal 
abnormalities (Moura et al, 1988) .
In conclusion BPV-4 was incapable of transforming PalF 
cells without a cooperating activated ras plasmid in any 
experiments performed. The data presented would suggest 
that the E7 ORF of BPV-4 encodes the major transforming 
function of the virus. There appears to be a role for the 
E8 ORF in anchorage independence although the E8 has no 
direct transforming ability on its own. HPV-16 E6 can 
cooperate with BPV-4 E7 to lead to immortalisation of
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PalF cells but the cells are non-tumorigenic. In 
addition, the mutagen quercetin can initiate PalF cells, 
allowing subsequent transformation by BPV-4 + ras to a 
malignant phenotype. The results of this section are 
summarised in Table 7.10.
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Table 7.10. Summary of BPV-4 + ras transformation 
experiments.
Characteristics of BPV-4 Transformed Cells
Viral Genes 
+Activated ras
M orphological
Transform ation
Growth in  
M ethocel
Im m ortalisation Tumorigenic 
in  Nude Mice
BPV-4 + + - -
E7 + - - -
E8 — - - -
E7+E8 + + - -
16E6 - - - -
16E6+E7 + - + -
16E6+E7+E8 + + + -
BPV-4 (Q u ercetin ) + + + + + + ? + + +
An overview of the characteristics of BPV-4 transformed 
PA1F cells.
-= does not display characteristic 
— = negative for characteristic 
+= positive for characteristic
vsry strongly positive for characteristic.
?= characteristic not fully determined
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7.3 Cellular Localisation of BPV-4 Oncoproteins 
7.3.1 Control Reactions
In order to establish the cellular localisation of the 
BPV-4 E7 and E8 proteins immunocytochemistry was used. 
PalF cells were transfected with various constructs 
containing the genes for these viral proteins. The cells 
were not selected in G418 containing medium and were 
grown for 48 hrs before immunocytochemistry was 
performed. Details of antisera used are given in the 
Table 7.11. The technique involves spinning a cell 
suspension on to a glass microscope slide, incubating 
this slide with an antiserum raised against the peptide 
to be localised, then visualising specifically-bound 
antibodies using a secondary antibody. This secondary 
affinity-purified anti-IgG antibody (Sera Lab) binds 
specifically to the primary antibody. The secondary 
antibody also has a conjugated alkaline phosphatase 
enzyme covalently linked to it. This allows the 
visualisation of a positive result by incubating the 
slide with the alkaline phosphatase substrate (3-hydroxy- 
2-napthonic acid 2,4 dimethylanilide / 4-chloro-0- 
toluidine-1, 5^ diazonium napthalene disulfonate).
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Table 7.11. Antisera used in immunolocalisation studies.
Antiserum Species
anti--ras (249) (Furth et al, 1982) RAT
antij bovine MHC class 1 (Alan Teale, ILRAD) MOUSE
anti BPV-4 E7 (G.J. Grindlay, unpublished) RABBIT
anti BPV-4 E8 (G.J. Grindlay, unpublished) RABBIT
Bound antibody was detected by using species specific secondary 
antibodies conjugated to an alkaline phosphatase enzyme (see 
Materials and Methods).
Anti E7 and Anti E8 antisera were raised in rabbits as 
follows. The E7 antiserum was raised against a bacterially 
produced fi-galactosidase E7 fusion protein and the E8 
antiserum was raised against a synthetic nonapeptide 
corresponding to the C-terminus of E8 conjugated to keyhole 
limpet haemocyanin. The specificity of the antisera was 
determined by Western blot analyses (G.J. Grindlay, personal 
communication).
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A local colour reaction takes place where the secondary 
antibody is bound due to the enzymatic conversion of the 
substrate to an insoluble red precipitate. This colour 
reaction can then be visualised by light microscopy.
A number of controls were employed to ensure that the 
reactions were working properly, positive results were 
not a result of background staining, and to establish 
that the antisera used did not cross-react. Two positive 
controls were used to establish if the reagents in the 
detection kit were functioning properly. Firstly a 
monoclonal antibody which recognizes antigens of the 
bovine major histocompatibility complex (MHC) class I was 
used (this was a gift from Dr Alan Teale of ILRAD, Kenya 
through Dr Liz Glass, AFRC, Edinburgh). The MHC complex 
should be expressed on the surface of primary cells and 
indeed using this antiserum as a primary antibody 
resulted in strong staining of all cells (Fig 7.16.). An 
additional control was a monoclonal antibody which 
recognises conserved regions of the Ha-ras gene product 
(Furth et al, 1982) and is therefore expected to cross 
react with the bovine Ha-ras protein. This antiserum also 
gives a strong positive staining (Fig 7.16.) confirming 
its cross-reactivity and the general suitability of this 
method for the detection of cellular proteins.
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Fig 7.16. Immunocytochemistry: positive control
reactions.
%
A) Untransfected PalF cells stained with an anti bovine 
MHC class I antibody.
B) Untransfected PA1F cells stained with an anti-ras 
antibody.
Magnification=xlOO
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To ensure that the secondary antiserum was not binding 
non-specifically, a negative control which had not been 
incubated with a primary antiserum was included. When the 
primary antiserum was replaced with TBS only, no
staining occurred (Fig 7.17.) demonstrating that the
reaction was indeed specific.
The specificity of the primary antisera was tested by
using untransfected PalF cells. When treated with the
anti-E7 antiserum these cells showed no staining (Fig 
7.17) confirming that the antiserum does not display any 
non-specific binding. Similarly, the anti-E8 antiserum 
also showed no reaction against untransfected PalF cells 
(Fig 1.11.).
Possible cross-reactivity of the antisera was examined as 
follows. Cells transfected with pZipE7 were examined 
using the anti-E8 antiserum. Under these conditions there 
was no staining, demonstrating that the E8-antiserum does 
not recognise the E7 protein (Fig 7.18.). The E7-
antiserum was also examined in this way and no staining 
was observed when this antiserum was used on pZipE8 
transfected cells (Fig 7.18.).
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Fig 7.17. Immunocytochemistry: negative control reactions
%» .
A) Negative control; 
untransfected PalF cells, 
no 1° antibody.
'JS- B) Negative control; untransfected PalF cells, 
anti-E7 1° antiserum.
C) Negative control; 
untransfected PalF cells, 
anti-E8 1° antiserum.
Magnification=xlOO
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Fig 7.18. Immunocytochemistry: cross-reactivity control
reactions.
A) PalF cells transfected with pZipE8 and treated with
anti-E7 1° antiserum.
B) PalF cells transfected with pZipE7 and treated with 
anti-E8 1° antiserum.
Magnification=xl00
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7.3.2 BPV-4 E7 Localisation
The cellular localisation of BPV-4 E7 was investigated in 
PalF cells transfected with either pZipE7, pBV4 or 
pSVE8+E7+ . Immunocytochemical staining was essentially 
equivalent between cells transfected by either pBV4 or 
pSVE8+E7+ but cells transfected with pZipE7 had a higher 
degree of staining which may be a reflection on the more 
efficient transcriptional control of the pZip vector (Fig 
7.19.). The low level of staining observed with pBV4 or 
pSVE8+E7+ was sufficiently higher than background to 
suggest that these constructs are expressing E7 at levels 
detectable by light microscopy. It is also known from 
western blotting studies that the anti-E7 antiserum is of 
low titre (G.J. Grindlay, personal communication) and 
this may be why the E7 protein staining in the pBV4 or 
pSVE8+E7+ transfectants was not as strong as that 
observed in cells transfected by pZipE7.
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Fig 7.19. Immunocytochemistry: BPV-4 E7 cellular
localisation.
A) pZipE7 transfected PalF cells. Anti-E7 1° antiserum 
(low magnification) . Magnification=xiOO
B) pZipE7 transfected PalF cells. Anti-E7 1° antiserum 
(high magnification) . Magnification=x350
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In the pZipEV transfectants the staining demonstrates 
that this protein localises chiefly to the cytoplasm with 
some staining being present in the nucleus (Fig 7.19.). 
This observation is in accordance with the observed 
functions of HPV 16 E7 namely transcriptional
transactivation (Phelps et al, 1988) and complexing with 
the product of the retinoblastoma anti-oncogene (Dyson et 
al 1989) . In addition it was observed that only 40-60% of 
cells displayed a positive staining. This would indicate 
that, as expected, only transfected cells producing E7 
protein stained with this technique. The observation that 
staining occurs in only a subset of cells is further 
evidence that the staining is not artefactual.
It was not always possible to observe a nuclear E7 
localisation in repeated experiments which may be due to 
the relative insensitivity of the technique. It has been 
observed, however, that levels of E7 expression in 
HPV-associated lesions in vivo are generally low. A more 
sensitive approach, such as using heavy metal tagged 
secondary antibodies followed by electron microscopy 
visualisation may be necessary to establish the extent 
of nuclear localisation of E7. This may be especially 
true when the E7 is under the normal transcriptional 
control of the BPV-4 LCR rather than when artificially 
overexpressed in the pZipE7 vector.
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The BPV-4 E7 localisation is in accordance with amino 
acid sequence data which would predict interaction with 
both DNA and the nuclear tumour suppressor protein 
plOS^. xhe localisation of BPV-4 E7 is also in agreement 
with previous studies on the HPV-16 E7 which localises to 
the cytoplasm by immunocytochemistry (Smotkin and 
Wettstein, 1987) and to the nucleus by immunofluorescence 
(Sato et al, 1989) . The effects of BPV-4 E7 in 
transformation assay, the conservation of crucial domains 
between the E7s of oncogenic HPVs and BPV-4 and the 
similar cellular localisation of both proteins make it 
reasonable to speculate that the E7 may function in very 
similar ways in both the human and bovine viruses.
7.3.3 BPV-4 E8 Localisation
PalF cells were transfected with either pZipE8, pBV4 or 
pSVE8+E7+ 48 hrs before immunocytochemistry was performed 
to determine the localisation of the BPV-4 E8 protein. 
The E8 protein proved to be easier to detect using this 
technique than did the E7, which is probably due to the 
anti-E8 antiserum being of higher titre as demonstrated 
by its efficacy in Western blotting (G.J. Grindlay, 
personal communication).
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Transfected cells showed E8 was localised primarily in 
the membrane compartments, particularly the plasma 
membrane, endoplasmic reticulum (ER) and Golgi apparatus. 
This was true for cells transfected with pBV4 and 
pSVE8+E7+ with particularly good staining observed in 
pZipE8 transfected cells (Fig 7.20.). This membrane 
localisation is in accordance with the ER and Golgi 
apparatus localisation of the BPV-1 E5 (Burkhardt et al. 
1989) which shows considerable sequence similarity and an 
almost identical hydrophobicity profile to the BPV-4 E8 
(Fig 7.5.). Determination of the orientation of the E5 
in membrane fractions has been achieved by the use of 
immunoelectron microscopy (Burkhardt et al, 1989) . In 
this work, using baculovirus expressed E5 in Sf9 insect 
cells, the E5 was found to localise in cytoplasmic as 
well as Golgi membranes, with the carboxyl-terminus 
facing either extracellularly or interluminarly 
respectively. This localisation is in contrast to the 
suggestions that BPV-1 E5 acts predominantly in the 
nucleus as a mitogenic stimulator (Green and Lowenstein,
1987). However the microinjection of synthetic E5 in C127 
and NIH3T3 cells has shown that it acts as a mitogenic 
stimulator only when introduced directly into the nucleus 
and has no effect when microinjected into the cytoplasm 
(Green and Lowenstein, 1987).
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Fig 7.20. Immunocytochemistry: BPV-4 E8 cellular
localisation.
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A) PalF cells 
transfected with 
pBV4 .
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antiserum.
IN
/■
Nr* '*
*
B) PalF cells 
transfected with 
pSVE8+E7+ . 
Anti-E8 1° 
antiserum.
C) PalF cells 
transfected with 
pZipE8.
Anti-E8 1° 
antiserum.
Magnification=x350
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BPV-1 E5 has not been demonstrated to have a nuclear 
localisation by immunolocalisation techniques. Indeed, it 
has been predicted, from studies of the membrane 
orientation of E5, that if any E5 were present in the 
nucleus, it would be orientated with the interactive 
carboxyl-terminus projecting into the space between the 
two nuclear membranes (Burkhardt et al, 1989) precluding 
the carboxyl-terminal from having a nuclear function.
The BPV-1 E5 localisation was confirmed by other workers 
using the technique of epitope addition (Field et al, 
1988) to engineer a functional BPV-1 E5 fusion protein 
which could be localised by the use of monoclonal and 
polyclonal antibodies against the inserted epitopes, 
followed by immunofluorescence microscopy (Goldstein and 
Schlegel, 1990). Indeed, when this method was employed in 
coprecipitation assays, the BPV-1 E5 was found to be 
complexed with a cellular protein of 16kd, a complex not 
observed when antisera against the carboxyl-terminal 
domain of E5 are used. The authors suggest that 
antibodies raised against the E5 carboxyl-terminal domain 
may potentially displace any BPV-1 E5 bound proteins or 
select for non-bound E5, problems not encountered when 
using the epitope addition technique. The 16Kd cellular 
protein complexed with E5 was later identified to be the 
component vacuolar proton channel-forming ATPases and gap
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junctions (Finbow et al 1988; Leitch and Finbow, 1990; 
Goldstein et al, 1991) .
The similar localisation of BPV-4 E8 and BPV-1 E5, 
together with their amino acid similarity and 
hydrophobicity profiles further suggests the possibility 
that the two viral proteins may share some common 
function(s). It is therefore feasible that the BPV-4 E8 
protein might interact with the 16k protein in a manner 
similar to BPV-1 E5. The role of BPV-1 E5 on membrane
receptor activation has been documented (Petti et al, 
1991; Martin et al 1989) but studies on observable
consequences of 16k complexing had not been performed at 
the time of commencement of this thesis. It can be 
hypothesised that the capacity of BPV-1 E5 expressing 
cells to communicate with adjacent cells via their gap 
junctions might be decreased as the 16k protein, a 
component of gap junctions (Finbow et al. 1991), would be 
bound by E5. By similar reasoning, cells producing BPV-4 
E8 may have a reduced communication capacity if this 
viral protein is also capable of binding the 16k protein. 
As the ability of papillomavirus genomes to affect
junctional communication had not been documented, it was 
decided to examine the communication potential of a 
variety of papillomavirus transformed cell lines. The
results of this investigation will be presented in the
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following section.
7.4 Microinjection/Dye Transfer
The possibility of papillomavirus proteins interacting 
with the gap junctional form of the 16k protein (Finbow 
et al, 1991) was assessed by dye transfer studies. The 
principle of the dye transfer technique is as follows. 
Cells are grown until subconfluent on glass coverslips. A 
single cell is iontophoretically microinjected with a 
solution of the fluorescent dye Lucifer Yellow CH (see 
Materials and Methods section 6.16.) which will pass 
freely through gap junction pores but will be retained by 
cells which do not possess these structures. The extent 
of passage of the dye from the injected cell to 
neighbouring cells in direct physical contact is a 
measure of how efficient the "chemical coupling" or gap 
junctional communication is between these cells.
The role of gap junctions in cellular growth control and 
tumorigenesis is at present unclear, with no general 
pattern in defects of junctional communication in 
tumorigenesis having been demonstrated (Weinstein and 
Pauli, 1987). Recent studies have suggested that in 
epidermal tumorigenesis an important aspect may be the
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breakdown of the patterns of junctional communication 
(Pitts et al, 1988). Dye-transfer experiments on normal 
mouse epidermis have produced a map of normal junctional 
communication patterns (Kam et al, 1986/ Pitts et al,
1988) . The stroma forms a large apparently limitless 
compartment of cells while the epidermal layer is 
composed of smaller communicating compartments. There is 
a distinct communication boundary between the stromal and 
epidermal layers marked by the basement membrane.
A chemical known to affect gap junctions is the tumour 
promoter 12-0-tetradecanoyl phorbol-13-acetate (TPA) 
which has been shown to inhibit junctional communication 
of sensitive cells in culture (Yotti et al, 1979) by 
reducing the rate of gap junction formation (Pitts and 
Burk, 1987) . As discussed in the Introduction, TPA is 
effective in a two stage mouse skin tumorigenicity model 
by acting as a promoting agent on populations of cells 
initiated with the mutagen dimethyl benzanthracene (DMBA) 
(Balmain et al, 1984). Work using cultured keratinocytes 
has suggested that TPA acts by activation of the 
differentiation pathway giving rise to prematurely 
differentiating basal cells which are in turn replaced by 
expansion of stem cells, some of which will have been 
initiated by DMBA treatment. The release of these 
initiated cells from normal growth control after several
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treatments with the promoter constitutes the observed 
hyperplasia (Parkinson, 1985) . The disturbance of the 
basal cells (which manufacture the constituents of the 
basal membrane) in this scheme may explain the loss of 
the basal membrane and could explain why the dermal- 
epidermal communication boundary is frequently observed 
to break down in TPA treated mouse skin (Kam and Pitts, 
1987) .
Junctional communication is a likely candidate for a 
feedback mechanism required to control the division rate 
of basal cells to match the loss of terminally 
differentiated cells by desquamation, and both positive 
and negative feedback mechanisms utilising junctional 
communication have been proposed for this control 
(Sheridan, 1976; Loewenstein, 1979). For example, the 
observation that ras proto oncogene products are 
expressed more strongly in proliferating layers than 
differentiated cells (Furth et al 1987) gives rise to the 
hypothesis that the upper layers of communicating cells 
act as a sink for second messengers (Loewenstein 1979), 
preventing threshold levels of inositol phosphates and 
other second messengers accumulating in the basal layers. 
This model has special significance in the case of BPV-4 
E8, as this viral protein is found to be expressed in the 
basal and suprabasal layers of BPV-4 induced papillomas
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(R. Anderson, personal communication). Should BPV-4 E8 
complex with the 16k gap junction protein and lead to a 
loss of junctional communication, the "sink" effect of 
the upper differentiating layers would be abolished, 
levels of second messenger would increase in basal and 
supra basal layers and consequently aberrant 
proliferation in these layers could occur. An assessment 
of the potential of papillomavirus transformed cells to 
communicate via their gap junctions was performed by 
microinjection / dye-transfer experiments.
In the first instance, the consequences of BPV-1 
transformation of primary bovine conjunctiva fibroblasts 
(CON cells) was examined (Smith et al, 1987). The binding 
of BPV-1 E5 to the 16K protein has been well documented 
(Goldstein and Schlegel, 1990) and therefore it is 
reasonable to assume that BPV-1 transformed cells will 
display any biochemical consequences of 16k-E5 
complexing. Control CON cultures showed moderate dye 
coupling, with the dye spreading to all cells in physical 
contact with the injected cell (Table 7.12.). This 
demonstrates that control, untransformed CON cells have 
functional gap junction structures. CON cells transformed 
by BPV-1 showed a completely disrupted junctional 
communication status however; no dye transfer occurred 
and the dye remained in the original injected cell (Table
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7.12.). This suggests that one consequence of 
transformation of CON cells by BPV-1 is the disruption of 
cell-cell communication. This disruption may well be a 
result of E5 and 16k complexing although these 
observations do not provide direct evidence for this. A 
possible way of providing a direct correlation between 
E5-16k complexing and junctional communication inhibition 
would be the use of inducible vector systems encoding the 
BPV-1 E5. In this way a population of normally 
communicating cells would be transfected with an 
inducible BPV-1 E5 construct. The gap junctional status 
of this transfected cell population could be assessed 
before the construct encoding BPV-1 E5 was induced. 
Following the induction stimulus, the same population of 
cells (now expressing the E5 transcript) could be 
examined for chemical coupling, and any loss of 
communication status attributed to E5 expression. This 
type of experiment is currently being initiated at the 
Beatson Institute (M. Finbow and M.S. Campo, personal 
communication).
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Table 7.12. Dye transfer capacity of papillomavirus
transformed cells.
Cell line % of injections 
displaying 
dye-spread
Avg No. 
coupled cells 
per group
PalF control 100 14 . 4
Con20 100 7.9
Con BPV-1 20 0.4
pBV4+ras 90 2.8
pSVE8+E7++ras(1) 40 1.3
pSVE8+E7++ras(2) 10 1.2
pSVE8+E7++ras+pZipE2 80 2.3
pZipE7+ras 100 9.2
PZipE7+pZipE8+ras 95 6.2
pJ4£116 .E6+pZipE7+ras 100 3.2
pJ4£2l6 .E6+pZipE7+pZipE8+ras 100 3.2
C12K (HPV-ve) 100 3.9
ClOK (HPV+ve) 8 0.1
Notes: Con20 BPV-1 are Con20 cells transformed by BPV-1. C10K cells 
were isolated from an HPV+ve cervical lesion and C12K cells were 
isolated from HPV-ve dysplastic tissue.
Each culture was injected at between 5 and 12 individual 
sites.
Fig 7.21. Microinjection / dye-transfer experiments on
PalF cells.
Magnification=x350
Dye-coupling in untransfected PalF cells.
PalF cells were microinjected with the the fluorescent 
dye Lucifer Yellow CH and photographed under UV light as 
described in Materials and Methods section 7.4.
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Fig 7.22. Microinjection / dye-transfer experiments on 
BPV-4 + ras transformed cells.
A) PalF cells 
transformed by 
pSVE8+E7+ + ras + 
pZipE2 and 
examined for dye- 
coupling as 
described in 
Materials and 
Methods section 
7.4.
B) Dye transfer 
in PalF cells 
transformed by 
p J4Q1 6 . E6 + 
pZipE7 + pZipE8 + 
ras.
C) Dye transfer 
in PalF cells 
transformed by 
pSVE8+E7+ + 
ras (2) .
Magnification=x350
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Disruption of junctional communication was also observed 
in human papillomavirus associated biopsy material. Cells 
from a squamous cell carcinoma sample, previously
demonstrated to be positive for HPV-16 DNA by the 
polymerase chain reaction (G.McGarvie, personal 
communication) were found to have disrupted communication 
potential when compared to cells from HPV -ve dysplastic 
tissue (Table 7.12.). In addition, the HPV-16 transformed 
keratinocyte line W12 (Stanley et al, 1989) was found to 
be uncoupled (G.Sibbett personal communication, Table
7.12.) . The small number of samples examined in these
studies preclude any general conclusions but it would be 
interesting to examine a larger number of papillomavirus 
associated cell lines and biopsies to see if the loss of 
junctional communication is a common feature of 
papillomavirus transformation biology.
BPV-4 transformed PalF cell lines were also examined for 
their communication potential. Clonal populations of 
cells (originally isolated as single G418r colonies from 
transfection experiments) were expanded and grown on 
coverslips to a suitable density. This analysis was 
limited to clones of cells which recovered well from
liquid N2 storage and had sufficient life-span when
recovered to obtain healthy cultures of cells. This 
precaution was taken to avoid metabolically inactive,
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senescing or dead cells being scored as non­
communicating. Control untransfected PalF cells displayed 
moderate dye coupling; the injected dye spreading freely 
to neighbouring cells (Table 7.12, Fig 7.21). BPV-4+ras 
transformed cells showed an almost normal coupling with 
only a very slight reduction in communication (Table 
7.12., Fig 7.22.). This situation was also found to be 
true for cells transformed by pSVE8+E7++ras+pZipE2 (Table
7.12.). In addition, pZipE7+pZipE8+ras transformed PalF 
cells also had essentially normal communication patterns 
(Table 7.12, Fig 7.22).
Immortalisation of cultures by the joint action of HPV-16 
E6, BPV-4 E7 and ras was not accompanied by a disruption 
of junctional communication in the case of
pJ4£2l60E6 + ZipE7+ras transformed cells (Table 7.12.) as
these cells communicated freely. The addition of the E8 
encoding pZipE8 construct (in pJ4Ql6.E6+ZipE7+ZipE8+ras 
transformed PalF cells) did not detectably alter this 
communication (Table 7.12.). This implies that sustained 
loss of junctional communication is not a necessary 
feature of immortalisation of this cell type.
A very interesting result was observed in the case of a
clone of cells transformed by pSVE8+E7++ras (2) . In this 
population of cells, junctional communication was totally
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abolished (Table 7.12, Fig 7.22.)/ the dye remained in 
the injected cell only. Lack of communication was not due 
to cell death or senescence, as the pSVE8+E7++ras cells 
could be expanded for several population doublings after 
the stage at which they were used for the microinjection 
studies.
The observation that only one cell line transformed by 
BPV-4 genes + ras (of six examined) shows an abnormal 
junctional communication pattern suggests that sustained 
loss of junctional communication is not important for the 
transformed phenotype of these cells and indeed may not 
take place at any stage in the transformation process. It 
could be proposed that the BPV-4 E8 protein does not 
complex with the 16k protein and therefore does not 
normally interfere with junctional communication. If this 
hypothesis was correct, the lack of junctional 
communication observed in the pSVE8+E7++ra.s 
non-communicating line would possibly be due to a random 
genetic mutation, giving rise to an alteration in the 
production, modification or localisation of the 16k 
protein and thus an aberrant communication pattern. Such 
a hypothesis is unlikely however, as such a genetic event 
is likely to be very uncommon and searches for such 
mutants in cultured cells are rarely successful (J. 
Pitts, personal communication).
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An alternative possibility is that the communicating and 
non-communicating cell lines differ in their maintenance 
of viral DNA or patterns of expression. As outlined in 
the Introduction, BPV-4 mediated cell transformation in 
vitro has been found to mimic the in vivo situation; 
viral DNA is not required for the maintenance of the 
transformed state (Smith and Campo, 1988; Campo et al, 
1985) . In earlier Southern blot analyses I demonstrated 
that in pBV4 + ras transformed PalF cells BPV-4 DNA was 
often lost on continued passage (Jaggar et al, 1990) . It 
is possible therefore, that the pSVE8+E7++ras(2) 
non-communicating cell line had maintained a significant 
copy number of BPV-4 DNA while the non-communicating 
lines had lost the majority of the transfected DNA. The 
status of the E8 gene, encoding the putative 16k 
interacting protein, is of particular interest in this 
respect. It is reasonable to assume that E8 may exert any 
effects at an early stage in the transformation process, 
as immunolocalisation experiments of E8 production in 
BPV-4 induced papillomas has demonstrated that the E8 is 
produced at early stages of papilloma development (R. 
Anderson, personal communication).
The possibility of a difference in maintenance of viral 
DNA between the communicating and non-communicating cell
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lines was addressed by preparation of genomic DNA from 
the transformed cell lines and the analysis of their
viral DNA status by Southern blotting and DNA 
hybridisation. This will be presented in the following 
section.
7.5 Southern Blotting
As discussed in the Introduction, presence of BPV-4 DNA 
is not required either for the maintenance of malignancy 
in vivo (Campo et al, 1985) or for the maintenance of the 
transformed phenotype in C127 cells in vitro (Smith and 
Campo, 1988) . The presence of viral DNA in BPV-4
transformed PalF cells was investigated by Southern 
blotting. The DNAs from fifteen cell lines were digested 
with EcoRl and 20fig of each of the digested samples was 
electrophoresed and blotted as described in the Materials 
and Methods section.
Four cell lines transformed by pBV4+ras (out of seven)
were found to contain no detectable viral DNA (Fig 7.23.) 
when probed with a BPV-4 full genome radioactive probe. 
One genome equivalent of pBV4 DNA could easily be 
detected in a reconstruction experiment performed at the 
same time. The reconstruction control experiment 
consisted of adding 1, 5 or 10 genome equivalents of
BPV-4 to EcoRl digested untransfected PalF DNA (Fig
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7.23) . The reconstruction blot was incubated in the 
same prehybridisation and hybridisation solutions as the 
transformed cell DNA blot. In addition, multiple 
integrations of neo sequences were detected in the BPV-4 
negative cell lines when the blot was probed with a 
radioactive probe prepared from the neo resistance gene 
of pZipneo (Fig 7.23), a result which demonstrates the 
ability to detect transfected sequences in PalF cells.
Seven of the fifteen genomic DNA samples contained 
detectable viral DNA at various levels (Fig 7.24., Table
7.13.). Of the positive cell lines, three contained less 
than one genome equivalent per cell, as judged by 
comparison to a reconstruction experiment performed at 
the same time (such as that shown in Fig 7.23.) . These 
lines were transformed by pBV4+ras+pZipE2, pZipE7+ras and 
pJ4£2l6.E6+pZipE7+ras. The line transformed by 
pBV4+ras+pZipE2 appeared to have three discernible bands 
at approximately 10-15kb, 4.5kb and 1.8kb while the
pZipE7+ras and the pJ4£2l6. E6+pZipE7+ras transformed cell 
DNAs both had a barely detectable smeared high molecular 
weight band (>15kb) . The high molecular weight of this 
band would suggest an integrated and rearranged E7 in 
these samples or partial digestion of the sample DNA.
The three DNA positive BPV-4+ras transformed lines all
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appeared to maintain viral DNA at around 1 ge per cell as 
judged by the reconstruction experiment. In all three 
lines three bands of approximately 10-15kb, 4.5kb and
1.8kb were detected. The line transformed by 
pSVE8+E7++ras (2) maintained a very high level of viral 
DNA compared to the other cell lines. This is 
particularly interesting as this was the line which 
displayed a reduced junctional communication potential 
(see Table 7.12. and Fig 7.22.) . This line appeared to 
maintain viral DNA at greater than 100 ge per cell (Fig 
7.24.). A short exposure autoradiograph of this blot (see 
Fig 7.24. panel b) allowed the identification of three 
major bands: two high molecular weight bands which may 
represent incompletely digested DNA and/or integration 
events, a strongly positive band at approximately 9kb and 
a smaller molecular weight band (approximately 800bp).
The pAT153 vector contains a single EcoRl site (Twigg and 
Sherratt, 1980) while the BPV-4 genome contains three 
EcoRl sites at nucleotides 906, 1139 and 3147. EcoRl
digestion of pBV4 is known to produce the following 
fragments (Jaggar, 1990) :
4.9 kb containing the major portion of the BPV-4 genome 
encompassing the 31 portion of the E2 ORF, the late ORFs, 
the non coding region, the complete E8 and the 5 1 two
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thirds of the E7 ORF; 5 kb encompassing the pAT153 EcoRl 
site to BPV-4 nucleotide 3147 encoding a 3' portion of El 
and a 5' portion of the E2 ORF; 200 bp from BPV-4 
nucleotides 906-1139 which represent the 3' third of the 
E7 ORF and a 5' part of the El ORF; 1.65 kb from BPV-4 
nucleotide 1139 to pAT153 EcoRl site which encodes the a 
portion of the El ORF.
Thus in the pBV4 transfected cells which are positive for 
viral DNA the 4.5kb band may be the 3147-906 fragment of 
pBV4 (ie major portion of the genome), the 1.8kb band 
would correspond to the expected 1.65kb fragment (El) 
while the high molecular weight band would represent the 
remainder of the recombinant plasmid integrated in the 
host genome. The differences between the observed and the 
expected band sizes is within the limits of measurement 
error. The lack of detection of the 200bp fragment 
(E7/E1) is probably due to this fragment having migrated 
off the gel.
EcoRl digestion of the pSVE8+E7+ plasmid generates three 
fragments (Jaggar, 1990): 6.7kb ( approx 4.9 kb of the
vector with 1.8kb of BPV-4 representing the 31 end of the 
LI, the ncr, E8 and 5 1 two thirds of the E7 ORFs) , 0.8kb 
(approx 700bp of vector and lOObp of the BPV-4 El ORF) 
and 200bp (the 31 third of the E7 ORF and the 5' end of
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the El ORF). In the genomic digest therefore, the 
observed band of 8 00bp may be the fragment containing the 
El portion, the band at 9kb may represent one arm of an 
integration event, and the high molecular weight band(s) 
may represent integrated and/or rearrangement events.
To assess in more detail which regions of the viral 
genome were present in these cell lines the blot was 
stripped clean and reprobed as described in the Materials 
and Methods section and rehybridised using an E7 probe 
(prepared by BamHl digestion of the pZipE7 plasmid). 
The high molecular weight bands observed in the 
pZipE7+pT24 and pJ4£2l6.E6+pZipE7+pT24 transformed cell 
lines were detectable as a stronger signal strengthening 
the hypothesis that this band represents pZipE7 
integration event(s) (Fig 7.25). The high molecular 
weight bands in the pSVE8+E7++pT24(2) lane again were 
detectable as was the band at 9 kb. The 8 00bp band 
detectable by a full genome probe (Fig 7.24) (postulated 
to contain lOObp of the El) was not detected (Fig 7.25). 
In the pBV4 containing positive lanes, no distinctively 
positive bands were observed. It is possible, however 
that the shorter E7 probe is not as sensitive as the 
full genome BPV-4 probe, and therefore did not pick up 
the expected band at 4.5kb which would contain the 5 1 two 
thirds of E7.
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After being stripped a second time, the blot was reprobed 
using a BPV-4 E8 probe which was prepared by BamHl 
digestion of pZipE8 (Fig 7.26). The high molecular weight 
bands in the pZipE7+pT24 and pJ4£2l6 .E6+pZipE7+pT24 
transformed cell lines were not detectable as expected,
as these cell lines had not been transfected with E8 DNA
(Fig 7.26). The 9kb and high molecular weight bands of 
the pSVE8+E7++T24 cell line were very strong when using 
this probe, suggesting that this line maintains a large 
amount of the E8 ORF. This observation is in accordance 
with this line's abnormal junctional communication 
potential, postulated to be the result of E8-16k 
complexing (see Fig 7.22 and Table 7.12). Curiously the 
800bp band, (which is proposed to contain lOObp of El and 
no E8), gave a strong signal when probed with E8. 
Sequence analysis has shown no significant homology 
between the El and E8 ORFs (data not shown) and the 
observation that this band is detectable with an E8 probe 
remains unexplained but could possibly be due to residual 
vector sequences in the probe. In the DNA positive pBV4 
containing lines, the 1.8kb (El containing) band is 
undetectable and high molecular weight bands (proposed to 
represent the integrated portions of the recombinant) are
only readily detectable in the pBV4+pT24(3) lane. The
4.5kb band (observed with the whole genome probe) which
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contains the major portion of the genome, including the 
E8 ORF, is easily detectable with the E8 probe.
The observation that several cell lines maintain DNA but 
are not immortal (Table 7.13; Table 7.10) would suggest 
that the senescence of these lines in culture is not a 
consequence of viral DNA loss. Indeed both DNA positive 
and negative cell lines appeared morphologically 
transformed at the time they were harvested for genomic 
DNA preparation.
In summary the Southern analyses would suggest that 
maintenance of viral DNA is not required for the 
transformed phenotype of PalF cells. The observation that 
the cell line transformed by pSVE8+E7++ras(2) maintains 
an unusually high copy number of viral DNA (in particular 
the E8 ORF) and has an abnormal junctional communication 
pattern strengthens the hypothesis that the BPV-4 E8 
protein may interact with the 16k component of gap 
junctions in a manner similar to that demonstrated for 
BPV-1 E5.
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Fig 7.23. Loss of viral DNA in pBPV4+ras transformed PalF
cells.
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Notes: PalF cells examined for the presence of viral DNA by Southern 
blotting. After transfection with pBV4, pT24 and pZipneo, individual 
G418r clones were picked and expanded and genomic DNA prepared as 
described (Section 7.5). The blot was probed with a full genome BPV-4 
DNA probe isolated by BamHl digestion of pBV4. A control 
reconstruction experiment was performed at the same time to ensure 
that the experimental conditions were correct. As an additional 
control, the blot was probed to detect pZipneo sequences.
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Fig 7.24. Southern blot analysis of transformed PalF
cells: presence of BPV-4 DNA.
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Notes: A) A panel of cell lines was examined for maintenance of BPV-4 
sequences by Southern blotting. The probe used was a full genome BPV-
4 probe isolated from pBV4 by BamHl digestion and the blot was
exposed for 3 days. Control reconstruction experiments (such as that 
shown in Fig 7.23.) were performed to ensure the procedure had worked 
and to assess copy number of maintained DNA (reconstruction not
shown) . All lanes contain 20*g of EcoRl digested DNA. B) The result
of an overnight exposure allowed the individual bands in the
SVE8+E7++T24 (2) lane to be sized.
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Fig 7.25. Southern blot analysis of transformed cells:
presence of BPV-4 E7 sequences.
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N o te s : The blot was probed with a BPV-4 E7 DNA probe isolated by
BamHl digestion of pZipE7. A control reconstruction experiment (as in 
Fig 7.23.) was performed at the same time to ensure that the 
experimental conditions were correct (reconstruction not shown). All 
lanes contain 20pg of EcoRl digested DNA and the blot was exposed for 
two days.
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Fig 7.26. Southern blot analysis of transformed cells: 
presence of BPV-4 E8 sequences.
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204
Table 7.13. Summary of Southern blot analyses of
transformed PalF cells.
Cell Line Viral DNA. Region (s) of Viral
Genome Retained
pBV4+ras (a) -ve
pBV4+ras (b) -ve
pBV4+ras (c) -ve
pBV4+ras (d) -ve
pBV4+ras (1) +ve <, E7, E8
pBV4+ras (2) +ve 4*, E7, E8
pBV4+ras (3) +ve 4*, E7, E8
pBV4+ras+pZipE2 +ve 4% E7, E8
pSVE8+E7++ras (1) -ve
pSVE8+E7++ras (2) +ve E7, E8
pSVE8+E7++ras+pZipE2 -ve
pZipE8+E7++ras -ve
pZipE8+E7++ras+pZipE2 -ve
pZipE7+ras +ve E7
16.E6+pZipE7+ras +ve E7
Notes: 16.E6 refers to the plasmid pJ4£2l6.E6. Cell lines marked as 
+ve contained detectable viral DNA of at least 1 genome equivalent 
per cell as judged by reconstruction control experiments (see Fig 
7.23.) .
in the "Region(s) of Viral Genome Retained" column, cell 
lines marked E7 were shown to contain E7 sequences using 
a probe derived by BamHl digestion of the pZipE7 plasmid. 
Similarly those cell lines marked E8 were positive when 
probed with the E8 fragment isolated by BamHl digestion 
of pZipE8. Where cells transfected with whole genome 
(pBV4) were DNA positive (using a probe from pBV4), the 
cell line is marked 4 to indicate that sequences other 
than E7 and E8 may be present.
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8. Conclusions and Speculations
Bovine Papillomavirus type 4 cooperates in vivo with the 
mutagens, carcinogens and immunosuppressants found in 
bracken to cause alimentary canal carcinoma in 
bracken-grazing cattle. The virus functions via a "hit 
and run" mechanism, being present in premalignant 
papillomas but absent from carcinomas. The transformation 
biology of BPV-4 was examined in a tissue culture system 
utilising primary bovine palate fibroblasts (PalF cells) .
BPV-4 is incapable of transforming PalF cells without the 
introduction of a cooperating activated ras gene. In 
cooperation with ras, BPV-4 can morphologically transform 
PalF cells and give rise to cells which have an extended 
life-span and are able to grow in methocel. The cells are 
not immortal and do not cause tumours when injected into 
athymic mice. A 2.0kb subgenomic fragment encoding the E7 
and E8 open reading frames (ORFs) can substitute for the 
whole BPV-4 genome in these assays and efficiency of 
transformation may be linked to the level of expression 
of this region. The main transforming protein of BPV-4 in 
this assay system was shown to be the E7 protein. The E7 
product of most papillomaviruses has an important role in 
cellular transformation due to its ability to bind the 
product of the retinoblastoma gene plOS1^ . BPV-4 E7 has
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the necessary plOS1^ 5 binding domains and is thus 
postulated to act primarily in this way. The BPV-4 E8 has 
no independent transforming potential in this assay and 
indeed is lethal when over-expressed. When expressed at 
normal levels in cooperation with E7 however, the E8 
gives an additional growth advantage to the transformed 
cells, allowing anchorage independent growth. The E8 ORF 
encodes a small hydrophobic protein with sequence 
similarity to the transforming BPV-1 E5, a protein shown 
to interact with the 16Kd component of gap junctions 
suggesting that BPV-4 E8 may also act in this way. As in 
vivo, the BPV-4 DNA is lost from the majority of BPV-4 
transformed cultures with passage.
A curious aspect of the BPV-4 genome is that it lacks an 
E6 ORF. Sequence analysis of the other epitheliotrophic 
bovine papillomaviruses (BPVs 3 and 6) demonstrated that 
these viruses also lack an E6 ORF. In other 
papillomaviruses the E6 protein has been shown to have 
a major role in cell transformation by binding to and 
enhancing the degradation of the cellular p53 protein, 
thus deregulating the cell cycle. The absence of an E6 
function in BPV-4 poses interesting questions regarding 
the way in which the virus transforms cells. PalF cells 
were co-transfected with the E6 ORF from HPV-16, various 
BPV-4 constructs and an activated ras gene, to see what
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effect introducing an E6 function has on the 
transformation efficiency of the virus and on the 
phenotype of resultant transformed clones. HPV-16 E6 does 
not transform PalF cells on its own, and has a low
transformation rate when introduced in cooperation with 
activated ras. However, in conjunction with BPV-4 E7 and 
activated ras, transformation efficiency is increased 
over that observed with either BPV-4 E7 plus ras or that 
of HPV-16 E6 plus ras. In all cases the requirement for 
an activated ras is essential for cell transformation. 
Cells transformed with BPV-4 E7 and HPV-16 E6 are 
immortal in culture but not tumorigenic in nude mice.
These lines do not grow in methocel but the introduction 
of BPV-4 E8, which has no transformation potential per se 
and is lethal when over-expressed in the absence of other 
BPV-4 genes, allows methocel growth, confirming that E8 
plays an important part in cell transformation. These 
results, while showing that BPV-4 encoded functions
cooperate with HPV-16 E6 in vitro, raise the question of 
whether E6 functions are unnecessary for BPV-4
transformation in vivo, or whether these functions are 
provided by another viral or host protein. Alternatively 
BPV-4 may have evolved another mechanism of evading p53 
growth suppression.
Given the involvement of the E7 and E8 proteins in cell
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transformation, the cellular localisation was
determined. PalF were transfected with either the E7 or 
the E8 ORF under the strong transcriptional control of 
the MoMLV promoter. Immunocytochemistry was utilised to 
allow the localisation of the E7 and E8 proteins to be 
determined. In all cases, control untransfected cells 
showed no staining and the antisera of E7 and E8 did not 
cross react. An anti-MHC class I antibody was used as a 
positive control. The E7 protein, which contains DNA 
binding motifs, was found to localise both to the 
cytoplasm and to the nucleus, which confirms other 
workers' localisation of the HPV E7 product. The E8 gene 
encodes a very hydrophobic protein and this was found to 
localise exclusively in membrane fractions, chiefly the 
Golgi, endoplasmic reticulum and perinuclear membranes 
and staining was also observed in the plasma membrane. 
The localisation of E8 is very similar to that reported 
for BPV-1 E5, and the two protein show sequence 
similarity and almost identical hydrophobicity profiles.
The E5 oncoprotein of BPV-1 has recently been shown by 
other workers to directly bind the 16K component of 
vacuolar ATPases. The 16K protein is also a major 
structural component of gap junctions, cellular 
structures which mediate cell-cell communication by 
allowing the passage of small molecules from one cell to
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another and are therefore implicated in growth control. 
In order to establish if the presence of this 
papillomavirus product can interfere with junctional 
communication, microinjection dye transfer experiments 
were performed. While non transformed control cells 
communicated freely, cells transformed by BPV-1 showed 
dramatically reduced junctional communication capacity. 
This was also found to be the case for HPV-containing 
cells explanted from cervical biopsies; HPV-positive 
cells had much reduced communication potential compared 
to HPV-negative controls. In the case of BPV-4, most 
transformed cell lines lose the viral genome on 
continuous passage, a phenomenon akin to the loss of BPV- 
4 DNA during malignant progression in vivo. The viral DNA 
negative cell lines invariably communicated with similar 
efficiency to control, untransfected cells. However, a 
few cell lines maintain viral DNA and those harbouring 
the BPV-4 E8 gene, which displays high sequence 
similarity to BPV-1 E5, were found to have reduced 
junctional communication capacity. These observations 
strengthen the hypothesis that the E5/E8 protein 
interferes with junctional communication, probably 
through its binding to the 16K component, and suggests 
that the abolition of junctional communication may be an 
important aspect of papillomavirus transformation 
biology. Direct evidence for BPV-4 E8 complexing the 16k
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protein will only come when immunoprecipitation studies 
similar to those used to identify the BPV-1 E5 to 16k 
interaction are performed. The use of inducible vectors 
(considered in the Results and Discussion section) 
encoding the E8, and immunoprecipitation assays should 
provide a suitable system for these studies. This avenue 
is currently being explored by other workers in the 
Beatson Institute and may provide formal proof of the 
E8-16k complexing in the near future.
The consequences of the postulated complexing of BPV-4 
E8 and the 16k gap junction may be a disruption of the 
control of basal and supra-basal cell proliferation. A 
model proposed by Loewenstein (1979) and extended by 
Pitts (see Pitts et al, 1988) suggested that the 
junctional communication pattern in epithelia could give 
rise to a concentration gradient of second messenger 
molecules. The dividing populations in epithelia are 
known to produce greater quantities of second messenger 
molecules (Furth et al, 1987) which could diffuse through 
gap junction pores to the differentiating, non-dividing 
layers above. In this way the upper layers of the 
epithelium, which have no receptors for second messenger 
molecules and hence do not respond to them (discussed in 
Pitts et al, 1988) would act as a "sink", preventing the 
second messenger concentration in the basal layers
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reaching a threshold concentration for mitogenesis. This 
"epithelial brake" could represent one mechanism for 
control of regeneration following for example a wound; 
when the upper "sink" layer of cells is absent, the 
second messenger concentration would rise in the 
proliferative layers, giving rise to mitogenesis and 
repair of the damaged tissue. BPV-4 E8 has been localised 
in papillomas by immunocytochemistry to the basal and 
suprabasal cells, and if it disrupts junctional 
communication by binding the 16k protein as proposed, it 
is feasible that it could release the "epidermal brake" 
thus preventing diffusion of second messengers through 
the gap junction pores. The resultant hyperplasia would 
be the equivalent of a deep wound response by the 
basal/supra-basal layers of the epithelium, giving rise 
to hyperplasia. In this respect E8 may turn out to be an 
important oncoprotein in BPV-4 and indeed could 
conceivably be the major protein involved in papilloma 
formation.
This proposed mode of action of E8 would require a 
differentiated epithelium and would not be evident in a 
monolayer culture of PalF fibroblasts, suggesting why E8 
is unable to transform these cells. The use of collagen 
raft cultures of epithelial cells would provide an ideal 
system to test this hypothesis. Epithelial cells would be
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transfected with an E8 construct and allowed to stratify 
on a collagen gel. Induction of E8 expression would give 
rise to hyperproliferation of the basal and supra basal 
layers, leading to a disruption of stratification. The 
hypothesis could be further strengthened by the use of 
constructs containing a mutant E8 with changes in the 
residues equivalent to those shown to be crucial for 
BPV-1 E5 binding to 16k. The model would predict no 
hyperproliferation in this case and these experiments are 
currently being considered by workers at the Beatson 
Institute.
One of the best characterised bracken mutagens is 
quercetin, a flavonoid which has been shown to cause a 
number of genetic lesions in vitro including point 
mutations and gross chromosomal abnormalities. Possible 
synergism between quercetin and BPV-4 has been examined. 
As previously observed, morphological transformation of 
cells requires the presence of both BPV-4 and ras, 
regardless of presence or absence of quercetin. However, 
cells which had been treated with quercetin and then 
transfected with BPV-4 plus ras showed dramatic changes 
in their growth potential compared to similar cultures 
which received no quercetin. These cells grew 
exceptionally well in methocel, displayed a very high 
cell division rate and a much more aggressive transformed
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appearance. More strikingly, they were fully tumorigenic 
in nude mice, a feature previously unreported for primary 
cells transformed in vitro by papillomavirus. From these 
results, it appears that quercetin initiates cells with 
high frequency, which are subsequently transformed by 
BPV-4 and ras. Initial studies suggest that the 
initiation event by quercetin does not appear to be at 
the level of large scale chromosomal damage (Rueudi 
Fries, personal communication) , and is thus likely to be 
the result of dysfunction of individual genes perhaps by 
point mutation. Future work on the initiating role of 
quercetin may serve to identify possible target genes, 
perhaps by utilising a "shotgun" cloning strategy; 
examining the transformation potential of cloned DNA from 
tumorigenic PalF lines may serve to identify activated 
oncogenes, although the dysfunction of tumour suppressor 
genes would not be identified by this technique. The 
status of candidate genes could thus be examined by in 
situ chromosome hybridization of initiated cells or by 
the polymerase chain reaction followed by DNA sequencing. 
Thus the use of quercetin in investigating the 
transformation biology of BPV-4 provides us with a system 
which more closely mimics the in vivo situation and 
should help us reach a better understanding as to the 
roles of all the contributing factors in disease 
progression.
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In the light of observations on the action of BPV-4 in 
vivo and in the in vitro situations discussed in this 
thesis, it is tempting to propose a tentative model for 
the role of BPV-4 in carcinogenesis. In the field of
papillomaviruses, BPV-4 appears very much to be the black 
sheep. The accepted paradigm for HPV-associated 
malignancies is that the viral DNA often integrates into 
the host genome as part of the progression to carcinoma. 
This integration event (discussed more fully in the 
Introduction) is highly specific in that the E6 and E7 
genes are usually maintained and transcriptionally active 
and the transcription regulatory regions of the virus
(encompassing the LCR, El and E2 regions) are usually 
interrupted. Thus although host genome site into which 
the viral DNA integrates does not appear to be important,
the portions of the viral genome retained are, in that
the reading frames of the virus encoding the "oncogenic" 
functions are generally maintained and their expression 
deregulated. This fairly consistent pattern of viral 
integration suggests that there exists a plethora of 
possible integration events which give no selective 
growth advantage to the host cell. Thus the integration 
patterns observed in both pre-malignant and malignant 
lesions would therefore be the result of a particular 
integration event giving rise to a selective growth
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advantage (over cells with a less favourable integration 
or an episomal state of viral genome), in turn giving 
rise to a clonal expansion of that cell. It has been 
suggested that viral gene expression and cell growth may 
vary among cancers of different clonal origins due to 
viral integration pattern (Doeberitz et al, 1991) .
When the involvement of BPV-4 in "hit-and-run" 
carcinogenesis is considered in the light of this 
hypothesis it becomes apparent that BPV-4 integration 
does not give this selective growth advantage, as viral 
DNA is never encountered in malignant lesions. The BPV-4 
genome is postulated to be involved in the initiation of 
transformation, but not its maintenance and the viral DNA 
must therefore only proffer a growth advantage when in 
the episomal state. Indeed it may also be feasible that 
integration gives a positive disadvantage under many 
circumstances. For example the work presented in this 
thesis has shown that under certain conditions the over­
expression of BPV-4 E8 can prove toxic. Little is known 
about the transcriptional machinery of BPV-4, but it is 
reasonable to hypothesise that possible deregulated 
expression of E8 following an integration event 
(following a pattern as described for the human PVs) may 
be disadvantageous.
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It can be envisaged that the BPV-4 viral DNA may provide 
an initial growth stimulus to a cell, causing cell 
proliferation and perhaps the expansion of populations of 
cells initiated by the action of bracken mutagens such 
as quercetin. The expansion of such cell populations, 
with associated increase in DNA replication, would in 
turn provide a further target for the mutagens leading to 
additional genetic damage. Significant in this respect is 
the observation that cell turnover is required for the 
action of chemical initiators (Cayama et al, 1978). With 
the acquisition of several "hits" in this fashion the 
"oncogenic" functions provided by the viral genome could 
be replaced by a genetic lesion in the host genome, Eg. a 
mutation in the plOS^ gene. Under these circumstances, 
the episomal viral genome would be under no pressure to 
be maintained and would be lost by clonal expansion. This 
model would account for the long latency period of the 
disease progression, as the carcinoma development would 
require a number of distinct, and most probably rare 
genetic mutations.
In summary the proposed model for BPV-4 associated 
carcinogenesis is as follows. Viral infection gives rise 
to a proliferative lesion, possibly expanding a 
population of cells initiated by the chemical mutagens, 
such as quercetin, present in bracken fern. The
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proliferative action of BPV-4, only effective while the 
viral genome is in an episomal state, serves to give a 
target of replicating DNA for the mutagens to act on. The 
postulated E8-16k coupling may be a principal mechanism 
by which this proliferation occurs, by leading to the 
disruption of junctional communication and thus causing 
an increase in second messenger concentration in the 
basal and supra basal cells of the epithelium (by 
dysfunction of the suggested "epithelial brake" system). 
In addition the action of E7 in complexing with the 
tumour suppressor gene product plOS^*3 would further 
deregulate cell division. With time, further genetic 
damage is sustained, such as the mutation of ras genes 
and possibly p53 genes, which offer a further growth 
advantage thus abolishing the requirement for BPV-4 
maintenance. The BPV-4 genome is lost by a process of 
clonal expansion and is not observed in frank carcinoma.
Possible cellular targets for interaction with BPV-4 
proteins are thus being identified by sequence 
comparisons of BPV-4 products with those of the better 
characterised PVs, and by the use of in vitro models such 
as the PalF cell system (presented) or collagen rafts 
(proposed). It is therefore becoming feasible to 
speculate on the role of BPV-4 in multistage 
carcinogenesis in terms of actual cellular targets, as
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indeed I have attempted in this thesis.
As mentioned earlier, the general paradigm for HPV 
involvement in carcinoma follows the pattern of 
integration, maintenance and expression of particular 
viral functions and is thus very different from that 
observed for BPV-4 both in vivo and in vitro. There is 
however an increasing body of work from various 
laboratories which suggests that other papillomavirus 
types may occasionally transform by a "hit and run" type
mechanism. For example, the loss of viral DNA sequences
in lymph-node metastases from invasive HPV-16 containing 
cervical cancer has been reported, suggesting that in 
this case HPV-16 is involved in tumour formation but not 
required for maintenance of the tumorigenic phenotype of 
the metastatic cells, even when the viral genome was 
integrated in the primary cancer (Fuchs et al, 1989; 
Matsukuru et al, 1989) . In two independent studies of the 
transcriptional activity of HPV-16 in cervical
carcinomas, it was observed that viral mRNAs were not 
detected in all the tumours examined, suggesting that 
malignancy of these tumours does not require continuous
expression of the papillomavirus genome (Lehn et al, 
1985; Schwarz et al, 1985).
In vitro observations have also demonstrated that HPV can
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be lost from cultures. Cells from laryngeal papillomas 
containing either HPV 6 or 11 have been observed to lose 
viral DNA with repeated passage (DiLorenzo et al, 1992) . 
Similar results have been observed for HPV-5 where 
malignant cells from an EV patient lost the 
extrachromasomal viral genome with passage in culture 
which is discussed in Fuchs and Pfister, 1990. Indeed 
these authors suggest that in immunocompetent patients 
the absence of HPV 5 or 8 in skin carcinomas may indicate 
that "the HPV DNA is not essential for the maintenance of 
the malignant state, but leaves the possibility of a 
role in cancer induction" (p3).
It seems to me reasonable to postulate that the genital 
HPVs may have an even greater involvement in 
carcinogenesis than the incidence of HPV positive 
carcinomas may suggest. Currently the evidence, as 
outlined above, for HPV "hit and run" is mostly indirect 
and circumstantial and consequently the possibility is 
not widely considered. Indeed, many HPV workers feel that 
viral DNA "negative" carcinomas may in fact harbour 
uncharacterised papillomavirus types not detectable by 
the probes used in current hybridization schemes.
The model for BPV-4 associated carcinogenesis predicts 
that the episomal viral DNA is maintained only until
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crucial target genes have been mutated by environmental 
factors. After these events the proliferative stimulus
afforded by BPV-4 presence is redundant and the viral DNA 
is lost. In a similar way episomal HPV genomes in 
pre-malignant cervical lesions may serve to induce cell 
proliferation. It is interesting to note that cervical
mucus from cigarette smoking women has been shown to
have mutagenic properties (Holly et al, 1989), a probable 
explanation for smoking as a risk factor in the
progression of cervical carcinoma. In this respect, the 
cervix is comparable to the alimentary canal of bracken 
grazing cattle which is subject to high local 
concentrations of mutagens during rumination. Should HPV 
genomes remain episomal in this environment there is a
chance that the crucial cellular genes, possibly
including the targets of HPV oncoproteins, will be
mutated leading to redundancy and loss of the HPV genome 
(Indeed, the HPV-16 E7 has been demonstrated to induce
cytogenetic abnormalities in cultured keratinocytes 
(Hashida and Yashimoto, 1991)). In these proposed cases 
the HPV genome would, as suggested for BPV-4, serve to 
give an initial proliferative stimulus (possibly leading 
to expansion of initiated cells) which would in turn give 
rise to a greater "target" for mutagenesis.
Should the situation outlined above occur, the behaviour
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of the resultant HPV-negative cancer might be expected to 
be more aggressive; the epigenetic dysfunction of target 
gene products by papillomavirus oncoprotein binding 
and/or enhancing degradation will surely be less 
effective than if the genes for these products have been 
mutated irreversibly. This situation has been observed in 
HPV negative anogenital carcinomas where the p53 gene is 
found to be mutant (Crook et al, 1991a, b) and in HPV 
negative cervical carcinoma cell lines where there in a 
disruption in the expression of both the retinoblastoma 
and the p53 genes (Wrede et al, 1991). An in vitro study 
has demonstrated that loss of the requirement for E7 
expression in transformed cells is associated with 
elevation of the c-myc protein, suggesting that 
alterations in the expression of cellular genes can free 
transformed cells from their dependence of papillomaviral 
functions (Pirn and Banks, 1991). A similar situation has 
been found in BPV-1 transformed primary mouse 
fibroblasts; expression of BPV-1 was required for 
transformation, but did not correlate with tumorigenicity 
and tumorigenic cell lines were found to have elevated c- 
myc expression (R.A.Mantyjarvi, personal communication). 
This observation confirms earlier results using hamster 
cell lines derived from BPV-1 induced transplantable 
tumours where neither the presence of viral DNA or levels 
of transcription correlated directly with tumorigenicity
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(Jaureguiberry et al, 1983)
The above would explain why HPV negative carcinomas have 
a poorer prognosis, in terms of relapse rate and 
metastases formation, than carcinomas harbouring HPV 
genomes (Riou et al, 1990). Thus should the oncogenic 
genital papillomaviruses be shown to occasionally 
transform by the suggested mechanism in vivo, this could 
give rise to the most serious presentations of cancer. 
Direct in vivo evidence for HPV "hit and run" may prove 
difficult to attain, but indirect evidence may be 
obtained by attempting to establish the viral history of 
HPV negative tissue. For example, presentations of HPV 
negative carcinomas from individuals with a previous 
history of HPV positive premalignant lesions may imply an 
involvement for HPV in the initial stages of these 
tumours. In addition, the examination of premalignant 
dysplastic and / or normal tissue from a patient 
presenting an HPV negative carcinoma may indicate that 
the negative carcinoma arose from HPV positive tissue, 
although a direct correlation may prove difficult to 
establish. Interestingly, a recent report has 
demonstrated the presence of HPV 31 DNA in a cervical 
dysplasia but not in the resultant metaplasia (Shimano et 
al, 1991) .
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I should stress at this point that I suspect that if HPV 
"hit and run" does occur, it does so at a low frequency, 
with viral DNA maintenance being the "preferred" mode of 
action. In this respect the oncogenic HPVs and BPV-4 
could be thought of as being at opposite ends of the 
viral DNA maintenance spectrum; HPV usually is maintained 
and expressed and often integrates, while BPV-4 is never 
observed to integrate and is lost in the conversion of 
papilloma to carcinoma. Interestingly several 
papillomaviruses, including BPV-1, have been shown to 
exist primarily as an extrachromosomal episome (for 
example see Lancaster, 1981). It is conceivable that the 
apparently contrasting mechanisms of transformation are 
due to differences in integration preference and that 
non-integrated HPV may behave in the manner as proposed 
for BPV-4. The fidelity of loss of the BPV-4 genome on 
progression to carcinoma may thus prove to be a trump 
card; indicating a possible mechanism of transformation 
by the oncogenic HPVs which would otherwise be 
overlooked. More epidemiological study and the analysis 
of viral DNA presence and status in normal, premalignant 
and malignant lesions may in the future confirm or deny 
this hypothesis.
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"A clash of doctrines is not a disaster r it is an 
opportunity"
Alfred North Whitehead 
Science and the Modern World
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